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Outline of the thesis
Despite recent advances in diagnostic techniques, fever of unknown origin (FUO) and suspected 
focal infection or inflammation remain challenging diagnostic problems. Timely identification and 
localization of infectious and inflammatory lesions is critical in appropriate treatment of these 
patients. Early diagnosis, however, is often difficult, especially in patients without signs pointing 
to a specific localization. Conventional imaging techniques, such as computed tomography (CT), 
magnetic resonance imaging (MRI) and ultrasonography are less suitable as a screening method 
when clues for specific sites of disease are absent. Furthermore, infectious and inflammatory 
foci cannot be detected by these techniques in an early phase because of the lack of substantial 
anatomical changes at this time. Also, discrimination of active infectious or inflammatory lesions 
from residual changes due to cured processes or surgery is difficult in some cases. Scintigraphic 
imaging allows delineation of the localization of foci in all parts of the body, based on functional 
changes. Since activated inflammatory cells take up large amounts of glucose as a result of an 
increased metabolic rate, 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) 
represents a promising imaging technique in patients suspected of infectious or inflammatory 
disorders. The aim of this thesis was to investigate the clinical value of FDG-PET in diagnosis of 
fever of unknown origin and several infectious and inflammatory diseases.
Scintigraphy using autologous leukocytes, labeled with 111In or 99mTc, is still generally considered 
the “gold standard” nuclear medicine technique for imaging of infection and inflammation, but 
this is a cumbersome and potentially hazardous approach. Over the past years, a variety of other 
radiopharmaceuticals have been used for the visualization of infectious and inflammatory disease. 
Chapter 1 presents an overview of both well-established and widely available radiopharmaceuticals 
and of “new” radiolabeled compounds for the scintigraphic diagnosis of infectious and 
inflammatory processes. The results of previous clinical studies of FDG-PET in patients with FUO 
and several infectious and inflammatory disorders are also discussed.
The initial interest in the subject of this thesis further increased after experiencing the value of 
FDG-PET in individual patients with difficult diagnoses of infectious or inflammatory diseases in 
daily clinical practice. In these cases, specific signs were absent and extensive investigation by 
conventional diagnostic tests did not provide a correct diagnosis. In chapter 2, several of these 
patients are described in four case reports.
Previously, FDG-accumulation on PET-scanning had been reported in patients with giant cell 
arteritis, Takayasu arteritis, and aortitis. To further assess the role of FDG-PET imaging in 
diagnosis and follow-up of patients with different types of vasculitis, the results of FDG-PET scans, 
performed either because of suspected vasculitis or because of fever of unknown origin with 
results suggesting the presence of vasculitis were evaluated in chapter 3.
In chapter 4, the ability of FDG-PET to visualize lipodystrophy in HIV-infected patients was 
prospectively studied. Treatment with highly active antiretroviral therapy has dramatically reduced 
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HIV-associated morbidity and mortality, but has also caused lipodystrophy in many patients. It was 
hypothesized that FDG-PET would be able to visualize lipodystrophy by showing the increased 
adipose tissue inflammatory activity together with mitochondrial toxicity of nucleoside reverse 
transcriptase inhibitors, which induces metabolic stress causing increased glucose-uptake.
One of the main complications of blood stream infections, especially in case of S. aureus bacteremia or 
candidemia, is secondary metastatic infection. Failure to identify metastatic complications increases 
morbidity and mortality. In chapter 5, the value of FDG-PET in detecting metastatic infectious foci in 
patients with bacteremia or fungemia at high risk of metastatic infection was assessed.
Since the first definition of FUO by Petersdorf and Beeson, this definition has been modified 
several times. Before starting a prospective study in patients with FUO, establishing a correct 
definition and a standardized diagnostic protocol was necessary. In chapter 6, a review is provided 
describing the adjusted definition of FUO and possible causes of continuous and periodic FUO. 
Furthermore, suggestions for a diagnostic and therapeutic approach are presented. 
After the introduction of FDG-PET in 1998 and after the first reports on the possible value of 
FDG-PET in patients with FUO and focal infection or inflammation, FDG-PET was ordered in many 
patients with FUO and several patients suspected of various infectious or inflammatory diseases. In 
chapter 7, the results of all FDG-PET-scans performed because of FUO or suspected focal infection 
or inflammation in the Radboud University Nijmegen Medical Centre between January 1999 and 
December 2002 were reviewed in order to provide information on the possible value of FDG-PET 
in the specific patient population of this hospital.
Comparing the results of previous studies and our retrospective study of the value of FDG-PET 
in patients with FUO is difficult: the definition of FUO differed, FDG-PET was performed at 
different stages of the diagnostic process, no structured diagnostic protocol was used and the 
FDG-PET technique differed between the studies, resulting in considerable selection bias. For a 
validation of FDG-PET in patients with FUO and for determination of its position in the order of 
diagnostic tests in the work-up of FUO, we designed a prospective study of FDG-PET as a part of a 
structured diagnostic protocol. The standardized diagnostic protocol in this study was based on our 
recommendations for a diagnostic and therapeutic approach described in chapter 6. The results of 
this prospective multicenter study with regard to the value of FDG-PET in patients with FUO are 
presented in chapter 8. 
In literature, no data are available on patients with FUO diagnosed outside of tertiary care 
and academic hospitals. From the prospective study described in part in chapter 8, data on the 
diagnostic yield of the standardized protocol including FDG-PET and other investigations in our 
tertiary care hospital and in five general hospitals in the same region, as well as the influence of 
several parameters on the chance of reaching a diagnosis are described in chapter 9.
In chapter 10, a general discussion and future perspectives are provided. 
Radiolabeled compounds in diagnosis of 
infectious and inflammatory disease
Chapter 1
 C.P. Bleeker-Rovers
O.C. Boerman
H.J.J.M. Rennen
F.H.M. Corstens
W.J.G. Oyen
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Abstract
Nuclear medicine offers powerful noninvasive techniques for visualization of infectious and 
inflammatory disorders using whole body imaging enabling the determination of both localization 
and number of inflammatory foci. A wide variety of approaches depicting the different stages of 
the inflammatory response have been developed. Non-specific radiolabeled compounds, such 
as 67Ga-citrate and radiolabeled polyclonal human immunoglobulin accumulate in inflammatory 
foci due to enhanced vascular permeability. Specific accumulation of radiolabeled compounds 
in inflammatory lesions results from binding to activated endothelium (e.g. radiolabeled anti-
E-selectin), the enhanced influx of leukocytes (e.g. radiolabeled autologous leukocytes, anti-
granulocyte antibodies or cytokines), the enhanced glucose-uptake by activated leukocytes 
(18F-fluorodeoxyglucose) or direct binding to micro-organisms (e.g. radiolabeled ciprofloxacin 
or antimicrobial peptides). Scintigraphy using autologous leukocytes, labeled with 111In or 99mTc, 
is still considered the ”gold standard” nuclear medicine technique for the imaging of infection 
and inflammation, but the range of radiolabeled compounds available for this indication is still 
expanding. Recently, positron emission tomography with 18F-fluorodeoxyglucose has been shown to 
delineate various infectious and inflammatory disorders with high sensitivity. New developments in 
peptide chemistry and in radiochemistry will result in specific agents with high specific activity. A 
gradual shift from non-specific, cumbersome or even hazardous approaches to more sophisticated, 
specific approaches is ongoing. In this review, the different approaches to scintigraphic imaging of 
infection and inflammation, already in use or under investigation, are discussed.
Introduction
Timely identification and localization of infectious and non-infectious inflammatory lesions is 
critical in appropriate treatment of patients. Scintigraphic imaging is a non-invasive method 
allowing delineation of both localization and number of infectious and inflammatory foci in all 
parts of the body, based on functional (physiological and/or biochemical) changes of tissues. Focal 
infectious and inflammatory processes can also be detected by several radiological techniques 
including computerized tomography (CT), magnetic resonance imaging (MRI) and ultrasonography. 
However, these techniques show anatomical changes, so infectious and inflammatory foci cannot 
be detected in an early phase because of the lack of substantial anatomical changes at this time. 
Also, discrimination of active infectious or inflammatory lesions from residual anatomical changes 
due to cured processes or surgery is often difficult. In addition, nuclear medicine techniques permit 
whole-body imaging, whereas CT and MRI routinely provide only information on a part of the body. 
Over the past years, a variety of radiolabeled compounds detected by gamma cameras have been 
used for the visualization of infectious and inflammatory disease. The number of these radiolabeled 
compounds available for diagnosing infection or inflammation is still increasing. Also, recently, 
positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) has entered the field 
of clinical infectious and inflammatory diseases. This review will focus both on well-established 
and widely available radiopharmaceuticals as on “new” radiolabeled compounds and the value of 
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FDG-PET in the diagnosis of infectious and inflammatory processes. Before discussing the various 
scintigraphic methods, the pathophysiology of inflammation and infection is briefly described.
Inflammation and infection
Inflammation is defined as the response of tissues to any kind of injury in order to bring serum 
molecules and cells of the immune system to the site of damage. Such injury can be caused 
by trauma, ischemia, a neoplasm or an infection. Infection simply means “contamination with 
micro-organisms” [1]. Infection is not always accompanied by inflammation, for example in 
the case of a severely immunocompromized patient. In general, the inflammatory response is 
characterized by locally increased blood supply, increased vascular permeability in the affected 
area, enhanced transudation of plasma proteins and enhanced influx of leukocytes. In response 
to tissue damage, powerful defense mechanisms are activated, consisting of leukocytes and 
plasma proteins (opsonins, antibodies, complement). Furthermore, a complex variety of chemical 
mediators are involved. These are molecules that are generated during the inflammatory response 
and that modulate the inflammatory process. The migration of leukocytes from the blood stream 
is facilitated by chemical mediators which upregulate the expression of adhesion molecules on 
both endothelial cells and leukocytes. First, the leukocytes adhere to the vascular endothelium 
due to locally enhanced expression of these adhesion molecules. Subsequently, they pass through 
the endothelium and the basal membrane (diapedesis) and migrate into the inflammatory 
focus (chemotaxis). This process starts within minutes from the injury and usually resolves in 
hours or days [1]. It causes the classical symptoms of acute inflammation: rubor (redness), calor 
(warmth), tumor (edema), dolor (pain) and functio laesa (impaired function). In acute infection 
or inflammation, infiltrating cells are predominantly polymorphonuclear cells (PMNs). In chronic 
infection or inflammation, persisting for weeks or months, the cellular infiltrate mainly consists of 
mononuclear cells, such as lymphocytes, monocytes and macrophages.
Approaches to imaging infectious and inflammatory processes
A wide variety of approaches to scintigraphic imaging of inflammatory and infectious disorders, 
depicting the different stages of the inflammatory response, have been developed (Table 1). Non-
specific radiolabeled compounds show increased extravasation at the site of inflammation by 
utilizing the locally enhanced vascular permeability. Examples are 67Ga-citrate and radiolabeled 
non-specific immunoglobulins. The second approach to imaging inflammation is to utilize the 
influx of leukocytes, either by radiolabeling the patient’s leukocytes ex vivo or by directly targeting 
leukocyte antigens or receptors in vivo via administration of radiolabeled antigranulocyte 
monoclonal antibodies or receptor-binding ligands (chemotactic peptides, cytokines and 
complement factors). Most of these radiolabeled compounds preferentially bind to granulocytes 
and are thus most suitable for visualizing acute inflammatory processes. Radiolabeled interleukin-
2 (IL-2) is suitable for imaging chronic inflammatory processes, because the IL-2 receptor is 
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preferentially expressed on T-lymphocytes. Alternatively, imaging of activated endothelium is 
possible and this involves targeting activated endothelial adhesion molecules, for example anti-E-
selectin. The mechanism of FDG-uptake in inflammatory cells is related to leukocytes using glucose 
as an energy source only after activation during the metabolic burst [2]. The accumulation of FDG in 
cells with increased glucose metabolism is specific. Increased glucose metabolism, however, is also 
present in malignant cells, so FDG-uptake is not specific for inflammatory processes as such. A new 
class of radiolabeled compounds consists of radiolabeled antibiotics and microbial peptides, which 
directly bind to micro-organisms. The specific nature of uptake of these radiolabeled compounds 
in inflammatory processes is still a matter of debate, however. 
Characteristics of an ideal radiolabeled compound
General characteristics of an ideal infection-imaging agent should include efficient accumulation 
and good retention in inflammatory foci, rapid clearance from the background, easy low-hazard 
preparation and wide availability at low cost. Absence of accumulation in non-target organs, 
specifically in the blood pool and the bowel is also important. High blood pool activity complicates 
the imaging of vascular infections and vasculitis. Similarly, accumulation in the bowel would 
complicate detection of abdominal infection or inflammation. Early diagnostic imaging is generally 
preferable but not always necessary, as in the case of chronic osteomyelitis for example. A one-day 
protocol is preferred especially in cases of severe and acute illnesses. Delivering high radiation 
doses or using radiolabeled compounds with possible side effects is in general unwanted and 
should be considered only when significant clinical benefit is to be expected. In many cases 
differentiation between infection and non-infectious inflammation is preferred, but this is not 
necessary in patients with fever of unknown origin (FUO). In these patients scintigraphic imaging 
is most often used to evaluate the presence of focal abnormalities, which can subsequently 
be further evaluated by specific diagnostic procedures. At present, no radiolabeled compound 
perfectly meets all of these criteria. In clinical practice, the choice of the imaging agent is based on 
careful evaluation of each individual case.
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Table 1  Overview of characteristics of radiopharmaceuticals used for imaging inflammatory processes.
Physiological 
characteristics
Targeting mechanism Tracer class Radiolabeled compound
Enhanced vascular 
permeability
Non-specific uptake 67Ga-citrate [3-8]
Non-specific immunoglobulins [9-11,13-20]
Liposomes [21-27]
Avidin/111In-biotin [29-32]
Endothelial activation Antigen binding Antibodies F(ab’)2-anti-E-selectin [34-37]
Anti-ICAM-1 Mab [39,40]
Binding to E-selectin Peptide IMP-178 [38]
Enhanced influx of 
granulocytes 
Granulocyte influx Radiolabeled granulocytes 
[41-44,47-49]
Antigen binding Antibodies Anti-NCA-95 IgG: BW 250/183 [53-67]
Anti-SSEA-1 IgM: LeuTech® [69-74]
Anti-NCA-90 Fab’: sulesomab, LeukoScan® [76-89]
Receptor binding Chemotactic peptides f-Met-Leu-Phe [90-96]
Cytokines IL-1, IL-1ra [97-99,101,102]
IL-8 [103-110]
PF-4 derivative: P483H [111,112]
Complement factors C5a, C5a-des-Arg [113]
LTB4-antagonists RP517 [114,115]
DPC11870-11 [116]
Binding to elastase Peptides Human neutrophil elastase inhibitor (EPI-HNE-2) 
[117]
Enhanced influx of 
mononuclear cells
Receptor binding Cytokines IL-2 [118-125]
MCP-1 [126,127]
Peptides RP128 [128,129]
Galactoside J001X [130-136]
Antigen binding Antibodies Anti-CD4 IgG [137-140]
Increased metabolic 
requirements
Enhanced glucose uptake FDG [2,141-174,178,179,182-189]
Presence of micro-
organisms
Affinity for micro-
organisms
Antimicrobial agents Ciprofloxacin: Infecton® 
[190-200,210]
Fluconazole [205]
Antimicrobial peptides [207-211]
Non-specific radiolabeled compounds
67Ga-citrate
After injection, 67Ga-citrate accumulates as an iron analogue through binding to circulating 
transferrin. This complex extravasates at the site of inflammation due to locally enhanced vascular 
permeability. In the inflamed tissue, 67Ga is transferred to lactoferrin that is locally excreted by 
leukocytes or to siderophores produced by micro-organisms [3]. Physiologically 10 to 25% of the 
radionuclide is excreted via the kidneys during the first 24 hours. After 24 hours the principal route 
of excretion is hepatobiliary. After 48 hours about 75% of the injected dose remains in the body 
and is equally distributed among the liver, bone, bone marrow and soft tissues [4]. 67Ga-citrate has 
been used extensively in clinical practice in several pathological conditions demonstrating high 
sensitivity for both acute and chronic infection and non-infectious inflammation [5]. There are 
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several shortcomings that limit its clinical application, however. Specificity is poor owing to the 
physiological bowel excretion and accumulation in malignant tissues and areas of bone modeling 
[6,7]. In addition, the radiopharmaceutical has unfavorable imaging characteristics such as a long 
physical half-life (78 h) and high-energy gamma radiation (93-889 keV), causing high radiation 
absorbed doses. Moreover, optimal imaging often requires delayed imaging up to 72 hours after the 
injection. These unfavorable characteristics and the development of newer radiopharmaceuticals 
have resulted in the replacement of 67Ga-citrate scintigraphy by scintigraphy with labeled 
leukocytes in the majority of inflammatory conditions. Leukocyte scanning, however, is of limited 
value in patients with suspected vertebral osteomyelitis and sequential gallium imaging appears to 
be a better way to diagnose this condition [5]. Also, in immunocompromized patients, 67Ga-citrate 
imaging is the procedure of choice for detecting opportunistic respiratory tract infections [5]. 
Finally, 67Ga-citrate scintigraphy is still the gold standard for radionuclide imaging in patients with 
FUO, where it is able to detect both acute and chronic inflammatory conditions and neoplasms 
[5,8]. However, its limited specificity and the generally unfavorable characteristics when compared 
to FDG-PET will most probably result in replacement of this technique by FDG-PET in patients with 
FUO in the near future.
Non-specific immunoglobulins
Initially it was thought that human polyclonal immunoglobulin (HIG) was retained in inflammatory 
processes by interaction with Fc-γ-receptors expressed on infiltrating leukocytes [9]. Later it was 
shown, however, that radiolabeled HIG accumulates primarily in inflammatory foci by non-specific 
extravasation due to locally enhanced vascular permeability [10]. HIG has been labeled with 111In 
and 99mTc for clinical use. Disadvantages of the use of 111In are a relatively high radiation burden, 
suboptimal gamma radiation for in vivo imaging, often limited availability and high cost. 99mTc is a 
more attractive alternative in most cases because of its short half-life (6 h), availability and lower 
cost. Both agents have slow blood clearance and physiological uptake in the liver and spleen. A 
general limitation is the long time span of 24 h between injection and diagnosis. In a comparative 
study, it was shown that 99mTc-HIG labeled via the chelator hydrazinonicotinamide (HYNIC) has 
in vivo characteristics highly similar to those of 111In-HIG and in most cases is suitable to replace 
the 111In-labeled compound [11]. 99mTc-HIG imaging, however, has more limited sensitivity in chest 
disease and in chronic inflammatory processes than 111In-HIG scintigraphy [12]. Direct comparison 
of 111In-HIG and 111In-leukocytes in 35 patients with various subacute infections showed a slightly, but 
significantly better overall accuracy of 111In-HIG scintigraphy [13]. The major indication for imaging 
with radiolabeled HIG is localization of acute infection or inflammation of the musculoskeletal 
system [14,15]. 99mTc-HIG scintigraphy appears to be an effective method for monitoring of disease 
activity in patients with rheumatoid arthritis [16]. In addition, 111In-HIG scintigraphy is clinically 
useful in pulmonary infection, particularly in immunocompromized patients [17-20]. In conclusion, 
111In- or 99mTc-HIG scintigraphy can be successfully used in various infectious and inflammatory 
diseases with a diagnostic accuracy comparable to that of radiolabeled leukocytes. When facilities 
for labeling leukocytes are not available or in severely granulocytopenic patients, HIG scintigraphy 
can be an alternative for radiolabeled leukocytes. However, commercial kits are not available, 
impeding its general use in most clinics.
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Liposomes
Liposomes are spheres consisting of one or more lipid bilayers surrounding an aqueous space. 
About 30 years ago they were proposed as vehicles for imaging of infection [21], but the 
preparations used at that time were cleared from the circulation very rapidly by the mononuclear/
phagocyte system. If the surface of the liposomes is coated with a hydrophilic polymer such as 
polyethylene glycol (PEG), however, they circumvent recognition by the mononuclear/phagocyte 
system. This results in a prolonged residence time in the circulation and enhanced uptake at 
pathological sites by extravasation due to locally enhanced vascular permeability [22]. For infection 
imaging these stabilized PEG-liposomes can be labeled with 111In-oxine or with 99mTc either using 
hexamethylpropylene amine oxime (HMPAO) as an internal label or via HYNIC as an external 
chelator. The labeling procedure is simple and takes only minutes [23]. Because of the unfavorable 
characteristics of 111In, labeling with 99mTc is preferred in most cases. In several animal models good 
accuracy of radiolabeled liposomes when compared to 111In-leukocytes was shown [24,25]. In 35 
patients suspected of having infectious or inflammatory disease, sensitivity of imaging with 99mTc-
PEG-liposomes was 94% and specificity was 89% [26]. A subsequent study demonstrated only a 
moderate relation between 99mTc-liposomes scintigraphy and conventional verification procedures 
in nine patients with inflammatory bowel disease [27]. More importantly, this study was prematurely 
terminated because of unacceptable side effects (tightness in chest, mild hyperventilation and 
erythema of the face and upper extremities) in three out of nine patients. Although these studies 
indicate that imaging with 99mTc-PEG-liposomes is an effective and convenient scintigraphic 
method to visualize focal infection and inflammation, the side effects impede further use in 
patients until a new formulation lacking these side effects will be developed. Recent studies have 
provided increased understanding of these adverse reactions and current research is directed at 
developing new liposome formulations without these side effects [28].
Avidin/111In-biotin
Avidins are proteins present in eggs of amphibians, reptiles and birds. Streptavidin is a member 
of the same family and is produced by Streptomyces avinii. Biotin is a compound of low molecular 
weight that can be radiolabeled and that binds to avidin and streptavidin (molecular weight 66 
and 60 kD, respectively) with extremely high affinity (Kd=10
-15 mol/L). Infection imaging with 
avidin/111In-biotin is based on non-specific accumulation of unlabeled avidin or streptavidin at 
sites of inflammation due to locally enhanced vascular permeability. Avidin or streptavidin is 
injected as a pretargeting agent, followed approximately 4 hours later by intravenous injection 
of 111In-biotin. Free 111In-biotin is cleared rapidly via the kidneys with minimal uptake by normal 
tissues [29]. Advantages of this method are a good target-to-background radioactivity ratio and 
early imaging. The alternative use of streptavidin as a pretarget does not improve imaging and it 
is more immunogenic than avidin [29]. One study demonstrated uptake of avidin/111In-biotin in 
Escherichia coli infections in mice comparable to or slightly higher than uptake of 111In-HIG [29]. 
Good diagnostic accuracy has also been demonstrated in humans with vascular infection [30] and 
chronic osteomyelitis [31], especially in the central skeleton and in cases of spondylodiscitis [32].
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Limitations of non-specific radiolabeled compounds in infection/inflammation 
imaging
Although infectious and inflammatory processes can be visualized with radiolabeled compounds 
without a specific interaction between the agent and a tissue component in the inflammatory 
focus, this method has several limitations. Extravasation of molecules via diffusion is a slow 
process requiring prolonged high blood levels to allow for sufficient accumulation in the target 
tissue. High blood levels, however, entail relatively high background levels, especially in well-
perfused tissues. Furthermore, in chronic inflammatory processes the vascular permeability tends 
to normalize. Finally, because non-specific radiolabeled compounds accumulate as a result of a 
common feature of infection and inflammation, these agents cannot distinguish between infection 
and inflammation. It must be emphasized, however, that all radiolabeled compounds accumulate 
to some extent in this non-specific way in inflammatory foci [33]. This mechanism is of particular 
importance in evaluating new radiolabeled compounds, because non-specific accumulation can be 
erroneously interpreted as being specific.
Specific radiolabeled compounds
Imaging of endothelial cell activation
Anti-E-selectin antibodies and antibody fragments
E-selectin is an endothelial adhesion molecule exclusively expressed on the luminal surface of 
activated endothelial cells and capable of binding to different populations of leukocytes. The 
endothelial expression of E-selectin is stimulated by interleukin-1 (IL-1), tumor necrosis factor 
α, and bacterial lipopolysaccharide. A F(ab’)2 antibody fragment, derived from an anti-E-selectin 
monoclonal antibody (Mab) has been synthesized and labeled with 111In. Uptake of 111In-F(ab’)2-
anti-E-selectin was demonstrated in the inflamed joints of patients with rheumatoid arthritis. 
Compared with 111In-HIG, 111In-F(ab’)2-anti-E-selectin provided superior images in these patients 
[34]. Imaging with 111In-F(ab)2-anti-E-selectin also identified areas of inflammation in Crohn’s 
disease and ulcerative colitis, concordant with the results of 99mTc-leucocyte scanning in 14 out 
of 17 patients [35]. More recently, diagnostic accuracy of 99mTc-F(ab’)2-anti-E-selectin proved to be 
comparable to 111In-F(ab’)2-anti-E-selectin and higher than diagnostic accuracy of conventional bone 
scanning in patients with rheumatoid arthritis [36]. Another study showed that imaging with 111In-
anti-E-selectin-Mab is also a sensitive method for assessment of disease activity in patients with 
rheumatoid arthritis and that targeting is more intense and specific than using 99mTc-HIG [37].
IMP-178
Recently, an E-selectin-binding peptide, IMP-178, has been labeled with 99mTc. In a rat model of 
induced pyogenic osteomyelitis, 99mTc-IMP-178 visualized the infection with a moderate target-to-
background ratio and showed a fast clearance from blood and from non-inflamed tissues [38].
22
_____  Chapter 1  ______________________________________________________________________________________________________________ _______________________________________  Radiolabeled compounds in diagnosis of infectious and inflammatory disease  _____ 
23
Anti-intercellular adhesion molecule-1 antibodies
Intercellular adhesion molecule-1 (ICAM-1) is expressed on endothelial cells, but it is strongly 
upregulated during inflammation. In rat models, imaging with 111In-labeled Mab against rat ICAM-1 
correctly detected early acute bleomycin-induced lung injury [39] and acute respiratory distress 
syndrome [40]. 111In-anti-ICAM-1 Mab was characterized by fast blood clearance and by specific 
uptake in inflamed tissues.
Imaging of infiltrating granulocytes
Radiolabeled leukocytes
Imaging using ex vivo labeled autologous leukocytes was developed in the 1970s. A blood sample 
of approximately 50 ml is collected and leukocytes are separated in vitro from red blood cells. 
These leukocytes are then labeled with radioactive isotopes (111In or 99mTc) and reinjected. Using 
standard labeling procedures, only a few granulocytes are damaged by labeling, whereas most 
lymphocytes are damaged. The damaged cells are rapidly cleared from the circulation after 
reinjection [41]. After intravenous administration, the radiolabeled leukocytes initially sequestrate 
in the lungs with subsequent rapid clearance from the lungs. The radiolabel rapidly clears from 
the blood and in most cases uptake in granulocytic infiltrates is high while a substantial portion of 
the leukocytes accumulate in the spleen and the liver. Autologous leukocytes can be labeled with 
111In using oxine [42]. The use of HMPAO, a lipophilic chelator, allows for efficient labeling of white 
blood cells with 99mTc [43]. In contrast to 111In-oxine, some of the 99mTc-HMPAO is released from the 
leukocytes after injection and subsequently is excreted via the kidneys (within minutes) and the 
hepatobiliary system (after several hours) [44]. 99mTc-labeled leukocytes have replaced 111In-labeled 
leukocytes for most indications, because of the more optimal radiation characteristics. As a result 
of the biodistribution of 99mTc-HMPAO-labeled leukocytes, the use of 111In-labeled leukocytes is 
preferred for evaluation of the kidneys, bladder and gall bladder. 111In-labeled leukocytes are also 
preferred if late images are needed as in chronic infection [44]. With regard to diagnostic accuracy, 
there is no need for a better imaging agent than radiolabeled leukocytes. The preparation of this 
radiopharmaceutical, however, is laborious: isolating and labeling a patient’s white blood cells 
takes a trained technician approximately 3 hours. In addition, the need to handle potentially 
contaminated blood can result in transmission of blood-borne pathogens such as hepatitis virus and 
human immunodeficiency virus to technicians or patients [45,46]. The principal clinical indications 
for radiolabeled leukocytes include inflammatory bowel disease, osteomyelitis, the follow-up of 
patients with infections of vascular or orthopedic prostheses and soft tissue infections [44,47,48]. 
There has always been concern that chronic infections could be missed by labeled leukocyte scans, 
because these infections generate a smaller granulocyte response than acute infections. However, 
a study in 155 patients demonstrated that sensitivity of labeled leukocytes for detection of acute 
infections (90%) was not significantly different from sensitivity for detection of chronic infections 
(86%) [49].
Anti-granulocyte antibodies and antibody fragments
Ever since it became clear that infectious and inflammatory foci could be visualized by radiolabeled 
autologous leukocytes, investigators have tried to develop a method aiming to label white blood 
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cells in vivo. The use of radiolabeled monoclonal antibodies against surface antigens present on 
granulocytes has the advantage that labeling procedures are easier and do not require handling of 
potentially contaminated blood. Disadvantages of the use of Mab, however, are the high molecular 
weight, resulting in slow diffusion into sites of inflammation, a long plasma half-life, and uptake 
in the liver due to clearance by the reticulo-endothelial system. A long interval is often required 
between administration of radiolabeled antibodies and acquisition of images in order to improve 
target-to-background ratios. Use of Mab of murine origin sometimes induces production of human 
antimouse antibodies (HAMA), which can lead to allergic reactions and altered pharmacokinetics 
when repeated injections are given [50]. This is, of course, a major limitation for follow-up studies. 
The use of antibody fragments (Fab’ or F(ab’)2) or humanization of the antibodies could overcome 
most of these limitations: theoretically, immunogenicity is lower, blood clearance is faster and 
accumulation in inflammatory foci is higher. Moreover, since Fab’ antibody fragments have an 
intrinsic lower affinity for the epitope, bone marrow uptake is lower, which is an advantage for 
imaging of infections of the central skeleton. Although radiolabeled anti-granulocyte antibodies 
and antibody fragments are included among radiolabeled compounds for specific targeting 
of infiltrating granulocytes, recent studies have demonstrated that they localize in infectious 
processes to a large extent by non-specific extravasation due to locally enhanced vascular 
permeability [51,52]. Binding of the antibodies to infiltrating leukocytes may contribute to the 
retention of the radiolabel in the inflammatory focus.
Anti-non-specific-cross-reacting antigen-95. One of the most widely used anti-granulocyte antibodies 
is the commercially available murine anti-NCA-95 IgG (BW 250/183), labeled with 99mTc, which 
recognizes the non-specific cross-reacting antigen 95 (NCA-95) expressed on human granulocytes 
and (pro)myelocytes. This Mab has been used successfully for imaging of various infectious and 
inflammatory processes [53-55] including subacute infectious endocarditis [56], lung abscesses [57], 
septic loosening of hip and knee prostheses [58,59] and diabetic foot infections [60]. Peripheral 
bone infections were also adequately visualized [57,61], but sensitivity decreased in case the focus 
was located closer to the spine because of physiological bone marrow uptake, so imaging with 
99mTc-anti-NCA-95 is less suitable for diagnosing vertebral osteomyelitis [62]. Pulmonary infections 
other than abscesses were not visualized [57,63]. 99mTc-anti-NCA-95 scanning appeared to be a safe 
and reliable method for detecting infectious foci in neonates and infants with fever of unknown 
origin [64]. The preparation was also used in the evaluation of patients with inflammatory bowel 
disease, but it appeared to be less accurate than radiolabeled leukocytes partly due to non-specific 
bowel uptake [65-67]. Due to the relatively slow blood clearance, imaging 24 hours after injection 
is generally necessary for correct localization of the inflammatory process. The major drawback of 
radiolabeled anti-NCA-95, however, is the production of HAMA after the first injection.
Anti-stage specific embryonic antigen-1. Another Mab, anti-stage specific embryonic antigen-1 (anti-
SSEA-1) IgM (LeuTech®), recognizes CD15 antigens on granulocytes with high affinity (Kd=10
-11 
mol/L). The in vivo binding exceeds 50%, suggesting involvement of more specific accumulation in 
inflammatory sites, such as in vivo migration of leukocytes from the circulation to the focus [68]. 
99mTc-anti-SSEA-1 IgM was successfully used in patients with various inflammatory and infectious 
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diseases, such as osteomyelitis, diabetic foot ulcers and post-surgical infection [69-72] with 
similar diagnostic accuracy when compared to radiolabeled leukocytes [70]. Imaging with 99mTc-
anti-SSEA-1 IgM also proved to be a highly sensitive test for detection of appendicitis in equivocal 
cases [72-74]. Presently, 99mTc-anti-SSEA-1 IgM is being evaluated for early detection of inhalation 
anthrax [72]. 99mTc-anti-SSEA-1 IgM is a convenient radiolabeled compound (imaging after 1 hour, 
easy preparation) and no HAMA production has been found. Disadvantages are high liver uptake 
and transient mild neutropenia that has been observed after 99mTc-anti-SSEA-1 injection in several 
patients. This adverse effect can also be caused by other Mabs as well as some cytokines. In most 
cases, however, this does not represent a clinical problem and does not impair image quality [75].
Anti-non-specific-cross-reacting antigen-90 Fab’. 99mTc-labeled anti-NCA-90 Fab’ (sulesomab, LeukoScan®), 
which binds to NCA-90 surface antigen on granulocytes, is a commercially available infection 
imaging agent. Promising results have been obtained in the scintigraphic detection of endocarditis 
[76] and nonclassic appendicitis [77]. Scintigraphy using 99mTc-anti-NCA-90 Fab’ also helped 
reach a final diagnosis in 8 out of 20 patients with FUO [78]. 99mTc-anti-NCA-90 Fab’ proved to 
be no alternative for radiolabeled leukocytes in patients with inflammatory bowel disease due 
to limited sensitivity [79,80]. Also, non-specific bowel activity is often present, especially in the 
delayed images [81]. At first, scintigraphy using 99mTc-anti-NCA-90 Fab’ appeared to provide rapid 
localization of bone and soft tissue infections with a negligible HAMA response rate and accuracy 
comparable to that of leukocyte scanning [82-85]. In other studies, however, 99mTc-anti-NCA-90 
Fab’ scintigraphy was found to be less specific for the diagnosis of musculoskeletal infections than 
leukocyte scanning [86-89]. In addition, false-negative results were found in several patients with 
chronic infections [89]. These studies suggest that 99mTc-anti-NCA-90 Fab’ scintigraphy could be 
used for imaging of acute orthopedic infections, with its greatest strength being a high negative 
predictive value. Positive studies may require further correlative imaging.
Chemotactic peptides
A wide variety of peptides that bind to receptors expressed on leukocytes have been tested for 
the detection of infections. One of the first receptor-binding peptides that was tested for this 
purpose was formyl-methionyl-leucyl-phenylalanyl (f-Met-Leu-Phe or fMLP), a small chemotactic 
peptide produced by bacteria, which binds to receptors on granulocytes and monocytes with high 
affinity (Kd=1-3 x 10
-9 mol/L). Radiolabeled f-Met-Leu-Phe and synthetic analogues of this peptide 
showed a high target-to-background ratio and rapid clearance from blood and noninflamed tissue 
in experimental animal models. The majority of the accumulation of 99mTc-f-Met-Leu-Phe at sites of 
infection appears to be receptor mediated [90]. In rabbits with sterile inflammation and Escherichia 
coli and Staphylococcus aureus infections, it was demonstrated that localization of infection using 
99mTc-labeled f-Met-Leu-Phe-analogues was possible and appeared to be superior to 111In-labeled 
leukocytes [91-93]. In a rat model of pancreatitis, uptake of a 99mTc-labeled f-Met-Leu-Phe-analogue 
correlated with the presence of granulocyte sequestration assessed by myeloperoxidase activity 
and histology [94]. Despite radiolabeling at high specific activity, a peptide dose as low as 10 
ng/kg still caused transient mild granulocytopenia in Rhesus monkeys [95]. Several antagonists 
lacking biological activity were developed to circumvent this undesirable biological effect of the 
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radiolabeled peptide [90]. However, these antagonists had lower uptake in the infectious focus, 
most likely due to reduced affinity for the receptor [96]. In conclusion, rapid imaging of infection 
and inflammation with radiolabeled chemotactic peptides is feasible, but the side effects of these 
peptides seem to impede further clinical development.
Cytokines
Cytokines are (glyco)proteins acting via interaction with specific cell surface receptors expressed 
mainly on leukocytes, but also on other cell types. Cytokine receptors are usually expressed at low 
levels on resting cells, but their expression is upregulated during activation. Cytokines potentially 
can be used to specifically target leukocytes in vivo, because they bind to specific receptors 
with high affinity in the nanomolar range, they have low molecular weights (<25 kD) and plasma 
clearance is rapid. Finally, many cytokines are of human origin and are therefore readily available 
and supposedly non-immunogenic. 
Interleukin-1 and interleukin-1-receptor antagonist. IL-1 is an important pro-inflammatory cytokine, 
which binds with high affinity to a specific receptor, mainly expressed on granulocytes, monocytes 
and lymphocytes. Studies in mice and rabbits with focal S. aureus infection demonstrated specific 
uptake of radio-iodinated IL-1 at the site of infection [97,98]. Using IL-1 receptor blocking antibodies, 
it could be shown that accumulation of radio-iodinated IL-1 in the inflammatory focus was mainly 
due to binding to the IL-1 type II receptor [99]. Unfortunately, side effects (e.g. hypotension, 
headache) due to the biological activity of IL-1, even at very low doses of 10 ng/kg, precluded 
clinical application of radiolabeled IL-1. Therefore, attention was focused on the naturally occurring 
IL-1 receptor antagonist (IL-1ra). This equally sized protein (17 kD) binds IL-1 receptors with similar 
affinity but lacks biological activity. Doses of up to 10 mg/kg could be safely administered to 
humans without any side effects [100]. In a comparative study in rabbits with E. coli infections, 
the abscess uptake of radio-iodinated IL-1ra was lower than that of radio-iodinated IL-1 [98,101]. 
In patients with rheumatoid arthritis, inflamed joints could be visualized within a few hours after 
injection of 123I-IL-1ra. However, major retention of the radiolabel in the intestinal tract in humans 
indicated that this agent cannot be used to visualize abdominal lesions [102].
Interleukin-8. Interleukin-8 (IL-8) is a small protein (8.5 kD) belonging to the CXC subfamily of 
chemokines or chemotactic cytokines, in which the first two cysteines are separated by one 
amino acid. IL-8 binds with high affinity (0.3-4 x 10-9 mol/L) to two different receptors (CXCR1 and 
CXCR2) expressed on granulocytes and promotes chemotaxis of these cells. In rats with sterile 
inflammation, uptake of radio-iodinated IL-8 peaked at 1 to 3 hours after injection and subsequently 
declined with relatively low target-to-background ratios [103]. In a pilot study in eight patients, the 
same investigators showed that 123I-IL-8 could visualize osteomyelitis and cellulitis correctly [104]. In 
these studies IL-8 was labeled using the chloramine T method. Despite similar in vitro cell binding 
characteristics, the labeling method proved to have major effects on the in vivo biodistribution of 
radio-iodinated IL-8. The scintigraphic imaging characteristics of IL-8 labeled via the Bolton-Hunter 
method were clearly superior to those of IL-8 labeled via the iodogen method [105]. In rabbits with 
E. coli infection, accumulation of 123I-IL-8 in the abscess was rapid and high. The specific activity 
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of the 123I-IL-8 preparation was relatively low and as a result an imaging dose of 25 µg/kg of IL-8 
was needed, resulting in transient granulocytopenia followed by granulocytosis for several hours 
[105]. Recently, a 99mTc-labeled IL-8 preparation was developed using HYNIC as a chelator resulting 
in a significantly higher specific activity. The labeling of IL-8 with 99mTc using HYNIC was further 
optimized by the use of alternative coligands (nicotinic acid and tricine) to stabilize the 99mTc-
protein-complex [106]. Protein doses to be administered were lowered substantially due to much 
higher specific activity of this new 99mTc-IL-8 preparation ameliorating concerns about the influence 
on leukocyte counts when this preparation will be tested in patients in the future. In rabbits with 
E. coli infections, high abscess uptake of 99mTc-IL-8 and high abscess-to-background ratios were 
obtained [107]. 99mTc-IL-8 has also been successfully used in rabbit models of osteomyelitis [108] and 
colitis [109]. Studies in neutropenic and normal rabbits with turpentine-induced abscesses have 
shown that accumulation of 99mTc-IL-8 in the abscess is a highly specific, neutrophil-driven process 
and that the total fraction of 99mTc-IL-8 that accumulates in the inflamed tissue is extremely high (up 
to >15% of injected dose) [110]. 
Platelet factor 4 derivative. Platelet factor 4 (PF-4), like IL-8, is a member of the CXC subfamily. 
PF-4 binds to receptors expressed on granulocytes and monocytes. A synthetic peptide, P483H, 
containing the heparin-binding region of PF-4, complexed with heparin to increase binding to 
leukocytes and containing a lysine-rich sequence to facilitate rapid renal clearance, has been 
labeled with 99mTc. In a rabbit model of E. coli infection, 99mTc-P483H clearly delineated the infectious 
foci as early as 4 hours after injection. No systemic side effects were observed [111]. In a study of 30 
patients with various infections, 99mTc-P483H safely, rapidly and accurately detected focal infection. 
Results were comparable to radiolabeled leukocyte imaging [112]. 
Complement factors
The complement factor C5a and its natural metabolite C5a-des-Arg are involved in several stages of 
the inflammatory process. C5a-des-Arg only differs from C5a by the absence of the C-terminal Arg-
residue of C5a. Both act on a common receptor on different cell types, including neutrophils and 
monocytes. The receptor binding affinity of C5a is one or two orders of magnitude higher than the 
affinity of C5a-des-Arg. The biologic activity of C5a-des Arg is considerably lower than that of C5a. 
In a rabbit model of E. coli induced intramuscular infection, 99mTc-C5a could rapidly visualize the 
infection with high uptake of the radiolabel in the affected muscle while uptake of 99mTc-C5a-des-
Arg in the abscess was low [113]. The ideal combination of reduced biologic activity and preferable 
imaging characteristics was, thus, not found in C5a-des-Arg.
Leukotriene B4-antagonists
RP517. Leukotriene B4 (LTB4) is a potent chemoattractant that activates granulocytes and 
macrophages. It is considered an important mediator in both acute and chronic inflammatory 
diseases. LTB4 binds to receptors abundantly expressed on granulocytes after an inflammatory 
stimulus. In search for an effective infection-imaging agent, the LTB4 receptor antagonist RP517 
was synthesized. In rabbits with E. coli infections, 99mTc-RP517 rapidly visualized the abscesses 
with high abscess-to-background ratios [114]. 99mTc-RP517 was also successfully used in dogs with 
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experimental myocardial inflammation [115]. The disadvantage of 99mTc-RP517, however, is its 
hepatobiliary clearance, causing high uptake in the organs of the digestive tract relatively early 
after the injection, which limits its applicability as an infection-imaging agent [114]. 
DPC11870-11. Recently, a new hydrophilic LTB4-antagonist with a comparable receptor binding 
affinity, DPC11870-11 was developed and labeled with 111In. In rabbits with intramuscular E. coli 
infection, 111In-DPC11870-11 rapidly revealed the infection with high abscess-to-background ratios. 
No accumulation of radioactivity was observed in the gastrointestinal tract. Blocking experiments 
with an excess of the nonradiolabeled agent showed a specific receptor-ligand interaction of 111In-
DPC11870-11 [116].
Human neutrophil elastase inhibitor
Human neutrophil elastase inhibitor (EPI-HNE-2) is a peptide with a low molecular weight that 
binds to neutrophil elastase released in inflammatory sites by activated neutrophils. After labeling 
with 99mTc, human neutrophil elastase inhibitor accumulated specifically in inflammatory lesions 
in a monkey model and provided early images with good diagnostic quality. Plasma clearance was 
rapid and there were no side effects [117].
Imaging of infiltrating mononuclear cells
Cytokines
Interleukin-2. IL-2 is a glycoprotein with a molecular weight of 15.5 kD, which is synthesized and 
secreted by T-lymphocytes after specific antigen stimulation. During inflammation, activated 
lymphocytes express high-affinity IL-2 receptors and become a target for radiolabeled IL-2. IL-2 has 
been labeled with 123I and 99mTc to enable imaging of chronic infection or inflammation. In several 
rat models of autoimmune diabetes and in rats with renal allografts, 123I-IL-2 adequately detected 
areas of lymphocytic infiltration. Specific accumulation of 123I-IL-2 has been confirmed by ex vivo 
autoradiography [118-120]. 123I-IL-2 has also been used successfully in patients with type 1 diabetes 
[121]. 99mTc-IL-2 was able to identify a subgroup of patients with type 1 diabetes with persistent 
inflammation at the time of diagnosis that might benefit from the use of immunomodulating 
drugs to preserve β cell function [122]. In patients with active Crohn’s disease, 123I-IL-2 allowed 
imaging of activated T-lymphocytes infiltrating the gut wall. The uptake of 123I-IL-2 decreased after 
corticosteroid therapy, so this technique could be valuable in monitoring the effect of therapy 
[123]. Scintigraphic results using 123I-IL-2 in patients with celiac disease was consistent with the 
histologically determined number of infiltrating IL-2 receptor-positive cells in the jejunal mucosa 
[124]. 99mTc-IL-2 also strongly accumulates in the thyroid glands of patients with Hashimoto’s 
thyroiditis and Grave’s disease [125]. No side effects were observed. These results suggest that 
radiolabeled IL-2 could be a suitable radiopharmaceutical for in vivo targeting of mononuclear cell 
infiltration as present in several autoimmune diseases.
Monocyte chemoattractant protein 1. The chemotactic cytokine monocyte chemoattractant protein 
1 (MCP-1), a monomeric polypeptide, is involved in the recruitment of monocytes that express its 
specific receptor (CCR2B). 125I-MCP-1 showed rapid blood clearance in normal mice and in rabbits 
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with experimental arterial lesions. The uptake of 125I-MCP-1 in damaged artery walls was higher than 
in normal vessels and correlated well with the histologically determined number of macrophages 
[126]. 99mTc-labeled MCP-1 localized preferentially in subacute inflammation in a rat model of sterile 
subacute and chronic turpentine-induced inflammation, reflecting the density of macrophages 
[127]. In the characterization of subacute inflammation, radiolabeled MCP-1 may prove to be useful 
by in vivo targeting of monocytes and macrophages.
RP128
Tuftsin is a chemotactic tetrapeptide derived from the Fc portion of IgG, which promotes 
chemotaxis and phagocytosis of neutrophils, monocytes and macrophages by binding to the 
tuftsinreceptor. RP128 is a bifunctional peptide chelate designed to target this receptor. The ability 
of 99mTc-RP128 to detect central nervous system (CNS) inflammation was shown in experimental 
allergic encephalomyelitis, an animal model of multiple sclerosis. In addition, 99mTc-RP128 
successfully monitored glucocorticoid suppression of inflammation, recording a typical dose-
response to increasing steroid concentration [128]. In 10 patients with long-standing rheumatoid 
arthritis, 99mTc-RP128 was able to visualize clinically affected joints [129]. 
J001X
J001X is a non-pyrogenic acylated polygalactoside isolated from the membrane proteoglycans of 
a non-pathogenic strain of Klebsiella pneumoniae. J001X interacts with macrophages, mainly in the 
activated state, by binding to CD11b, the complement receptor 3 expressed on monocytes, natural 
killer cells and macrophages, and to CD14, the lipopolysaccharide receptor expressed on monocytes 
and macrophages. 99mTc-J001X has been used for the detection of alveolitis and inflamed lymph 
nodes in experimental chronic berilliosis in baboons [130], radiation-induced inflammatory lesions 
in pigs [131] and arthritis in a rabbit model [132,133]. In humans, 99mTc-J001X scintigraphy appeared 
to be a sensitive and rapid technique for imaging of sarcoidosis [134]. 99mTc-J001X was also able to 
visualize active pulmonary involvement in patients with scleroderma [135] and rheumatoid arthritis 
[136]. In the patients with rheumatoid arthritis, however, sensitivity was low compared with high-
resolution CT, pulmonary function tests and bronchoalveolar lavage [136]. 
Anti CD4 IgG
The abundance of CD4 molecules on inflammatory cells in the synovial membrane renders anti-
CD4 monoclonal antibodies or their fragments potentially useful for specific imaging of arthritis. 
Following intravenous injection, Mabs are present both in the free form and bound to CD4-positive, 
circulating monocytes and T-cells. In a rat model of experimental arthritis, specific accumulation of 
99mTc-labeled anti-rat CD4 Mab and 99mTc-anti-CD4-Fab’ was shown in the affected joints [137,138]. 
In patients with rheumatoid arthritis, scintigraphy with 99mTc-anti-human CD4 Mab demonstrated 
higher target-to-background ratios in arthritic joints in comparison to HIG [139] . Recently, however, 
it was shown that the overall contribution of cell-bound Mabs to the imaging of arthritic joints with 
anti-CD4 Mabs is minimal [140].
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Imaging of enhanced glucose uptake: FDG
FDG accumulates in tissues with a high rate of glycolysis, which not exclusively occurs in neoplastic 
cells. FDG-uptake is present in all activated leukocytes (granulocytes, monocytes as well as 
lymphocytes) enabling imaging of acute and chronic inflammatory processes. The mechanism 
of FDG-uptake in activated leukocytes is related to the fact that these cells use glucose as an 
energy source only after activation during the metabolic burst. FDG, like glucose, passes the cell 
membrane. Phosphorylated FDG is not further metabolized and remains trapped inside the cell 
in contrast to phosphorylated glucose that enters the glycolytic pathway. 18F is a positron-emitting 
radionuclide with a physical half-life of 110 minutes. After annihilation of a positron with an 
electron, two 180o-opposed gamma rays are emitted simultaneously, which can subsequently be 
detected by a PET camera. Increased uptake and retention of FDG has been shown in lesions with 
a high concentration of inflammatory cells, such as granulocytes and activated macrophages [2]. 
In an experimental rat model of turpentine-induced inflammation, FDG-uptake was elevated even 
more in chronic inflammation than in an acute inflammatory process [141]. In another rat model 
of E. coli infection, FDG-uptake in the infectious process was higher than uptake of 67Ga-citrate, 
radiolabeled thymidine, methionine and human serum albumin [142]. Since the first report on 
high FDG-uptake in a human abdominal abscess [143], there have been many reports of FDG-
accumulation in different infections and inflammatory lesions [144,145].
Fever of unknown origin
In several studies, the percentage of FDG-PET scans helpful in the diagnostic process in patients 
with FUO varied from 37% to 69% [146-149], which is very high compared to radiological techniques 
and 67Ga-citrate scintigraphy. Although comparing these studies is difficult, because FDG-PET was 
performed at different stages of the diagnostic process, no structured diagnostic protocol was 
used and the patient characteristics differed, FDG-PET appears to be a valuable new imaging 
technique in these patients. The impossibility to differentiate between malignancy and infection 
or inflammation appears to be an advantage rather than a drawback in the investigation of patients 
with FUO. Another major advantage of FDG-PET in the work-up of patients with FUO is the vascular 
FDG-uptake in patients with vasculitis [150-152]. In a direct comparison between FDG-PET and 67Ga-
citrate scintigraphy in patients with FUO, FDG-PET proved to be superior [146,147]. Based on the 
results of these studies and resulting from the favorable characteristics of FDG-PET, conventional 
scintigraphic techniques may be replaced by FDG-PET in the investigation of patients with FUO in 
institutions where this technique is available. However, for a final validation of FDG-PET in patients 
with FUO and for determination of its exact position in the order of diagnostic tests, a larger 
prospective study of FDG-PET being part of a structured diagnostic protocol is warranted. 
Osteomyelitis and spondylodiscitis
FDG-PET has been used successfully in diagnosing acute osteomyelitis [153,154], but it has no 
added value to physical examination, laboratory results, three-phase bone scanning and MRI in 
the absence of complicating factors. The diagnosis of chronic osteomyelitis is more complex. In 
patients with chronic osteomyelitis, excellent accuracy and interobserver agreement was found for 
FDG-PET comparable to scintigraphy with antigranulocyte antibodies and 111In-labeled leukocytes 
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[153,155-159]. In the central skeleton, accuracy of FDG-PET was even higher than for antigranulocyte 
antibody scintigraphy [155]. The usefulness of antigranulocyte antibody or radiolabeled leukocyte 
scintigraphy is low in the central skeleton due to physiological uptake in normal bone marrow. 
In several studies, FDG-PET enabled correct visualization of spondylodiscitis [160-162]. FDG-PET 
proved to be superior to MRI, 67Ga-citrate scintigraphy and three phase bone scan in these patients 
[160,162]. FDG-PET was also able to differentiate between mild infection and degenerative changes 
[162]. PET images are not disturbed by the presence of metallic implants, which is a major advantage 
when compared to CT and MRI. In addition, FDG-PET is a very sensitive tool even for chronic and 
low-grade infections. In conclusion, FDG-PET is very useful in cases of suspected osteomyelitis of 
the central skeleton, spondylodiscitis or chronic low-grade infections of the peripheral skeleton. 
Prosthetic joint infection
Diagnosing prosthetic joint infection is very difficult, because radiographic methods and three-
phase bone scanning cannot differentiate adequately between septic and aseptic loosening. FDG-
PET is very sensitive in detecting infected joint prostheses, but specificity varies from 47 to 73% 
[163-167]. This limited specificity probably results from persisting FDG-uptake around the prosthesis 
for many years after arthroplasty, even in uncomplicated cases [163,167]. Location of FDG-uptake 
is probably important since FDG-uptake along the interface between bone and prosthesis appears 
to be more specific for infection [159,168]. However, FDG-PET should not be routinely used for 
this indication in a clinical setting until the criteria for differentiation between septic and aseptic 
loosening are more clearly defined.
Miscellaneous infectious diseases
FDG-PET seemed to have higher sensitivity in detecting blood vessel graft infection than 
conventional imaging techniques in a small number of patients [159,169]. In children with chronic 
granulomatous disease, a primary immunodeficiency leading to granuloma formation and 
numerous infections, FDG-PET was able to differentiate active infected lesions from chronic 
granuloma [170]. In patients with Echinococcosis, a serious parasitic infection, FDG-PET correctly 
identified the active lesions and appeared to be helpful in assessing response to treatment [171]. 
Recently, successful use of FDG-PET in detection of infected liver and renal cysts in patients with 
autosomal dominant polycystic kidney disease was reported [172]. FDG-PET also appears to be 
a promising imaging technique in the early detection of complications and for the differential 
diagnosis of central nervous system lesions in patients with HIV or AIDS [173,174]. A possible 
pitfall of FDG-PET in these patients, however, is the difficulty in differentiating between persisting 
generalized lymphadenopathy and lymphoma.
Vasculitis
Increased FDG-uptake has been found in patients with giant cell arteritis [175,176], Takayasu 
arteritis [147,177,178], periaortitis due to Wegener’s granulomatosis, and unspecified large vessel 
vasculitis [152,179-182]. In a prospective study, vascular FDG-uptake was seen in 76% of 25 patients 
with biopsy-proven temporal arteritis or polymyalgia rheumatica [150]. In 15 patients with aortitis 
due to giant cell arteritis (n=14) or Takayasu arteritis (n=1) at the time of diagnosis and during 
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follow-up (n=7), FDG-PET identified more vascular regions involved in the inflammatory process 
when compared to MRI [178]. In conclusion, FDG-PET appears to be useful for diagnosing and 
determining the extent of various types of vasculitis. Furthermore, FDG-PET could become a useful 
tool for evaluating the effect of treatment.
Inflammatory bowel disease
High FDG-uptake has been reported in areas with inflammation in patients with inflammatory 
bowel disease [183-185]. Specificity of FDG-PET was comparable to MRI and antigranulocyte 
antibody scintigraphy in 59 patients with Crohn’s disease, but sensitivity of FDG-PET was 
significantly higher [185]. FDG-PET also correctly detected histologically confirmed eosinophilic 
colitis, collagenous colitis and bacterial colitis in a small number of patients [186]. FDG-PET could 
become a useful tool to detect disease activity in the terminal ileum and colon in patients with 
inflammatory bowel disease, but physiological, non-specific bowel uptake could be an important 
problem in clinical practice. More data are needed to justify routine application of PET in the 
management of inflammatory bowel disease.
Sarcoidosis and rheumatoid arthritis
In several patients with sarcoidosis, FDG-uptake in hilar and mediastinal lymph nodes and erythema 
nodosum has been described [187,188]. FDG-uptake levels appeared to reflect disease activity [188]. 
FDG-PET does not have a major role in the initial diagnosis of sarcoidosis, because conventional 
diagnostic techniques are very well able to establish this diagnosis in most cases. FDG-PET may 
prove to be useful in evaluating response to treatment, but larger prospective studies are needed 
to define the role of FDG-PET in these patients. In patients with rheumatoid arthritis, FDG-PET 
allowed quantification of metabolic changes in joint inflammation comparable to volumetric 
changes visualized with MRI, but FDG-uptake was not associated with treatment outcome [189].
Imaging the presence of micro-organisms
Ciprofloxacin
Ciprofloxacin is a fluoroquinolone that binds to bacterial DNA gyrase, which is present in all 
dividing bacteria. Since it binds only to living bacteria, even to most bacteria that are resistant 
to this antibiotic, the use of 99mTc-labeled ciprofloxacin (Infecton®) theoretically allows distinction 
between sterile inflammation and infection. 99mTc-ciprofloxacin is mainly excreted via the kidneys, it 
has low liver metabolism and bowel uptake is usually very low [190]. The lack of bone marrow uptake 
is particularly useful for the detection of bone infections. In patients with known or suspected sites 
of various bacterial infections, sensitivity of scintigraphy with 99mTc-ciprofloxacin varied from 70 to 
85% and specificity was 82 to 96% [191-194]. Comparison between 99mTc-ciprofloxacin and leukocyte 
imaging gave comparable sensitivities and specificity was 96% and 77%, respectively [191]. 99mTc-
ciprofloxacin was shown to be a very sensitive and quite specific marker of bone and joint infections 
[195-197]: sensitivity of 99mTc-ciprofloxacin imaging was higher when compared to scintigraphy with 
99mTc-HMPAO-leukocytes [195] and three-phase bone scanning in combination with 67Ga-citrate 
scintigraphy [196]. 99mTc-ciprofloxacin has also been used successfully in patients with suspected 
infections of hip or knee prostheses [198,199]. In addition, 99mTc-ciprofloxacin imaging appeared 
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to be useful in the diagnosis and follow-up of pelvic inflammatory disease [200]. Lately, the 
specificity of 99mTc-ciprofloxacin has been discussed extensively [201]. In one study, results of 
99mTc-ciprofloxacin imaging in rabbits suggested good sensitivity but lack of specificity for the 
detection of S. aureus infection of knee prostheses [202]. In patients with suspected osteoarticular 
infections and patients with osteoarticular diseases without signs of infection, 99mTc-ciprofloxacin 
scintigraphy did not discriminate between infected and aseptic osteoarticular diseases [203]. In 
a retrospective study in patients suspected of osteoarticular infections and controls with joint 
complaints without signs of infection, low specificity of 99mTc-ciprofloxacin scintigraphy was found. 
Evaluation of tracer uptake at late imaging did not improve discrimination between sterile and non-
sterile inflammation. Additionally, articular uptake was seen in many control patients [204]. 
Fluconazole
More recently, the antifungal drug fluconazole, which binds to fungal cytochrome P450, has been 
labeled with 99mTc. In mouse models, 99mTc-fluconazole rapidly detected Candida albicans and 
Aspergillus fumigatus infections without visualizing bacterial infections or sterile inflammatory 
processes [205]. Biodistribution studies with 18F-fluconazole in a rabbit model of infection, however, 
suggested non-specific uptake in the infection due to increased vascular permeability [206].
Antimicrobial peptides
Various natural and synthetic antimicrobial peptides have been investigated for specific imaging 
of bacterial infections. Neutrophil defensins or human neutrophil peptides (HNPs) are stored in 
the granules of neutrophils. In addition to their direct antimicrobial activity, these peptides have 
chemo-attractive activity for monocytes and lymphocytes. Use of 99mTc-HNP-1 in experimental 
thigh infections in mice resulted in low abscess-to-background ratios that decreased even further 
with time [207,208]. In these models, 99mTc-HNP-1 was shown to bind to bacteria rather than to 
leukocytes, but this agent still needs extensive optimization to enable reliable distinction between 
bacterial infection and sterile inflammation. Human antimicrobial peptide ubiquicidin (UBI) and 
human lactoferrin also bind to micro-organisms and have chemoattractive activity for monocytes 
and lymphocytes. 99mTc-labeled UBI 29-41 (residues 29–41 of ubiquicidin) and UBI 18-35 (residues 
18–35 of ubiquicidin) do not accumulate in sterile inflammation and lack immunological adverse 
effects [209]. In animal models of bacterial and fungal infection, 99mTc-labeled fragments of UBI 
29-41 and UBI 18-35 have better in vitro and in vivo behavior than human lactoferrin and defensin, 
showing higher binding activity to bacteria than to activated leukocytes [209-211].
Conclusions
Scintigraphy using autologous leukocytes, labeled with 111In or 99mTc, is still considered the ”gold 
standard” nuclear medicine technique for the imaging of infection and inflammation, but the range 
of radiolabeled compounds available for this indication is expanding rapidly. A gradual shift from 
basic, non-specific, cumbersome and even hazardous techniques to more intelligent approaches, 
based on small agents binding to their targets with high affinity, is ongoing. In general, the lower 
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molecular weight should also lead to enhanced blood clearance reducing blood pool activity. 
New agents should also obviate the need to handle blood as this presents potential hazards of 
transmission of hepatitis virus or human immunodeficiency virus to both patients and medical 
personnel. Radiolabeled compounds are being designed enabling specific distinction between 
infection and non-infectious inflammatory disease and between acute and chronic processes. 
The ideal agent will thus be determined by the clinical situation. The advantages of 99mTc as a 
radionuclide will be fully explored. Labeling with high specific activity will reduce the doses 
used resulting in less undesirable agonistic activities. Undesirable agonistic activities will also 
be alleviated by chemical modification of the agonist. Furthermore, FDG-PET may prove to be as 
useful in the rapid detection and management of infectious and inflammatory diseases as it is in 
the management of malignant diseases.
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Introduction
Vasculitis is a serious condition characterized by inflammation and necrosis of the blood vessel 
walls. Early and accurate assessment is important for successful management; however, diagnosis 
can be complicated by the absence of specific symptoms and signs, the limited specificity of 
biochemical tests, and the limitations of conventional imaging techniques in detecting frequently 
subtle vessel abnormalities. Although the American College of Rheumatology 1990 criteria for the 
classification of vasculitis (ACR criteria) are considered the gold standard for diagnosing vasculitis 
[1-11], diagnosis and assessment of the extent and location of the disease is often difficult or 
sometimes impossible. In a study of 198 patients suspected of vasculitis, these criteria were not 
effective in diagnosing specific types of vasculitis [12]. 
Imaging techniques are used in types of vasculitis in which it is difficult to obtain histological 
proof and may also be used to guide selection of a site for biopsy. In addition, a noninvasive tool 
to evaluate the effect of treatment during follow-up is warranted. In this respect, it would be more 
helpful to evaluate metabolic activity in the vessel wall. For this purpose, 18F-fluorodeoxyglucose 
(FDG) positron emission tomography (PET) is a promising new imaging technique. FDG accumulates 
in cells with a high rate of glycolysis [13], a metabolic process that is present in neoplastic cells and 
activated leukocytes. Lesions with a high concentration of inflammatory cells, such as granulocytes 
and activated macrophages, show increased uptake and retention of FDG [14,15]. Furthermore, FDG 
is cleared very rapidly from almost all other sites of the body, including the blood compartment. In 
this report, we describe the use of FDG-PET in the diagnosis and management of vasculitis in three 
patients who had different types of the disease, as well as review the literature to date.
Case Reports
Patient A was a 66-year-old man with a history of recurrent erythema nodosum since 1991. The 
results of a deep skin biopsy showed vasculitis of the small and medium arteries. Fatigue, weight 
loss, and recurrent arthralgias and myalgias were noted, in addition to an elevated erythrocyte 
sedimentation rate of 110 mm/h (normal, 1 to 5 mm/h), microcytic anemia, and an episode of 
iridocyclitis. The diagnosis of polyarteritis nodosa was made according to the ACR criteria. 
Treatment with prednisone (60 mg/d) resulted in the disappearance of symptoms, and after the 
dose was tapered to 5 mg/d he had no complaints for almost 10 years. Two months after prednisone 
treatment was stopped, severe pain developed in the lower legs with localized erythema nodosum 
and the erythrocyte sedimentation rate increased to 107 mm/h. Duplex ultrasonography 
demonstrated a nodular thickening of the wall of the femoral artery in both legs. PET imaging 
showed increased patchy uptake of FDG in the femoral and popliteal arteries in both legs (Figure 
1A). Recurrent polyarteritis nodosa was diagnosed. After treatment with high-dose prednisone (60 
mg/d), his symptoms again disappeared. Three months later, results of duplex ultrasonography and 
FDG-PET imaging (Figure 1B) were normal.
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Figure 1 Increased patchy uptake of FDG in the femoral and popliteal arteries in both legs in patient A, who had 
recurrent polyarteritis nodosa after discontinuation of corticosteroid therapy (Figure 1A). Normal FDG-PET 
scan 3 months after restarting high-dose corticosteroid treatment (Figure 1B). 
Patient B, a 77-year-old woman, was found to have Wegener’s granulomatosis in 1988 based on 
complaints of purulent nasal discharge, a saddle nose, an elevated erythrocyte sedimentation rate, 
a positive antineutrophil cytoplasmic antibody (ANCA) screen, and granulomatous inflammation in 
a nasal biopsy specimen, according to the ACR criteria. Her symptoms disappeared after treatment 
with high-dose prednisone (60 mg/d). The prednisone dose was reduced to 5 mg/d and she 
remained well until July 2002, when she complained of fatigue and progressive shortness of breath 
without coughing, sputum production, or edema. Physical examination revealed no abnormalities 
except for a low-grade systolic murmur that was heard in the right second intercostal space and 
over both carotid arteries. The erythrocyte sedimentation rate was slightly elevated at 28 mm/h, 
C-reactive protein level was 9.3 mg/dL (normal <1.0 mg/dL), and ANCA titer was normal. A chest 
radiograph was normal, but a ventilation-perfusion scan showed a notably decreased perfusion 
of the entire right lung with normal ventilation. Computed tomography (CT) angiography 
demonstrated a dilated ascending aorta with a diameter of 5.7 cm, with a pathologically thickened 
wall that compressed the proximal right pulmonary artery. PET showed increased uptake of FDG 
in the ascending aorta (Figure 2A). A differential diagnosis of active vasculitis of the aorta, mycotic 
aneurysm, or malignancy of the vessel wall, such as sarcoma, was considered. Because of her 
medical history and negative blood cultures, vasculitis seemed most likely and she was treated 
with prednisone (60 mg/d) and metoprolol (100 mg/d). Her symptoms improved shortly thereafter. 
A ventilation-perfusion scan performed 6 weeks later showed an improvement of the perfusion of 
A B
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the right lung. Results of FDG-PET imaging repeated after 6 weeks were normal (Figure 2B). The 
prednisone dose was tapered, and the patient’s condition improved further.
Figure 2  Increased uptake of FDG in the thoracic aorta (arrow) in patient B, who had Wegener’s granulomatosis and 
was diagnosed with active vasculitis of the thoracic aorta (Figure 2A). Normal FDG-PET scan after 6 weeks of 
corticosteroid treatment (Figure 2B).
Patient C, a 76-year-old woman, had a medical history of hypertension since 1981, and diabetes 
mellitus and hyperparathyroidism since 2001. She presented with complaints of headache, fatigue, 
weight loss, and jaw claudication. The findings from the physical examination were normal 
except for absent pulsation of both temporal arteries. The erythrocyte sedimentation rate was 
68 mm/h. Color duplex ultrasonography demonstrated thickening of both temporal arteries and 
a temporal artery biopsy specimen revealed signs of active arteritis with multinucleated giant 
cells. PET imaging showed increased uptake of FDG in the subclavian and carotid arteries on both 
sides (Figure 3). Temporal arteritis was diagnosed according to the ACR criteria. After treatment 
with prednisone 60 mg/d, her symptoms disappeared within a few days and the erythrocyte 
sedimentation rate normalized. The prednisone dose was slowly reduced to 5 mg/d. FDG-PET 
imaging has not been repeated.
Figure 3 Increased FDG-uptake in both subclavian and carotid arteries in patient C, who had temporal arteritis.
A B
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Discussion
These three cases illustrate the promising role of FDG-PET in imaging vascular inflammation. 
Compared with CT and magnetic resonance imaging (MRI), this technique allows whole body 
screening, without disturbance by metallic implants and side effects. Unlike conventional nuclear 
medicine techniques, it also allows early imaging (one hour) [16], higher spatial resolution, and 
high interobserver agreement [17]. Its disadvantages are the relatively high cost, limited availability, 
and more limited anatomic information as compared with CT and MRI. In the three patients with 
vasculitis presented here, PET showed increased vascular uptake of FDG that was consistent with 
vascular inflammation. In patient A and especially patient B, in whom biopsy was not possible, 
diagnosis with conventional diagnostic modalities was difficult and FDG-PET greatly attributed 
to an early diagnosis of vasculitis. In these two patients, FDG-PET was also used successfully for 
follow-up of the inflammatory process. A marked decrease in uptake of FDG corresponded with 
improvement of symptoms and laboratory results.  
Besides several case reports and a case series involving patients with giant cell arteritis [18-20], 
Takayasu arteritis [21-24], periaortitis due to Wegener’s granulomatosis [25], aortitis [26], or 
unspecified large vessel vasculitis [27,28], two prospective studies exploring the diagnostic value 
of FDG-PET imaging in giant cell vasculitis have been published [29,30] (Table 1). In the study by 
Blockmans et al. [29], vascular uptake of FDG was seen in 76% of the 25 patients with biopsy-proven 
temporal arteritis or polymyalgia rheumatica.  Uptake in the large thoracic arteries had a positive 
predictive value of 93% and a negative predictive value of 80% [29]. Meller et al. [30] compared 
FDG-PET with MRI in 15 patients with aortitis due to giant cell arteritis (n=14) or Takayasu arteritis 
(n=1) at the time of diagnosis and during follow-up (n=7). They concluded that FDG-PET was 
effective in the diagnosis and follow-up of patients with aortitis because it identified more vascular 
regions involved in the inflammatory process than did MRI. 
Although inflammation of the arterial wall is most prominent in vasculitis, inflammation 
also contributes to atherogenesis. Increased accumulation of FDG has also been shown in 
atherosclerosis [31,32]. In our experience, however, uptake in vasculitis is much higher than in 
atherosclerosis, so a distinction between these two diagnoses should be possible.
In conclusion, our observations and review of the literature suggest that FDG-PET is effective for 
diagnosing and determining the extent of various forms of vasculitis. Furthermore, it could be 
useful for evaluating the effect of treatment. These results warrant a prospective study to further 
determine the role of FDG-PET in the diagnosis and follow-up of patients with different types of 
vasculitis.
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Table 1  Studies of FDG-PET in vasculitis
First Author 
[Reference] Study Design
Type of Vasculitis 
(No. of Patients) Conclusions
De Winter [19] Case report Giant cell arteritis (n=1) Uptake in thoracic vessels and 
spleen
Turlakow [20] Case report Giant cell arteritis (n=1) Uptake in aorta and subclavian, 
carotid, vertebral, iliac arteries
Blockmans [18] Case series Polymyalgia rheumatica (n=5), giant 
cell arteritis (n=6)
Useful in investigation of 
polymyalgia rheumatica and giant 
cell arteritis
Blockmans [29] Prospective consecutive series of 
69 patients suspected of giant cell 
arteritis
Polymyalgia rheumatica (n=6), giant 
cell arteritis (n=19)
Uptake in thoracic arteries; 
sensitivity of 56% and specificity 
of 98%
Meller [30] Prospective consecutive series of 15 
patients with aortitis
Giant cell arteritis (n=14), Takayasu 
arteritis (n=1)
Uptake in aorta in all patients,
normalization of uptake correlated 
with normalization of clinical and 
laboratory results
Hara [21] Case report Takayasu arteritis (n=1) Uptake in aorta and brachiocephalic, 
subclavian, carotid, pulmonary 
arteries
Meller [22] Prospective 67Ga vs. FDG in fever of 
unknown origin
Takayasu arteritis (n=1) Uptake in thoracic aorta; 67Ga 
negative
Malik [23] Case report Takayasu arteritis (n=1) Uptake in aorta
Meller [24] Ongoing prospective consecutive 
series
Takayasu arteritis (n=5) Uptake in aorta in all patients
Blockmans [25] Case report Wegener’s granulomatosis 
(n=1)
Uptake in both lungs, nose, and 
shoulders; no uptake in vessels
Derdelinckx [26] Case report Aortitis thoracic aorta (n=1) Uptake in aortic arch
Wiest [27] Case report Large vessel vasculitis (n=1) Uptake in all large arteries
Wenger [28] Case report Unspecified large vessel vasculitis 
(n=1)
Uptake in aorta and subclavian, 
carotid, and iliac arteries
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Abstract
Background: Infection of a renal or hepatic cyst is a serious complication of autosomal dominant 
polycystic kidney disease (ADPKD). Although crucial for successful management, early diagnosis is 
difficult, largely due to nonspecific symptoms and limitations of conventional imaging techniques. 
Because of an increased metabolic rate, inflammatory cells take up large amounts of glucose. 18F-
fluorodeoxyglucose (FDG) therefore represents a promising agent for detection of cyst infections 
using positron emission tomography (PET). 
Methods: We studied the results of seven FDG-PET scans in three ADPKD patients suspected of renal 
or hepatic cyst infection. Two PET scans were performed in patient A (PET 1 and 2), one PET scan was 
performed in patient B (PET 3), and four PET scans were performed in patient C (PET 4, 5, 6 and 7).
Results: FDG-PET identified the infected cysts in two episodes of renal cyst infection (PET 2 and 
3), two episodes of hepatic cyst infection (PET 6 and 7) and one episode of both renal and hepatic 
cyst infection (PET 1). In patient C, FDG-PET was normal after six weeks of antibiotic treatment for 
hepatic cyst infection (PET 4) and again at a time when hepatic cyst infection was suspected, but 
eventually colchicine intoxication was diagnosed (PET 5). 
Conclusions: In these patients FDG-PET proved very helpful in diagnosing and in excluding renal 
and hepatic cyst infections. It is concluded that FDG-PET is a promising new imaging technique 
enabling early identification of renal and hepatic cyst infections in ADPKD patients.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common hereditary 
disorders affecting approximately one in 500 to 1000 individuals. It accounts for 8-10% of the 
cases of end-stage renal disease [1]. Infection of a single cyst within a polycystic kidney is a 
well-recognized and potentially serious complication of ADPKD, but the exact incidence of this 
complication is not known [1,2]. Hepatic cysts are common in patients with ADPKD, but usually 
remain asymptomatic. Infection of hepatic cysts occurs in up to 3% of patients with end-stage renal 
failure, but in less than 1% without end-stage renal failure [3]. Complications of cyst infections 
include abscess formation, sepsis and death. Although crucial for successful management, early 
diagnosis of cyst infection often is difficult. Symptoms and signs are nonspecific and diagnostic 
accuracy of conventional imaging techniques is reduced because of the changed anatomy of 
cystic kidneys and liver. Ultrasound, computer tomography (CT), and magnetic resonance imaging 
(MRI) cannot reliably differentiate infected from non-infected cysts in ADPKD patients [2,4]. 
Scintigraphic techniques have been used only sporadically [5-7]. 
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has become an established 
imaging tool in oncology and is now entering the field of clinical infectious diseases [8]. FDG is 
an analogue of glucose. Following cellular uptake, it is metabolically trapped and consequently 
provides an image, which portrays glucose utilization. Inflammatory cells take up large amounts 
of glucose as a result of an increased metabolic rate [9]. FDG therefore represents a promising 
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agent for detection of infected cysts. In this report the potential value of FDG-PET in cyst infection 
is demonstrated by presenting the results of seven FDG-PET scans in three ADPKD patients 
suspected of renal or hepatic cyst infection.
Cases
Patient A, a 73-year-old man, had a medical history of ADPKD, left-sided nephrectomy because of 
recurrent hemorrhage in 1999 and renal transplantation in May 2001. In August 2001 he was admitted 
because of fever and abdominal pain. Physical examination revealed a slightly enlarged liver and an 
enlarged, painless right kidney. C-reactive protein (CRP) was 99 mg/L (normal <10 mg/L), kreatinine, 
leukocytes and liver enzymes were normal. Blood cultures repeatedly grew Enterococcus faecium, but 
urine cultures were negative. He was treated with teicoplanin, but the fever persisted. Abdominal 
ultrasound and abdominal CT demonstrated multiple hepatic and renal cysts without signs of 
infection and a normal renal transplant. Because hepatic or renal cyst infection was suspected, a 
PET scan was performed (PET 1). PET demonstrated increased FDG-uptake in the peripheral border 
of several liver cysts and one focus in the right kidney, suggesting infection. Antibiotic treatment 
was changed to chloramphenicol. Two weeks later his temperature normalized. In October 2001 
he was readmitted because of fever. Physical examination had not changed. CRP was 72 mg/L and 
blood cultures were again positive for Enterococcus faecium and urine culture showed Pseudomonas 
aeruginosa and Escherichia coli. Chloramphenicol was discontinued and amoxicillin and teicoplanin 
were started. A PET scan (PET 2) demonstrated large and irregular uptake dorsally in the right kidney 
extending to the right liver lobe (Figure 1). Abdominal CT showed an infiltrate in the right kidney in 
contact with the liver. The patient’s condition deteriorated and surgery was considered impossible. 
Because of the dorsal localization percutaneous drainage was not feasible. Antibiotic therapy was 
changed to ciprofloxacin, but his condition continued to deteriorate and he died of sepsis. Autopsy 
was not performed.
Figure 1  Patient A with a history of ADPKD and renal transplantation presented with fever. Coronal (Figure 1A) and 
transverse (Figure 1B) projection of PET 2: the arrow indicates the large and irregular FDG-uptake dorsally in 
the right kidney extending to the right liver lobe, suggesting infection.
A B
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Patient B, a 52-year-old man, had a medical history of ADPKD and a right-sided nephrectomy in 
preparation of subsequent renal transplantation in April 2002. Two weeks before admission, he 
was treated with ciprofloxacin orally because of a lower urinary tract infection with Pseudomonas 
aeruginosa. On admission, he complained of fever and chills without abdominal pain. Physical 
examination revealed an enlarged left kidney, which was not painful. CRP was 284 mg/L, 
leukocytes were 16.0 x 109/L (normal 3.5-11.0 x 109/L), and kreatinine and liver enzymes were normal. 
Pseudomonas aeruginosa was cultured from urine and blood. Renal cyst infection was suspected 
and ceftazidime was started. After 2 days his temperature normalized. One week later a PET scan 
(PET 3) showed increased uptake in multiple foci in the left kidney compatible with cyst infection. 
After two weeks ceftazidime was changed to ciprofloxacin orally for a total duration of 8 weeks. 
Because of renal cyst infection during immunosuppressive treatment, left-sided nephrectomy 
was performed 6 weeks after diagnosis to prevent recurrence of infection. The resected kidney 
showed old hemorrhages and calcification, but no signs of active infection. The patient has made 
a complete recovery.
Patient C, a 54-year-old woman, had a medical history of ADPKD, hemodialysis since 1997, right-
sided nephrectomy in 1996 and left-sided nephrectomy in 1999 because of infection, and infected 
liver cysts in 1997. In October 2000 she was admitted with fever. Physical examination revealed an 
enlarged liver. CRP was 264 mg/L, alkaline phosphatase was 171 U/L (normal <120 U/L), and other 
liver enzymes and leukocytes were normal. Blood cultures grew Enterococcus faecium. Abdominal CT 
scan demonstrated multiple liver cysts without signs of infection. She was treated with ciprofloxacin. 
After three days her temperature normalized and she was discharged. After six weeks, treatment was 
stopped and she remained well. However, CRP was still elevated (40 mg/L) and a PET scan (PET 4) 
was performed to exclude cyst infection. FDG-PET proved to be normal and CRP slowly decreased. 
In May 2001 she was admitted with nausea, vomiting, abdominal pain and diarrhea, but no fever. 
Physical examination had not changed. CRP was 157 mg/L and creatine kinase was elevated to 974 
U/L (normal <170 U/L). Blood and feces cultures were negative. Hepatic cyst infection was suspected, 
but a PET scan (PET 5) was again normal. Eventually a diagnosis of accidental colchicine-intoxication 
was made and hepatic cyst infection was considered highly unlikely. After discontinuation of 
colchicine, her symptoms resolved and laboratory results normalized. In February 2002 she was 
admitted with fever and abdominal discomfort. Physical examination revealed a painful, enlarged 
liver. CRP was 257 mg/L and blood cultures grew Escherichia coli. Hepatic cyst infection was 
suspected and she was treated with ciprofloxacin. FDG-PET (PET 6) showed increased uptake 
in two foci in the liver indicating cyst infection (Figure 2). After two days her fever disappeared 
and one week later she was discharged. CRP decreased slowly to 35 mg/L without complete 
normalization. Because of her extensive medical history and deteriorated condition, surgery was 
thought impossible and ciprofloxacin was continued. In August 2002 she complained of nausea and 
vomiting without fever. Physical examination had not changed, but CRP had increased to 198 mg/L. 
FDG-PET (PET 7) showed two foci of increased uptake dorsolaterally in the liver, different from the 
foci on the previous PET scan that had disappeared. New hepatic cyst infection was diagnosed, but 
before antibiotic treatment was adjusted or cultures were obtained, she suddenly died the next day. 
Autopsy was not performed.
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Figure 2  Patient C with a history of ADPKD, hemodialysis and bilateral nephrectomy presented with fever and 
abdominal discomfort. Coronal (Figure 2A) and transverse (Figure 2B) projection of PET 6: the arrow indicates 
the increased FDG-uptake in the liver, suggesting hepatic cyst infection. Physiological FDG-uptake by the 
stomach is visible on the left side.
Discussion
These cases illustrate some of the difficulties in diagnosis and treatment of renal and hepatic 
cyst infections in ADPKD patients. A major problem in diagnosing cyst infection is the absence 
of a “gold standard”. Cyst infection is a clinical diagnosis usually based on the presence of fever, 
tenderness of one kidney or the liver in combination with positive blood cultures [2,4,5]. Treatment 
of cyst infections requires lipid-soluble antibiotics, which penetrate the cyst wall [10,11] and some 
authors even suggest that failure of conventional antibiotic therapy, despite favorable in vitro 
sensitivities, may be the best single diagnostic indicator of the likelihood of cyst infection [4,5]. 
Despite advances in available imaging modalities, confirmation of infection of a cyst remains 
difficult. CT and ultrasonography are unable to specifically indicate the presence of infection in 
renal or hepatic cysts [2,4]. CT findings, such as thickening and irregularity of the cyst wall and 
increased attenuation of the cyst contents are not specific for cyst infection since these signs 
may also be caused by hemorrhage into a cyst [12]. In patients A and C, an abdominal CT scan did 
not show any of these signs when a probable diagnosis of cyst infection was made. CT is probably 
only helpful in detecting underlying abnormalities or complications, such as stones, obstruction, or 
abscess formation. Successful isolation of infected renal and hepatic cysts in ADPKD patients with 
MRI has been reported [13,14], but experience is limited. Scintigraphic techniques, using 67Ga-citrate 
(67Ga) and 111In-leukocytes, have been advocated, but uptake by overlying bowel can be confusing 
[4]. In addition, 67Ga scintigraphy, obtained in 12 ADPKD patients with renal cyst infection, showed 
positive results in only six cases [5], suggesting 67Ga imaging is not very helpful in diagnosing cyst 
infections in these patients. The successful use of 111In-leukocyte imaging in ADPKD has been 
described only in two case reports [6,7]. Moreover, the preparation of this radiopharmaceutical is 
laborious and can be hazardous due to handling of potentially contaminated blood [15]. Compared 
to conventional nuclear medicine techniques, advantages of FDG-PET in diagnosing inflammation 
are early imaging (one hour), higher spatial resolution, resulting in more anatomic information, 
high target-to-background ratio [16], low radiation burden [17], and high inter observer agreement 
[18]. Disadvantages are higher cost and limited availability.
A B
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Previously, FDG-PET has proved valuable in diagnosing soft tissue infections, osteomyelitis, 
intravascular infections and fever of unknown origin [8]. Kaim et al. described an ADPKD patient 
with an infected renal cyst that could not be identified by ultrasound, CT, and MRI. A combined PET 
and CT system in an experimental set-up was able to exactly localize the infected cyst in this case 
and CT-guided percutaneous puncture followed in the same procedure [19]. Diagnosing infections 
in kidneys with normal or slightly reduced function could be difficult because of physiological 
renal excretion of FDG. Most cyst infections, however, seem to occur in a later stage of ADPKD 
[2,3] when renal function is already impaired. Clearance of FDG occurs predominantly through 
the kidneys and it is not reabsorbed by the kidneys in contrast to glucose. FDG appears in the 
renal collecting system, the ureters, and the bladder, but the renal parenchyma no longer contains 
noticeable amounts of activity by the time PET scans are acquired. However, the renal calyces 
contain prominent activity in most patients, especially in patients with ectatic renal calyces [20]. 
In spite of this, FDG-PET has been successfully used in the detection of renal cell carcinoma in 
patients with normal renal function [21]. 
Sensitivity and specificity of FDG-PET in diagnosing cyst infections can not be defined because of 
the small number of PET scans performed in ADPKD patients suspected of cyst infection, but in 
our three patients, FDG-PET was very helpful in diagnosing and in excluding renal and hepatic cyst 
infection. FDG-PET identified the infected cysts in five episodes of renal (PET 1, 2, 3) and hepatic 
(PET 1, 6, 7) cyst infection. In patient C, FDG-PET was normal six weeks after antibiotic treatment 
for probable hepatic cyst infection (PET 4). In this patient, FDG-PET was also normal at a time when 
hepatic cyst infection was suspected, but colchicine intoxication was diagnosed eventually (PET 
5), suggesting FDG-uptake in liver cysts is specific for infection in ADPKD patients. In conclusion, 
the results of these seven PET scans in three ADPKD patients have illustrated that FDG-PET is a 
promising new imaging technique enabling early identification of renal and hepatic cyst infections 
in ADPKD patients with end-stage renal disease. 
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Abstract
Pylephlebitis or septic thrombophlebitis of the portal vein is a serious infectious disorder. Early 
diagnosis is difficult, due to non-specific symptoms and signs, limitations of diagnostic modalities 
and the lack of familiarity of physicians with this entity. We report the history of a 73-year-old 
man with fever of unknown origin in whom laboratory tests, blood and urine cultures, chest X-ray, 
abdominal ultrasound, and 111Indium-leukocyte scintigraphy did not reveal the cause of the fever. 
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) subsequently pointed to the 
diagnosis of pylephlebitis, which was confirmed by computed tomography and percutaneous 
puncture. We conclude that FDG-PET allows detecting inflammatory foci in patients with fever of 
unknown origin and offers to make the diagnosis of pylephlebitis at an early stage. 
Introduction
Septic or suppurative thrombophlebitis of the portal vein, also named pylephlebitis, is a rare but life-
threatening complication of intra-abdominal infections, most commonly caused by diverticulitis [1]. 
A wide variety of other causes have been described, including appendicitis, necrotizing pancreatitis, 
hemorrhoidal disease, foreign body perforation, perforated ileal diverticulum, acute cholecystitis, 
amoebic colitis, and inflammatory bowel disease [2]. The incidence of pylephlebitis has greatly 
declined since the introduction of antibiotics and modern surgical techniques [3]. In the past, most 
cases were diagnosed at laparotomy or autopsy. Mortality rates were very high: 50% overall [4] 
and 80% if pylephlebitis was not caused by appendicitis [1]. Recognition and prompt institution 
of adequate antibiotics has resulted in improved prognosis [5,6]. The high morbidity and mortality 
observed with suppurative pylephlebitis is at least in part attributable to the nonspecificity of the 
symptoms and signs, the limitations of available diagnostic modalities, and the increasing lack of 
familiarity of physicians with this entity. In the past, radiographic diagnosis of pylephlebitis usually 
relied on the presence of gas in the portal area and thrombus in the portal vein on angiography 
[4]. Contrast computed tomography (CT) [7,8], ultrasonography [8,9], magnetic resonance imaging 
(MRI) [10], and MR angiography [11] have proved valuable in the diagnosis of portal vein thrombosis, 
but have limitations in some cases [12,13]. Here, we present a case of fever of unknown origin in 
which 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) pointed to the diagnosis 
of pylephlebitis. A concise review of the literature on pylephlebitis is also presented.
Case report
A previously healthy 73-year-old man was admitted to our hospital because of a three-week history of 
fatigue, fever, chills, nausea, and vague left upper abdominal discomfort. In addition, he complained 
of a foul taste in his mouth that rendered him anorectic with subsequent weight loss. He was not 
taking any medication. On physical examination, he had a temperature of 37.9oC, a blood pressure of 
110/52 mmHg, and a heart rate of 100 bpm. There was no jaundice. Bowel sounds were normal, the 
abdomen was nontender, and no hepatomegaly or palpable masses were found. Rectal examination 
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was also normal. Initial laboratory studies revealed normal total and direct bilirubin, AST and ALT, 
alkaline phosphatase 189 U/l (normal <120 U/l), GGT 124 U/l (normal <50 U/l), albumin 22 g/l (normal 
37-53 g/l), and normal amylase. The white cell count was elevated to 18.6 x 109/l (normal 3.5-11.0 x 109/l) 
with 90% granulocytes and 6% band forms. CRP was 86 mg/l (normal <10 mg/l) and increased to 204 
mg/l before treatment was started. All blood cultures and a urine culture remained sterile during his 
prolonged hospital stay. A chest X-ray and radiographic studies of the upper gastro-intestinal system 
were normal. An abdominal ultrasound demonstrated slightly enlarged lymph nodes in the liver 
hilus, which were not considered abnormal at that time. In the second week of his hospital stay a 
radiographic study of the colon showed extensive diverticulosis. A transthoracic echocardiography 
and 111Indium-leukocyte scintigraphy were normal. Endoscopy revealed ulcerative esophagitis, but 
esophageal biopsy was normal. The patient had recurrent and ever progressing fever for more than 
three weeks and a PET scan was performed, which demonstrated increased FDG-uptake from the 
liver hilus to the right liver lobe (Figure 1). Contrast enhanced abdominal CT scanning, performed on 
the same day, showed thrombosis of the portal vein, slightly enlarged lymph nodes in the liver hilus, 
and extensive collaterals without evidence of abscesses, diverticulitis, or other abdominal infection 
(Figure 2). Based on these findings, septic thrombophlebitis of the portal vein was suspected. With 
an ultrasound-guided percutaneous needle aspiration of the portal vein, purulent material was 
obtained and treatment with intravenous ceftriaxon and metronidazole was started. The puncture 
material revealed Gram-negative rods, but a culture remained negative. The patient did not receive 
anticoagulant treatment. After two days his abdominal discomfort disappeared, his temperature 
normalized and his abnormal taste sensations resolved. Within two weeks CRP and liver enzymes 
had returned to normal. Treatment was changed to oral ciprofloxacin and metronidazole and he 
was discharged. Ultrasound one month after diagnosis showed no change in the thrombosis of the 
portal vein and revealed multiple collateral veins. Antibiotics were continued for a total of six weeks. 
Since then, the patient has been well without signs of portal hypertension. Endoscopy one year later 
showed no signs of esophageal varices and the esophageal inflammation had disappeared.
Figure 1 PET-scan: arrows indicate the increased FDG-uptake from the liver hilus to the right liver lobe indicating septic 
thrombophlebitis of the portal vein. (A: coronal projection, B: transverse projection).
A
B
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Figure 2  Abdominal CT scan (after intravenously administered contrast medium): thrombosis of the portal vein (arrow), 
slightly enlarged lymph nodes in the liver hilus, and extensive collaterals.
Discussion
Although imaging techniques have greatly improved over the recent years, diagnosing 
pylephlebitis remains difficult and in many cases the diagnosis has been made serendipitously 
[3,9], as in the case we describe here. In this patient, FDG-PET clearly revealed the site of the 
inflammatory process. FDG-PET has become an established imaging tool in oncology during recent 
years and is now entering the field of clinical infectious diseases. Following cellular uptake of FDG, 
an analogue of glucose, it is metabolically trapped and consequently provides an image, which 
portrays glucose utilization. Inflammatory cells take up large amounts of glucose as a result of 
an increased metabolic rate [14,15]. This uptake mechanism, however, is non-specific. FDG-PET is 
not able to differentiate between infection, non-infectious inflammatory disease and malignancy, 
so additional diagnostic measures are often necessary. In this case, for example, the needle 
aspiration was needed to establish a final diagnosis. In a prospective study of 58 patients with 
fever of unknown origin, FDG-PET imaging yielded diagnostic information in 41% of the patients 
in whom the probability of a diagnosis was only 64% [16]. Imaging techniques are necessary in 
most cases of pylephlebitis since the clinical features are non-specific. Symptoms include fever, 
chills, abdominal pain, diarrhea, and occasionally mild jaundice. Distortion of taste perception, 
also called dysgeusia, can be caused by various disorders [17], but in this patient the cause of his 
abnormal taste remains unresolved. Tender hepatomegaly is often observed, but may be absent [2]. 
Plemmons et al. reviewed all published cases of pylephlebitis from 1979 to 1993. In all 19 cases, fever 
was a presenting symptom, but abdominal pain or discomfort was present in only 74%. In six of 
these cases the cause of pylephlebitis was unknown and hepatic abscesses were present in 10 (53%) 
[6]. Laboratory studies may also be of limited value. Most patients showed leucocytosis, but liver 
tests were significantly abnormal in only 25% [4]. Blood cultures were positive in approximately 50-
80% of pylephlebitis patients [6,18]. The more common isolated bacteria are Escherichia coli, Proteus 
mirabilis, Bacteroides fragilis, and aerobic Gram-negative bacilli [6,19]. The overall mortality rate in 
the cases, reviewed by Plemmons [6], was 32% and especially a diverticular cause of pylephlebitis 
was associated with fatal outcome. Patients who died, showed severe sepsis before appropriate 
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antibiotic treatment was started, suggesting that uncontrolled infection is most life threatening in 
these patients rather than complications directly related to thrombosis [6].
Angiography demonstrates occlusion of the portal system when pylethrombosis is present [20]. 
Less invasive imaging techniques, such as CT, MRI, and (color duplex) ultrasonography have 
largely replaced angiography in diagnosing portal vein thrombosis. The presence of an intraluminal 
echogenic thrombus provides the best ultrasonographic evidence of portal vein thrombosis. 
Additional signs include dilation of vessels proximal to the occlusion, the presence of collateral 
vessels, and the absence of an identifiable portal vein [21]. Conversely, patent vessels may show 
increased intraluminal echogenicity because of artefact or erythrocyte rouleau formation and is, 
therefore, not sufficient evidence for a diagnosis of portal vein thrombosis [13]. Ultrasonographic 
examination using duplex Doppler technique is helpful in confirming the diagnosis of portal 
vein thrombosis and cavernous transformation of the portal vein, a possible complication of 
chronic obstruction of the portal venous system leading to portal hypertension [21]. CT scanning 
can show a thrombus as a filling defect in the contrast-enhanced lumen [7,8] and may identify 
the underlying cause of the disease. On MRI images, portal vein thrombosis causes an area of 
abnormal signal within the lumen [13]. MR angiography has also been shown to be of value in the 
evaluation of flow and patency within the portal system and diagnosing cavernous transformation 
of the portal vein [11]. These imaging techniques are usually able to demonstrate portal vein 
thrombosis, but differentiation between thrombosis and thrombophlebitis is not possible. Here 
FDG-PET has a major advantage. In this case, the suspected site of infection was further visualized 
by CT; percutaneous puncture revealed pus, thereby confirming the diagnosis pylephlebitis. This 
demonstrates the potential value of FDG-PET as a new imaging technique in patients with fever 
of unknown origin and patients suspected of pylephlebitis. Although increased FDG-uptake in 
thrombosis has been described [22], we postulate that FDG-PET should be able to differentiate 
between non-infectious portal vein thrombosis and thrombophlebitis, because of much higher 
FDG-uptake in the intense inflammatory process in pylephlebitis.
As soon as pylephlebitis is suspected, antibiotics with adequate coverage of Gram-negative 
aerobic bacilli, anaerobes, and Streptococcus species should be initiated. The ideal duration of 
antibiotic therapy is unclear. Given the frequency of hepatic abscesses as a complication of 
pylephlebitis, however, a minimum of four weeks seems prudent. Patients with demonstrated 
liver abscesses complicating pylephlebitis should probably receive at least six weeks of antibiotic 
therapy, in some cases with percutaneous or surgical drainage [6]. The role of anticoagulation in 
the treatment of pylephlebitis remains controversial. All available publications appear to have 
been based on limited data and personal experience, since no formal study has ever been done 
[3,6,18,23]. These considerations and the potential risk of anticoagulant treatment did us decide to 
omit anticoagulant treatment in this patient. Treatment should include localization and extirpation 
or decompression of any septic foci found, such as an inflamed appendix or diverticular abscess. 
The most serious complication with highest mortality rates is severe sepsis unresponsive to 
treatment [6]. The development of catastrophic vascular complications of portal thrombosis, such 
as acute portal hypertension with variceal hemorrhage or bowel infarction, is very uncommon in 
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pylephlebitis [6,18]. Follow-up CT examinations of five patients with pylephlebitis showed complete 
resolution of thrombosis in two patients and cavernous transformation in three patients [5]. In our 
patient extensive collaterals had already formed before portal vein thrombosis was diagnosed and, 
as is expected in such a late stage, no improvement was found after one month. This patient has 
not shown any signs of portal hypertension thus far.
In conclusion, septic thrombophlebitis of the portal vein is a serious infectious disorder, which is 
difficult to diagnose. In this patient, FDG-PET proved to be a powerful technique to diagnose this 
infectious condition.
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Abstract
In three patients with catheter-associated candidemia, 18F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET) led to the diagnosis of Candida lung abscesses, which was confirmed 
by computed tomography and favorable response to antifungal therapy. It is concluded that FDG-
PET is a promising new imaging technique enabling early identification of sites of disseminated 
candidiasis and that it can be used in the evaluation of therapy. 
Introduction
Candida spp. are an important cause of nosocomial bloodstream infection, associated with a 
mortality of 30-40% [1]. Patients at high risk for candidiasis are those receiving total parenteral 
nutrition (TPN) and critically ill patients [2-4]. Catheter-associated candidemia may lead to seeding 
of Candida spp. to multiple organs. Timely identification and localization of the infectious lesions 
is critical, but this is often difficult, especially in patients without signs pointing to a specific 
localization. We report three cases of Candida lung abscesses associated with central venous 
catheter (CVC)-related candidemia diagnosed by 18F-fluorodeoxyglucose positron emission 
tomography (FDG-PET).
Cases
Patient A, a 45-year-old woman, had received TPN since September 2003 because of short bowel 
syndrome resulting from acute bowel ischemia. In January 2004, she was admitted because of 
fever. Blood cultures repeatedly grew C. albicans, which was also cultured from the catheter tip after 
removal. Ophthalmologic examination revealed lesions compatible with Candida chorioretinitis. 
The MIC for fluconazole was 0.125 µg/ml. She was treated with fluconazole 400 mg qd intravenously, 
but the fever persisted. Blood cultures remained positive for C. albicans for seven days after start of 
fluconazole, and the dose was increased to 800 mg qd. Chest X-ray and abdominal ultrasound were 
both normal. Nine days after admission, FDG-PET was performed, which demonstrated increased 
FDG-uptake in the upper and lower lobes of the right lung. High-resolution chest computed 
tomography (CT) subsequently showed several densities with hypodense centers in the upper and 
lower lobes of the right lung, compatible with fungal abscesses. High-resolution chest CT after six 
weeks showed regression of the pulmonary densities. After nine weeks, FDG-PET was normal and 
treatment with fluconazole was discontinued.
Patient B, a 39-year-old woman, had received TPN because of chronic intestinal pseudo-obstruction 
since October 2003. In November 2003, she was admitted because of fever and rigors. Blood cultures 
repeatedly grew C. albicans, which was also cultured from the catheter tip after removal. The MIC 
for fluconazole was 0.125 µg/ml. She was treated with fluconazole 400 mg qd intravenously. Fever 
persisted and her clinical condition deteriorated. Blood cultures remained positive for C. albicans 
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for two days after start of fluconazole. Abdominal ultrasound and doppler ultrasonography of the 
subclavian and internal jugular veins were both normal. Chest X-ray was judged to be normal, but 
showed a small infiltrate in the left lower lobe upon re-examination. PET, performed one week 
after admission, demonstrated increased FDG-uptake in multiple foci in both lungs and subpleural, 
suggesting abscesses (Figure 1A). Two days later she developed pleuritic chest pain and a pleural 
rub on the right side. Chest CT showed multiple densities in both lungs compatible with fungal 
abscesses. Fluconazole was replaced by caspofungin. After three weeks, caspofungin was replaced 
by oral fluconazole. After seven weeks, chest CT showed regression of the lung abscesses. After 
nine weeks, FDG-PET was normal (Figure 1B) and antifungal treatment was stopped.
Figure 1  In patient B, positron emission tomography (PET) demonstrated increased uptake of 18F-fluorodeoxyglucose 
(FDG) in multiple foci in both lungs, suggesting abscesses (Figure 1A). After three months, FDG-PET was normal 
(Figure 1B).
Patient C, a 65-year-old woman, was treated with prednisone and azathioprine since 1995 because 
of mixed connective tissue disease. In May 2004, she was admitted to the intensive care unit 
with Streptococcus pneumoniae pneumonia for which mechanical ventilation was initiated. Blood 
cultures remained sterile. On the tenth hospital day, blood cultures grew C. glabrata. However, C. 
albicans and C. glabrata were both isolated from the CVC after removal. The MIC for fluconazole 
were 4 and 8 µg/ml, respectively. She was treated with fluconazole 400 mg qd intravenously, but 
the fever persisted and the dose was increased to 800 mg daily. Chest X-ray showed infiltrative 
changes in the left lower lobe, which had not changed. Abdominal CT revealed no signs of focal 
infection. Doppler ultrasonography of the subclavian and internal jugular vein was normal. The 
fever still persisted and blood cultures were positive for C. glabrata for thirteen days after start 
of fluconazole. PET, performed after 12 days of therapy, showed increased FDG-uptake in multiple 
foci in both lungs suggesting abscesses. Fluconazole was replaced by caspofungin. One week later, 
chest CT showed infiltrative changes in both upper lobes, compatible with metastatic infectious 
foci. After 6 weeks of antifungal treatment, chest CT showed regression of the infiltrative changes 
and caspofungin was discontinued. FDG-PET has not been repeated.
A B
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Discussion 
These cases illustrate the difficulties in diagnosis and treatment of complicated catheter-related 
candidiasis. FDG-PET clearly revealed the sites of the disseminated Candida infection, which was 
confirmed by clinical signs (patient B), findings on chest CT, and response to antifungal therapy 
(patients A, B and C). In patients A and B, FDG-uptake normalized after prolonged treatment in 
agreement with favorable clinical and laboratory response, enabling evaluation of the effect of 
antifungal treatment.
Candida species adhere avidly to vascular catheters. CVCs, even when not the primary source of 
candidemia, may continue to serve as the source of sustained fungemia as organisms adhere to 
the catheter surface and subsequently seed to target organs [5]. In a retrospective study in our 
hospital, 43 out of 147 patients who were treated for candidemia developed disseminated disease 
[6]. Documented Candida lung abscesses, however, are rare. In a study of 11 patients diagnosed with 
pulmonary candidiasis at necropsy, six cases were attributed to CVCs [7]. 
In patients A, B and C, chest X-ray did not reveal the lung abscesses, and is therefore not 
an appropriate diagnostic method to exclude disseminated pulmonary candidiasis. CT and 
ultrasonography are useful for diagnosing disseminated candidiasis, but are less suitable as a 
screening method in patients with candidemia suspected of disseminated infection without 
clues for specific sites of infection. Furthermore, these imaging techniques are not able to detect 
infectious foci in an early phase because of the lack of substantial anatomical changes at that time. 
Also, discrimination between active infection and residual changes remains difficult, which is a 
drawback during follow-up of the effect of treatment. 
Scintigraphic imaging allows delineation of the localization of foci in all parts of the body, based 
on functional changes of tissues. FDG-PET, an established imaging tool in oncology, has entered 
the field of clinical infectious diseases. After cellular uptake, FDG, an analogue of glucose, is 
metabolically trapped and consequently provides an image, which portrays glucose utilization. 
Inflammatory cells take up large amounts of glucose as a result of an increased metabolic rate 
[8]. Previously, FDG-PET has proved valuable in diagnosing soft tissue infections, osteomyelitis, 
intravascular infections and fever of unknown origin [9,10]. Compared to conventional nuclear 
medicine techniques (67gallium citrate and labeled leukocytes), advantages of FDG-PET are early 
imaging, and higher spatial resolution, resulting in more anatomic information [11].
In conclusion, FDG-PET appears to be a promising new imaging technique enabling early 
identification of sites of disseminated Candida infection as well as for evaluating the effect of 
antifungal treatment.
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Abstract
Background: 18F-fluorodeoxyglucose (FDG) accumulates in inflammatory cells due to an increased 
metabolic rate. Therefore, FDG positron emission tomography (PET) represents a promising 
imaging technique in patients with vasculitis. The aim of this study was to assess the value of FDG-
PET in the diagnosis of different types of vasculitis.
Methods: The results of FDG-PET performed because of suspected vasculitis or because of fever 
of unknown origin with results indicating vasculitis were reviewed. These results were compared to 
the final diagnosis, based on the “American College of Rheumatology 1990 criteria”.
Results: FDG-PET was ordered because of suspected vasculitis in 20 patients, because of fever of 
unknown origin in two patients, and for follow-up of vasculitis in five patients. Fourteen patients 
were diagnosed with vasculitis (giant cell arteritis n=5, polymyalgia rheumatica n=2, polyarteritis 
nodosa n=3, Takayasu n=1, Churge-Strauss n=1, Wegener’s granulomatosis n=1, vasculitis of the skin 
n=1), two patients were diagnosed with fibromuscular dysplasia and one patient had media necrosis 
of the aorta. In five patients no diagnosis could be reached. FDG-PET results were considered to be 
true positive in 10 patients, true negative in 14 patients and false negative in three patients resulting 
in a positive predictive value of 100% and a negative predictive value of 82%.
Conclusions: FDG-PET appears to be a promising new imaging technique in diagnosing and 
determining the extent of various forms of vasculitis. Furthermore, FDG-PET may become a useful 
tool for evaluating the effect of treatment of vasculitis. 
Introduction
Early and accurate diagnosis and assessment of the extent of vasculitis is important for adequate 
therapeutic measures and improvement of prognosis. Diagnosing vasculitis is often difficult due 
to the absence of specific symptoms and signs, the limited specificity of available biochemical 
tests and the limited sensitivity of detecting the frequently subtle vessel abnormalities with 
conventional imaging techniques. The various kinds of vasculitis are classified based on the type 
of inflammation, the predominant size of the involved arteries, and the extent and location of 
the inflammation. The “American College of Rheumatology 1990 criteria for the classification of 
vasculitis” (ACR criteria) [1-11] are considered to be the gold standard. Although these criteria 
were established for research, they are often used for clinical diagnosis of vasculitis. In a study 
of 198 patients suspected of vasculitis, however, the ACR criteria functioned poorly in the clinical 
diagnosis of specific types of vasculitis [12]. In clinical practice, diagnosing vasculitis and evaluating 
the extent and the location of the disease is difficult or even impossible in many cases. In those 
types of vasculitis in which it is difficult to obtain histological proof, imaging techniques are used 
for diagnosis. Vasculitis of the medium-sized and large blood vessels can be detected by several 
radiological techniques including classic angiography, computerized tomography (CT), magnetic 
resonance imaging (MRI) and ultrasonography. Since these techniques only show anatomical 
changes of the vessel lumen, inflammation of the vessel wall cannot be detected in an early 
phase due to the lack of substantial anatomical changes at this time. Also, to distinguish active 
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inflammatory lesions from residual anatomical changes due to previous inflammation is difficult 
or even impossible.
Scintigraphic imaging is a non-invasive method allowing delineation of both localization and number 
of foci in all parts of the body, based on functional changes of tissues. 18F-fluorodeoxyglucose (FDG) 
positron emission tomography (PET) has become an established imaging tool in oncology and is 
now entering the field of infectious and inflammatory diseases [13]. FDG accumulates in organ 
tissues with a high rate of glycolysis [14], which not exclusively occurs in neoplastic cells. Lesions 
with a high concentration of activated inflammatory cells also show increased uptake of FDG 
[15,16]. Furthermore, from almost all other sites of the body, including the blood compartment, it is 
cleared very rapidly. FDG-PET could thus be a promising new imaging technique for evaluation of 
metabolic activity in the vessel wall in both diagnosis and follow-up of patients with vasculitis. FDG 
accumulation on PET scanning has been reported in patients with giant cell arteritis and polymyalgia 
rheumatica [17-20], Takayasu arteritis [20-24], periaortitis due to Wegener’s granulomatosis [25], 
aortitis [20,26], unspecified large vessel vasculitis [27,28] and infectious vasculitis [29]. To further 
assess the role of FDG-PET imaging in diagnosis and follow-up of patients with different types 
of vasculitis, we evaluated the results of FDG-PET scans, performed either because of suspected 
vasculitis or because of fever of unknown origin with results suggesting the presence of vasculitis.
Materials and methods
Patients
The results of all FDG-PET scans ordered from January 1999 to April 2003 in the Radboud University 
Nijmegen Medical Centre because of suspected vasculitis or because of fever of unknown origin with 
results suggesting the presence of vasculitis were reviewed. Fever of unknown origin was defined 
according to the revised Petersdorf criteria: a febrile illness of >3 weeks duration, a temperature of 
>38.3°C on several occasions, and no diagnosis after one week of evaluation in the hospital or three 
visits to the outpatient department [30]. The patients were evaluated with other imaging modalities 
and laboratory tests as was considered clinically appropriate. Patients were included if the diagnostic 
process had been completed at the time of data-analysis in April 2003. The patients with fever of 
unknown origin are also included in a retrospective study investigating the diagnostic contribution 
of FDG-PET in patients with fever of unknown origin that has been published elsewhere [31].
FDG-PET
A dedicated, full-ring PET scanner (ECAT-EXACT, Siemens/CTI, Knoxville, TN., USA) was used for 
data acquisition. Prior to FDG-injection patients had fasted for at least 6 hours. Intake of sugar-
free liquids was permitted. Immediately prior to the procedure, the patients were hydrated with 
500 ml of water. One hour after intravenous injection of 200-220 MBq FDG (Tyco Healthcare/
Mallinckrodt Medical, Petten, The Netherlands) and 10 to 15 mg furosemide, emission images or 
emission and transmission images of the area between the proximal femora and the base of the 
skull were acquired (10 minute per bed position). When only an emission study was recorded, the 
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images were not corrected for attenuation and were reconstructed using filtered back-protection 
(Butterworth filter with a cut-off frequency of 0.4 Nyquist). When emission and transmission 
studies were recorded, the images were corrected for attenuation and were reconstructed using 
the ordered subsets-expectation maximization (OSEM) algorithm. Reconstructed images were 
displayed in coronal, transverse and sagittal planes.
Interpretation
FDG-PET scans were interpreted by two staff members of the department of nuclear medicine 
blinded for other diagnostic test results and the final diagnosis. FDG-PET scans were rated as 
normal or abnormal. Results were judged to be abnormal if focal accumulation of the tracer was 
detected outside of the areas of physiological uptake. Normally no visible FDG-uptake is present in 
blood vessel walls. Disagreements were resolved by consensus.
Clinical assessment of test results and diagnosis
Results were considered to be true positive when abnormal vascular FDG-uptake was present in 
patients with a clinical diagnosis of vasculitis. Abnormal results were categorized as false positive 
when the abnormality was not related to the illness or when no final diagnosis could be reached. 
A normal FDG-PET scan was considered to be true negative when no cause of the symptoms was 
identified despite an extensive diagnostic work-up. In cases of suspected vasculitis, the diagnostic 
work-up had to be complete according to the ACR criteria. A normal FDG-PET scan was considered 
false negative when vasculitis was diagnosed except for vasculitis limited to the brain because of 
known low sensitivity of FDG-PET due to high physiological FDG-uptake in the brain or vasculitis 
limited to the legs, because the legs are not routinely imaged if not specially mentioned on the 
FDG-PET request. A final diagnosis of vasculitis was based on the ACR criteria. When this was not 
possible, a probable diagnosis was made based on clinical follow-up and conventional radiological 
studies. No criteria defining an exacerbation or recurrence of a known vasculitis syndrome are 
available. To define a probable exacerbation or recurrence, the clinical diagnosis based on a 
combination of recurrence of symptoms resembling the symptoms at the time of the first episode 
with vasculitis, an elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) and 
other biochemical tests were used. The final or probable clinical diagnosis served as a standard of 
reference and was used for the comparisons with the FDG-PET results.
Results
From January 1999 to April 2003, 25 patients were referred for a total of 30 FDG-PET scans because 
of suspected vasculitis or because of fever of unknown origin with FDG-PET results indicating 
vasculitis. Three patients had to be excluded because of insufficient data in follow-up, so the results 
of 27 FDG-PET scans in 22 patients were evaluated. Of these patients, two were male and 20 were 
female with a median age of 60 years (range 17 to 81 years). Nine patients had at least one period of 
hospitalization with a median duration of 14 days (range 8 to 62 days). Thirteen patients only visited 
the outpatient department. 
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The clinical diagnoses of the patients are shown in Table 1. Fourteen patients (64%) were diagnosed 
with vasculitis based on the ACR criteria. Fibromuscular dysplasia was diagnosed in two patients: 
one patient was diagnosed with fibromuscular dysplasia of the right renal artery and the hepatic 
artery based on typical changes on angiography, which is the gold standard for diagnosing this 
disease. In the other patient, a probable diagnosis of fibromuscular dysplasia of the carotid arteries 
was reached based on typical changes on magnetic resonance angiography (MRA). One patient 
suspected of vasculitis of the thoracic aorta because of a progressively dilating ascending aorta and 
a variable elevation of CRP was eventually diagnosed with media necrosis of the ascending aorta 
after replacement of the affected part with an aortic graft. No signs of vasculitis or infection were 
found and the definite cause of the media necrosis remained unresolved. Possibly the media necrosis 
was caused by previous aortitis in this patient with a combined immunodeficiency. In five patients 
suspected of vasculitis, no cause of their symptoms could be established after a median follow-up 
of 7 months (range 1 to 17 months): one patient had persisting symptoms without treatment and 
died of cerebral hemorrhage 17 months after FDG-PET (no autopsy was performed), two patients 
had persisting symptoms while treated with non-steroidal anti-inflammatory drugs for one and six 
months, respectively, in one patient symptoms completely disappeared after prednisone treatment 
and in one patient severity of symptoms decreased and ESR normalized spontaneously.
Table 1 Clinical diagnosis in 22 patients suspected of vasculitis or with fever of unknown origin and FDG-PET results 
indicating vasculitis
Category No. of cases
Vasculitis 14
     Giant cell arteritis 5
     Polymyalgia rheumatica 2
     Polyarteritis nodosa 3
     Takayasu 1
     Churge-Strauss 1
     Wegener’s granulomatosis 1
     Vasculitis skin (unspecified) 1
Fibromuscular dysplasia 2
Media necrosis aorta (of unknown origin) 1
No diagnosis 5
The median duration of symptoms before FDG-PET was performed was five weeks (range 2 weeks 
to 41 months). In three patients (14%) the symptoms persisted for more than six months before 
FDG-PET was ordered. The first FDG-PET scan was requested because of suspected vasculitis in 
20 patients and because of fever of unknown origin in the remaining two patients. Table 2 shows 
the classification of the FDG-PET results. Ten of the total number of 22 “first” FDG-PET scans 
were abnormal (45%) and all these abnormal FDG-PET results were found in patients with active 
vasculitis and were thus considered to be true positive. Examples are shown in figures 1 and 2. In 
two patients with active temporal arteritis and in one patient with vasculitis limited to the skin 
who had not been treated with corticosteroids, the results of FDG-PET were classified as false 
negative. Normal FDG-PET results were categorized as true negative in five patients in whom no 
diagnosis could be reached, in two patients with fibromuscular dysplasia, and in the patient with 
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media necrosis. One patient with a history of Takayasu arteritis, which had been inactive for almost 
four years, was suspected of recurrence of active vasculitis because of painful shoulders and a 
slightly elevated ESR. Symptoms spontaneously disappeared, ESR normalized and no diagnosis of 
recurrence of active vasculitis was made, so the normal FDG-PET results were also considered to 
be true negative in this case.
Table 2 Classification of the results of 27 FDG-PET scans in patients suspected of vasculitis or with fever of unknown 
origin with FDG-PET results indicating vasculitis
Category True positive True negative False negative False positive
Vasculitis (diagnosis) 10 1 3 0
Vasculitis (control) 0 5 0 0
Fibromuscular dysplasia 0 2 0 0
Media necrosis aorta 0 1 0 0
No diagnosis 0 5 0 0
Total 10 14 3 0
In three patients with polyarteritis nodosa, one patient with temporal arteritis and one patient 
with Wegener’s granulomatosis, a second FDG-PET scan was performed to evaluate the effect of 
treatment with a median time between the first and second FDG-PET scans of 11 weeks (range 4 
to 25 weeks). FDG-PET results were normal in these five patients who all had a good clinical and 
biochemical response to therapy (Table 2). After the second FDG-PET scan proved to be normal, 
corticosteroid dose was tapered in all five patients without relapse of symptoms thus far. The 
results of these FDG-PET scans were considered to be true negative. The sensitivity of all 27 FDG-
PET scans in these 22 patients was 77%, specificity was 100%, positive predictive value was 100% 
and negative predictive value was 82%.
Figure 1 This 80-year-old woman was diagnosed with temporal arteritis in 1999 based on the ACR criteria including typical 
changes on temporal artery biopsy. She responded well to high dose prednisone, which was slowly tapered to 5 
mg. She remained well until January 2002 when she presented with headaches, painful shoulders and weight loss 
(8 kg). Physical examination had not changed and revealed absence of pulsation of the temporal arteries, but was 
otherwise normal. ESR was slightly elevated to 22 mm/h (normal <12 mm/h). She did not respond to prednisone 20 
mg daily. Since recurrence of giant cell arteritis was suspected, FDG-PET was performed to evaluate whether her 
symptoms were caused by active vasculitis. PET demonstrated increased FDG-uptake especially in the ascending 
aorta indicating active aortitis (Figure 1A: coronal projection, Figure 1B: sagittal projection). She was diagnosed with 
reactivation of giant cell arteritis and her symptoms disappeared again after high dose prednisone treatment.
A B
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Figure 2 This previously healthy 60-year-old woman presented 
with myalgia of the lower legs, skin ulcerations on both legs, livedo 
reticularis and mild polyneuropathy. A skin biopsy showed fibrosing 
panniculitis and necrotizing vasculitis of medium-sized arteries. 
Polyarteritis nodosa was diagnosed according to the ACR criteria. 
FDG-PET was performed to determine the extent of the vasculitis. 
Increased FDG-uptake was found in both femoral arteries and 
several superficial lesions on the lower legs (arrows); the latter 
were probably caused by the skin ulcerations. No vascular FDG-
uptake was noticed elsewhere (not shown). She was treated with 
high dose prednisone and her symptoms disappeared. 
Discussion
In this study we retrospectively evaluated the utility of FDG-PET in diagnosis and follow-up of 
vasculitis. The results demonstrate that vascular FDG-uptake is increased in different types of 
active vasculitis. To our knowledge, increased FDG-uptake on PET scanning has not been reported 
before in patients with polyarteritis nodosa or Churge-Strauss syndrome. In addition, a remarkable 
decrease in FDG-uptake corresponded well with improvement of symptoms and laboratory 
results in five patients, suggesting that vascular FDG-uptake is only seen in active vasculitis and 
not in non-inflammatory vascular disease such as fibromuscular dysplasia or in inactive disease. 
Although inflammation of the arterial wall is most prominent in vasculitis, inflammation also 
contributes to atherogenesis. In an atherosclerotic rabbit model, increased FDG accumulation was 
shown in the affected arteries [32]. FDG-uptake in the femoral and iliac arteries was increased in 
133 patients with at least one risk factor for atherosclerosis when compared to 23 controls [33]. In 
our experience, FDG-uptake in vasculitis is much higher than in atherosclerosis, so a distinction 
between these two diagnoses may very well be possible.
Besides several case reports and a case series in patients with giant cell arteritis or polymyalgia 
rheumatica [17,19,20], Takayasu arteritis [20-24], periaortitis due to Wegener’s granulomatosis [25], 
aortitis of the thoracic aorta [20,26] and large vessel vasculitis [27,28], only two prospective studies 
exploring the diagnostic value of FDG-PET imaging in vasculitis have been published. Blockmans 
et al. [18] found a sensitivity of FDG-uptake in the large thoracic arteries for the diagnosis of 
temporal arteritis or polymyalgia rheumatica of 56%, a specificity of 98%, a positive predictive 
value of 93% and a negative predictive value of 80% in 25 patients with biopsy-proven temporal 
arteritis or polymyalgia rheumatica. The extent of the vasculitis to a much larger part of the arterial 
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system than is usually suspected in giant cell arteritis, was remarkable. It was also suggested that 
the results of this study support the hypothesis that polymyalgia rheumatica is caused by the 
same kind of vasculitis [18], therefore these patients were included in the present study. Meller 
et al. [20] compared FDG-PET with MRI in 15 patients with aortitis due to giant cell aortitis (n=14) 
or Takayasu arteritis (n=1) at the time of diagnosis and during follow-up (n=7). It was concluded 
that FDG-PET is a valuable technique as well in diagnosis as in follow-up of patients with aortitis, 
because it identified more vascular regions involved in the inflammatory process than did MRI [20]. 
Sensitivity of FDG-uptake in vasculitis in the study by Blockmans et al. seems to be lower when 
compared to the results of the present study (56 versus 77%). However, we found false negative 
results in two out of seven patients diagnosed with temporal arteritis or polymyalgia rheumatica 
suggesting that sensitivity of FDG-PET may be lower in these patients than in patients with other 
types of vasculitis. Due to high uptake in the brain, the small diameter of the vessel, and the 
relatively high background of the skin, direct evaluation of the temporal arteries is not possible on 
whole body PET imaging. This could explain the difficulty of detecting giant cell arteritis by FDG-
PET, especially in cases where vasculitis is really limited to the temporal arteries. 
Conventional scintigraphic techniques have also been used occasionally in patients with vasculitis. 
In a prospective study of 19 patients with biopsy-proven temporal arteritis, 67Ga-citrate scintigraphy 
(67Ga) had a 94% specificity and a 90% positive predictive value with normalization of 67Ga-uptake 
after 6 months of steroid therapy [34]. In one study radiolabeled leukocyte scintigraphy seemed 
to be superior to conventional angiography and CT for detecting and monitoring vasculitic 
involvement of the respiratory tract [35]. In Takayasu arteritis, however, 111In-leukocyte scintigraphy 
had a low sensitivity for active disease [36]. Compared to conventional nuclear medicine techniques, 
advantages of FDG-PET in diagnosing inflammation are early imaging (one hour), resulting in early 
reporting [37], tomographic information with higher spatial resolution, resulting in more anatomic 
information, and high inter observer agreement [38].
Recently, imaging techniques for demonstrating anatomic blood vessel changes in vasculitis, 
such as CT angiography, MRI, and color duplex ultrasonography, have greatly improved. This 
improvement and the invasive nature of classic angiography causes an inclination to perform 
these imaging techniques instead of angiography in diagnosis and follow-up of patients with 
vasculitis. CT angiography is able to detect luminal and vessel wall changes in patients with 
Takayasu arteritis with high accuracy [39,40]. Vascular wall thickening is also an important finding 
on MRI in the acute phase of Takayasu arteritis, subsiding after appropriate therapy [41,42]. Mural 
edema is a characteristic pattern of active and progressive Takayasu arteritis, which is absent 
in the chronically active state [43]. In patients with giant cell arteritis, MRA is potentially useful 
for follow-up of the effect of treatment [44,45]. Duplex ultrasonography is able to demonstrate 
luminal changes, aneurysms, and a hypoechoic halo, most probably caused by vessel wall edema, 
in patients with temporal arteritis and Takayasu arteritis [46-48]. In a study of 86 patients with 
biopsy-proven temporal arteritis, it was concluded that color duplex ultrasonography made only a 
modest contribution to diagnosing temporal arteritis [49]. In another study, duplex ultrasonography 
was found to be a non-invasive, relatively inexpensive, and efficient method, suitable for repeated 
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follow-up in patients with Takayasu arteritis [40]. However, ultrasonography is limited in the extent 
to which it can detect all diseased vessels, especially the pulmonary arteries, the aorta, and the 
visceral vessels. Positive aspects of FDG-PET imaging compared to CT, MRI and ultrasonography are 
whole body screening, high contrast resolution, absence of disturbance by metallic implants (CT, 
MRI) and absence of contrast-related side effects (CT). Also, FDG-PET shows functional changes 
caused by activation of inflammatory cells and does not depend on anatomical changes in contrast 
to CT, MRI and ultrasonography. Disadvantages of FDG-PET are higher cost, still limited availability 
and more limited anatomic information due to lower spatial resolution as compared to CT and MRI. 
In conclusion, FDG-PET appears to be a valuable new imaging technique in diagnosing and 
determining the extent of various forms of vasculitis. Furthermore, FDG-PET may become a 
useful tool for evaluating the effect of treatment of vasculitis that cannot reliably be visualized 
by conventional techniques. However, for a validation of FDG-PET in patients with suspected 
vasculitis and for determination of its exact position in the follow-up of response to treatment, 
prospective studies in a larger number of patients are warranted.
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Abstract
Lipodystrophy is accompanied by increased adipose tissue inflammatory activity. Together with 
mitochondrial toxicity of nucleoside reverse transcriptase inhibitors, this induces metabolic 
stress causing increased glucose-uptake. We hypothesize that this can be visualized by FDG-
PET. Markedly increased subcutaneous FDG-uptake was observed in 3 out of 4 HIV-infected 
patients with lipodystrophy treated by a stavudine-containing HAART-regimen. This phenomenon 
was absent in HIV-infected controls without lipodystrophy. In conclusion, markedly increased 
subcutaneous FDG-uptake on PET is an appropriate tool to visualize lipodystrophy.
Introduction
Treatment with highly active antiretroviral therapy (HAART) has dramatically reduced HIV-
associated morbidity and mortality. However, an important side effect of HAART is lipodystrophy, 
a syndrome characterized by peripheral fat wasting (lipoatrophy), central adiposity and metabolic 
changes such as hyperlipidemia, hyperglycemia and insulin resistance. 
The etiology of adipose tissue changes and metabolic disturbances in patients with HIV-associated 
lipodystrophy is unclear, but is likely to be multifactorial. Increased cytokine secretion from 
adipose tissue and increased systemic pro-inflammatory cytokine activity appears to play a 
significant role in adipose tissue remodeling in lipodystrophy [1]. As a consequence, metabolic 
demand of adipose tissue is increased. Stavudine-based regimens have the highest incidence 
of lipoatrophy and switching treatment to zidovudine or abacavir may reduce this adverse 
effect [2]. It is well known that stavudine, like other nucleoside reverse transcriptase inhibitors 
(NRTI), compromises mitochondrial function. In addition, stavudine suppresses the expression of 
adipocyte differentiation markers [3]. The combination of an increased metabolic demand and a 
compromised oxidative phosphorylation induces metabolic stress in adipose tissue. In general, 
metabolic stress is accompanied by increased glucose-uptake as a result of the translocation of the 
specific glucose-transporter GLUT-1 [4]. Therefore, we investigated whether active lipodystrophy 
can be monitored in vivo by visualizing glucose-uptake using 18F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET).
Methods
In this prospective study, the diagnosis of HIV-related lipodystrophy was based on the following 
criteria: clinical evidence by doctor’s and patient’s report of fat wasting of the face, arms, legs, 
or buttocks and/or fat accumulation in the abdomen or over the dorsocervical spine and fasting 
hyperlipidemia (cholesterol ≥ 5.5 mmol/L or triglyceride ≥ 2.0 mmol/L), fasting C-peptide >2.5 mmol/
L or impaired fasting glucose or diabetes mellitus (fasting glucose >6.1 mmol/L) in the absence of an 
AIDS-defining event or other severe clinical illness or the use of anabolic steroids, glucocorticoids 
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or immune modulators within three months of assessment. FDG-PET was performed in 4 HIV-
infected patients with early features of lipodystrophy (all fulfilling the clinical definition) treated by 
a stavudine-containing HAART regimen for a maximum of 3 years, in 4 HIV-infected patients never 
treated by HAART (control 1) and in 5 HIV-infected patients without lipodystrophy treated for a 
maximum of 3 years by HAART that never included stavudine (control 2). In lipodystrophy patients 
with markedly increased subcutaneous FDG-uptake, stavudine was replaced by zidovudine, 
abacavir or tenofovir and FDG-PET was repeated 3 to 6 months later. The protocol was approved by 
the local Research Ethics Committee. All patients provided written informed consent.
Whole body PET scanning was performed using a dedicated full ring PET scanner (ECAT-EXACT, 
Siemens/CTI, Knoxville, TN., USA). Prior to FDG injection patients had fasted for at least 6 hours, 
inducing a low insulin-state. Immediately prior to the procedure, the patients were hydrated with 500 
ml of water. One hour after intravenous injection of 220 MBq FDG (Tyco Healthcare/Mallinckrodt 
Medical, Petten, The Netherlands) and 10 to 15 mg furosemide, emission and transmission images 
of the area between the proximal femora and the base of the skull were acquired (10 min per bed 
position). Images were reconstructed with segmented attenuation correction. Subcutaneous FDG-
uptake was evaluated by two nuclear medicine specialists without information on the prescription 
of HAART or the presence or absence of the lipodystrophy syndrome. Disagreements were 
resolved by consensus.
Results
All patients were male with a median age of 48 years in the lipodystrophy group (range 38 to 
56), 41 years in control group 1 (range 28 to 50) and 36 years in control group 2 (range 28 to 44). 
The median duration of HAART was 27 months in lipodystrophy patients (range 14 to 32) and 20 
months in control group 2 (range 14 to 36). Lipodystrophy patients were treated by 2 NRTI and 
protease inhibitors (n=3) or 2 NRTI and nevirapine (n=1). In control group 2, HAART consisted of 2 
NRTI and a protease inhibitor (n=1), of 2 NRTI and efavirenz (n=3) or of 2 NRTI and nevirapine (n=1). 
All of these patients had a favorable virological response (viral load <50 copies/ml) except for one 
control patient with a viral load of 100 copies/ml. Markedly increased subcutaneous FDG-uptake 
was observed in 3 out of 4 lipodystrophy patients (Figure 1A) and in none of the patients in both 
control groups. In all patients with markedly increased subcutaneous FDG-uptake, stavudine was 
replaced by zidovudine or abacavir. In these three patients, who reported a slight improvement of 
symptoms, FDG-PET, repeated 3 to 6 months later, showed normalization of subcutaneous FDG-
uptake (Figure 1B). 
88
_____  Chapter 4  _____________________________________________________________________________________________________________ ___________________________________________________  FDG-PET for visualization of lipodystrophy in HIV-infected patients  _____ 
89
Figure 1 This 46-year-old HIV-positive man who had been treated with HAART for 30 months developed lipodystrophy. 
PET showed markedly increased subcutaneous FDG-uptake in the thoracic, abdominal and pelvic areas (Figure 
1A). In this patient antiretroviral therapy was adjusted which resulted in a slight subjective improvement. 
FDG-PET 6 months after switching of therapy was completely normal without any evidence of increased 
subcutaneous FDG-uptake (Figure 1B).  
Discussion
Markedly increased subcutaneous FDG-uptake in 3 out of 4 HIV-infected patients with lipodystrophy 
and absence of this phenomenon in HIV-infected controls without lipodystrophy supports the 
hypothesis that stavudine-related lipodystrophy is associated with increased glucose-uptake as 
a result of metabolic stress of adipose tissue in response to HAART. Because of the low insulin-
state, glucose-uptake is probably mediated by GLUT-1. It is unlikely that increased subcutaneous 
FDG-uptake is mediated by translocation of the insulin-dependent GLUT-4-transporter, because 
lipodystrophy is associated with marked insulin resistance. In one study using FDG-PET in order 
to explain the mechanism of insulin resistance in HIV-infected patients with the lipodystrophy 
syndrome, a decreased cellular FDG-uptake in skeletal muscle was observed [5]. Our data show 
that FDG-PET is able to visualize lipodystrophy. As such, FDG-PET may become a promising tool 
to monitor lipodystrophy during the course of HIV-treatment. Moreover, in clinical trials, the 
lipodystrophy-inducing effect of newly developed antiretroviral regimens may be monitored 
objectively by this approach.
In conclusion, markedly increased subcutaneous FDG-uptake on PET-scanning is an objective tool 
to visualize stavudine-related lipodystrophy and supports the hypothesis that lipodystrophy is 
associated with increased glucose-uptake as a result of metabolic stress of adipose tissue in response 
to HAART. Reduction of subcutaneous FDG-uptake 3 to 6 months after replacement of stavudine 
suggests that this strategy is able to decrease HAART-related metabolic stress of adipose tissue.
A B
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Abstract
Timely identification of metastatic complications of blood stream infections due to spreading of 
the micro-organisms to distant sites, although critical, is often difficult. As 18F-fluorodeoxyglucose 
(FDG) accumulates in activated leukocytes in infectious lesions, FDG-positron emission 
tomography (PET) represents a promising imaging technique in these patients. The aim of this 
study was to assess the value of FDG-PET in detecting infectious foci in patients at high risk of 
metastatic complications.
Methods: The results of all FDG-PET-scans ordered because of suspected metastatic infection from 
October 1998 to September 2004 were analyzed retrospectively. These results were compared to 
conventional investigation techniques and the final clinical diagnosis. 
Results: The results of 40 FDG-PET-scans were evaluated. In 60% of all episodes, Gram-positive 
bacteria were cultured, in 18% Gram-negative bacteria, in 20% Candida spp., and in 3% the infection 
was polymicrobial. Metastatic complications were diagnosed in 75% of all episodes. A median 
number of four diagnostic procedures to search for metastatic infection had been performed 
before FDG-PET was ordered. FDG-PET diagnosed a clinically relevant new focus in 45% of cases 
and confirmed abnormalities already diagnosed in 30%. The positive predictive value of FDG-PET 
was 91% and the negative predictive value was 100%.
Conclusion: FDG-PET is a valuable imaging technique in patients at high risk of metastatic 
infectious disease even when the results of other diagnostic procedures are normal.
Introduction
One of the main complications of blood stream infections, especially in case of S. aureus bacteremia 
or candidemia, is secondary metastatic infection caused by spreading of the micro-organisms to 
distant sites. The prevalence of metastatic infection in patients with S. aureus bacteremia varies 
from approximately 2 to 30% [1,2]. In a retrospective study, 29% of patients who were treated 
for candidemia developed disseminated disease [3]. The frequency of metastatic complications 
after bacteremic episodes caused by other micro-organisms is not known. Known risk factors for 
developing metastatic complications of S. aureus bacteremia are community acquisition, unknown 
portal of entry, longer time span between first symptoms and initiation of antibiotic therapy, 
the presence of prosthetic devices, persistent fever after 72 hours, and positive follow-up blood 
cultures at 24 to 96 hours [4-8]. An important consequence of metastatic infection is the need 
for prolonged antimicrobial therapy. Failure to identify metastatic complications may lead to 
early cessation of therapy and relapse of blood stream infection and unfavorable outcome. Timely 
identification of infectious lesions, however, is often difficult, especially in patients without signs 
pointing to a specific localization. 
Focal infectious disease can be detected by computed tomography (CT), magnetic resonance 
imaging (MRI) and ultrasonography. These techniques, however, are less suitable as a screening 
method when clues for specific sites of infection are absent. Scintigraphic imaging allows 
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delineation of the localization of foci in all parts of the body, based on functional changes of tissues. 
Since activated inflammatory cells take up large amounts of glucose as a result of an increased 
metabolic rate [9], 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) represents 
a promising imaging technique in these patients. The aim of this study was to assess the value of 
FDG-PET in detecting metastatic infectious foci in patients with bacteremia or fungemia at high 
risk of metastatic infection.
Materials and methods
Patients 
The results of all FDG-PET-scans ordered because of suspected metastatic infectious disease 
from October 1998 to September 2004 at the Radboud University Nijmegen Medical Centre 
were analyzed retrospectively. The suspicion of metastatic complications was based on positive 
blood cultures and one or more of the following symptoms and signs: persisting fever or positive 
blood cultures for more than 48 hours after initiation of antibiotic therapy, clinical deterioration 
after initial improvement of symptoms, or metastatic infectious foci elsewhere. All patients 
were evaluated with other imaging modalities and laboratory tests as was considered clinically 
appropriate.
FDG-PET 
A full ring PET scanner (ECAT-EXACT, Siemens/CTI, Knoxville, TN, USA) was used for data 
acquisition. Prior to FDG-injection patients had fasted for at least 6 hours. Immediately prior to the 
procedure, the patients were hydrated with 500 ml of water. One hour after intravenous injection 
of 200-220 MBq FDG (Tyco Healthcare/Mallinckrodt Medical, Petten, The Netherlands) and 10 to 
15 mg furosemide, emission and transmission images of the area between the proximal femora and 
the base of the skull were acquired (10 minute per bed position). The images were corrected for 
attenuation and were reconstructed using the ordered subsets-expectation maximization (OSEM) 
algorithm. Reconstructed images were displayed in coronal, transverse and sagittal planes. FDG-
PET results were judged to be abnormal if focal accumulation of the tracer was detected outside 
areas of physiological uptake.
Clinical features
The portal of entry was defined as a localized focus of infection preceding bacteremia or fungemia. 
Primary infection of the respiratory or urinary tract was diagnosed only when symptoms and 
signs typically associated with bacterial infections of those systems were present in addition 
to appropriate culture results. Other foci were considered to be secondary metastatic infection. 
Endocarditis, defined according to the Duke criteria [10], and spondylitis were always considered 
as secondary metastatic infection. An intravascular catheter was considered to be the portal of 
entry if there was evidence of inflammation at the insertion site and/or culture of the vascular 
catheter tip was positive for the same micro-organism without clinical evidence of another source 
for infection. The infection was considered to be nosocomial if cultures obtained after >48 hours of 
94
_____  Chapter 5  _____________________________________________________________________________________________________________ __________________________________________________________________  FDG-PET in detecting metastatic infectious disease  _____ 
95
hospitalization were positive and clinical signs of infection were absent at the time of admission. 
The infection was considered to be community-acquired if cultures were positive within 48 hours 
after admission and/or signs of blood stream infection were present before admission. 
Clinical assessment of test results and diagnosis
The results of FDG-PET were evaluated for their diagnostic contribution. A normal FDG-PET-scan 
was called true negative when no metastatic complications or relapse of infection were diagnosed 
during clinical follow-up of at least three months. A normal FDG-PET scan was considered false 
negative when a focal infection was diagnosed except for infection in the brain, the heart, the 
kidneys or the bladder (sites known for low sensitivity of FDG-PET due to physiological uptake of 
FDG) or the legs (not routinely imaged). Results were considered to be true positive when abnormal 
FDG-uptake pointed to the organ or tissue where the cause of the symptoms was eventually found. 
FDG-uptake in the source of the infection as well as in metastatic infectious foci were considered as 
true positive results. True positive FDG-PET results were further categorized as “clinically relevant 
new finding” when the abnormality caused a change of treatment (longer duration of antibiotic 
therapy, switching to another antibiotic or combination of antibiotics, drainage of abscesses or 
surgical intervention), as “clinically irrelevant new finding” when the abnormality did not change 
treatment or as “already known” when FDG-PET only showed metastatic foci already diagnosed 
by other diagnostic techniques. Abnormal results were categorized as false positive when the 
abnormality could not be confirmed. The final or probable clinical diagnosis served as a standard of 
reference and was used for the assessment of the FDG-PET results.
Follow-up
Medical charts were reviewed for follow-up data. After a minimum follow-up of three months, the 
patient was considered to be cured when no symptoms or signs of infection were present after 
discontinuation of antibiotic therapy. Attributable mortality included all patients who died with 
persistent signs or symptoms of systemic infection, positive blood culture results or a persistent 
focus of infection in the absence of another explanation for death. Relapse was defined as a second 
episode of bacteremia or fungemia with the same micro-organism within 12 weeks of the initial 
episode.
Statistical analysis
Descriptive statistics for continuous variables are represented as medians ± standard deviations. 
Categorical variables are reported in terms of the number and percentage of patients affected. 
Differences between the group of patients eventually diagnosed with metastatic infection and 
the group of patients without metastatic infection were tested with unpaired student t-tests 
for continuous variables and with Fisher’s exact tests for categorical variables. Differences were 
considered to be statistically significant at P <0.05.
96
_____  Chapter 5  _____________________________________________________________________________________________________________ __________________________________________________________________  FDG-PET in detecting metastatic infectious disease  _____ 
97
Results
From October 1998 to September 2004, 40 FDG-PET-scans were performed because of suspected 
metastatic infection. In two patients, FDG-PET was performed during two separate episodes of 
central venous catheter (CVC)-related blood stream infection. Patient characteristics for the total 
number of infectious episodes and subdivided for patients eventually diagnosed with metastatic 
disease and patients without metastatic foci are shown in Table 1. Three-quarters of infections were 
community-acquired with a short duration of symptoms before presentation (median one day). All 
patients had at least one risk factor for developing complicated disease. None of the patients had 
neutropenia. The total number of positive blood cultures and the number of days for which blood 
cultures remained positive were significantly higher in patients with metastatic disease.
Table 1 Patient characteristics of 40 patients suspected of infectious metastatic disease in whom FDG-PET was 
performed 
Characteristic Total Metastatic Foci
(n=40) Yes (n=30) No (n=10)
Male 23 (58%) 17 (57%) 6 (60%)
Female 17 (42%) 13 (43%) 4 (40%)
Age (years) 60 ± 17 60 ± 17 60 ± 18
Community acquired infection 30 (75%) 23 (77%) 7 (70%)
Duration of symptoms until presentation (days)#† 1 ± 8 1 ± 7 1 ± 9
Duration of symptoms until adequate therapy (days)#† 2 ± 8 3 ± 8 2 ± 9
CVC present 13 (33%) 10 (33%) 3 (30%)
Duration of CVC present (weeks)† 12 ± 62 14 ± 69 1 ± 9
Total parenteral nutrition 9 (23%) 7 (23%) 2 (20%)
Diabetes mellitus 4 (10%) 3 (10%) 1 (10%)
Peritoneal dialysis 2 (5%) 1 (3%) 1 (10%)
Hemodialysis 1 (3%) 0 1 (10%)
Pacemaker 3 (8%) 3 (10%) 0
Congenital heart disease 3 (8%) 3 (10%) 0
Mechanic heart valve 2 (5%) 2 (7%) 0
Malignancy 1 (3%) 1 (3%) 0
Immunosuppressive drugs 8 (20%) 7 (23%) 1 (10%)
I.V. drug use 0 0 0
Positive blood cultures (number/patient)† 3 ± 3 4 ± 3‡ 2 ± 1‡
Duration of positive blood cultures (days)† 2 ± 8 3 ± 8‡ 1 ± 1‡
CVC=central venous catheter 
# One patient was excluded from these calculations because she had suffered from lower back pain, periodic low-grade fever and 
fatigue for almost three years before she was diagnosed with a S. aureus psoas abscess and before FDG-PET was performed.
† median ± SD
‡ P <0.05
Culture results are shown in Table 2. S. aureus was the most common cause of bacteremia (14 
episodes, 35%). All patients with Gram-negative bacteremia for whom an FDG-PET-scan was 
ordered were eventually diagnosed with metastatic complications. Metastatic infection was also 
found in 16 episodes of Gram-positive bacteremia (64%) and 7 episodes of candidemia (78%). The 
portal of entry was known in 28 episodes (70%, Table 3). In all patients with CVC-related blood 
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stream infections, the CVC was removed before FDG-PET was requested. In 30 cases (75%), 
metastatic infectious foci were eventually diagnosed by conventional diagnostic techniques, FDG-
PET or both. Metastatic infection was most often diagnosed in the cardiovascular system, the lungs 
and in bones or joints (Table 4). Of those with metastatic infection, 11 (37%) were diagnosed with 
metastatic foci in more than one organ system.
Table 2 Culture results
Category Species Total Metastatic foci
(n=40) Yes (n=30) No (n=10)
Gram-positive bacteria Staphylococcus aureus 14 7 7
Staphylococcus epidermidis 1 1 0
Streptococcus pneumoniae 3 3 0
Other Streptococcus spp. 5 4 1
Enterococcus spp.# 2 1 1
Gram-negative bacteria Escherichia coli 3 3 0
Proteus mirabilis 1 1 0
Enterobacter cloacae 1 1 0
Salmonella group D 1 1 0
Serratia marcescens 1 1 0
Yeasts Candida albicans 6 6 0
Candida parapsilosis 2 1 1
Candida tropicalis# 1 0 1
# In one patient, blood cultures were positive for Enterococcus faecium as well as Candida tropicalis.
Table 3 Portal of entry: source of the bacteremia or fungemia
Diagnosis Total Metastatic foci
(n=40) Yes (n=30) No (n=10)
CVC-related blood stream infection 12 9 3
Soft tissue-/skin-infection 5 1 4
Pneumonia 1 1 0
Urinary tract infection 4 4 0
CAPD-peritonitis 2 1 1
Wound infection 1 0 1
Cholangitis 2 1 1
Meningitis 1 1 0
Not known 12 12 0
CVC=central venous catheter
CAPD=continuous ambulatory peritoneal dialysis
A median number of four diagnostic procedures to search for metastatic complications was performed 
before FDG-PET was requested (range 1 to 10). Chest X-ray was performed in 34 patients (85%), chest 
CT in seven patients (18%), abdominal ultrasound in 25 patients (63%), abdominal CT in 18 patients 
(45%), doppler ultrasonography of the subclavian and internal jugular veins in six patients (50% of all 
patients with CVC-related infection), and echocardiography was performed in 21 patients (53%). 
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Table 4 Localization of metastatic infectious foci in 30 patients eventually diagnosed with metastatic disease
Organ system Number (n=30)
Endocarditis 5
Endovascular 10
Lungs 7
Liver/biliary tract 2
Spleen 2
Arthritis 4
Nonvertebral osteomyelitis 1
Vertebral osteomyelitis 3
Psoas abscess 1
Skin/soft tissue 5
Brain 2
Eye 1
  In 11 patients, metastatic infectious foci were found in more than one organ system.
Results of FDG-PET were negative in six patients (Table 5). None of these patients were diagnosed 
with metastatic complications or relapse after a follow-up period of at least three months, so 
these results were considered true negative. FDG-PET results were true positive in 31 cases 
(78%). FDG-PET diagnosed a clinically relevant new focus (Figure 1) in 18 cases (45%), a clinically 
irrelevant new focus in one patient and confirmed already diagnosed abnormalities in 12 cases 
(30%). In 27 of these 31 episodes, FDG-PET results were fully confirmed by conventional diagnostic 
techniques. Results were partially confirmed in three cases. In the first patient, PET demonstrated 
increased FDG-uptake in the right wrist and the left hip. Infection of the wrist was confirmed by 
ultrasound showing a small fluid collection and an infiltrate surrounding the ulnar artery, but no 
diagnostic procedure was performed to confirm arthritis of the left hip. In the second patient, 
PET showed increased FDG-uptake in the liver and both total hip prostheses. Abdominal CT and 
culture confirmed liver abscesses, but ultrasound only partially confirmed infection of both total 
hip prostheses by demonstrating a large fluid collection around the left hip prosthesis. In the 
third patient, PET demonstrated abnormal FDG-uptake in multiple foci in both lungs and the liver 
hilus and irregular uptake in the spleen. Pulmonary abscesses and cholangitis were confirmed by 
other diagnostic procedures, but abdominal CT did not show any abnormalities of the spleen. In 
one patient with endocarditis, PET showed increased FDG-uptake around a vascular prosthesis 
of the abdominal aorta. Infection of his vascular prosthesis was supported by clinical signs and 
favorable reaction to antibiotic therapy, but was not confirmed otherwise. In this case, surgery was 
not possible because of his deteriorated cardiovascular condition. The histories of three patients 
with Candida lung abscesses diagnosed with FDG-PET have been described in a research note [11]. 
In three other patients, FDG-PET results were false positive. The first patient was diagnosed with 
a urinary tract infection and abdominal CT showed extensive thrombosis of both femoral veins, 
iliac veins and the inferior caval vein extending from a caval filter, which was suspected to be 
infected. PET showed increased FDG-uptake in the thrombosed blood vessels, but also in several 
mediastinal lymph nodes. On chest CT, however, no pathologically enlarged lymph nodes were 
found. In the second patient, PET demonstrated increased FDG-uptake in the right hip and the left 
femur. Arthritis of the right hip was confirmed by 111Indium-labeled polyclonal immunoglobulin G 
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(IgG)-scintigraphy, but no abnormal IgG-uptake in the left femur was found. In the third patient 
who was treated with azathioprine and prednisone because of a renal transplant, PET showed 
right-sided retroperitoneal FDG-uptake, but abdominal ultrasound was normal. In the remaining 
7 patients treated with immunosuppressive drugs, FDG-PET was true positive. In the 40 cases 
studied, positive predictive value of FDG-PET was 91% and negative predictive value was 100%.
Table 5 FDG-PET results in 40 patients suspected of metastatic infectious disease
FDG-PET results Number Confirmation
(n=40) Total Partial Not
Negative
True-negative 6
False-negative 0
Positive
True-positive 31# 27 3 1
Clinically relevant 18 15 2 1
Clinically irrelevant 1 0 1 0
Already known 12# 12 0 0
False-positive 3 0 0 3
# In one patient with Staphylococcus aureus bacteremia without metastatic infection, FDG-uptake was seen in the abscess of 
his right arm, which was the source of his bacteremia. FDG-PET was otherwise normal.
Figure 1 In a 45-year-old woman with Staphylococcus aureus septicemia and persistent fever during therapy, PET showed 
increased FDG-uptake in multiple lesions in both lungs, the mediastinum and in the upper abdomen (Figure 1A). 
Subsequently, chest CT also showed multiple lesions in both lungs and the mediastinum. Cholangitis caused 
by gallstones was confirmed by abdominal ultrasound and endoscopic retrograde cholangiopancreatography 
(ERCP). The fever disappeared within two days after ERCP. After three months, FDG-PET was normal (Figure 1B) 
and antibiotic therapy was discontinued.
The median duration of follow-up was 12 months (range 3 to 51 months). The duration of 
hospitalization was significantly longer in the patients with metastatic complications (median 47 
vs. 23 days, Table 6). The patients with metastatic complications were also treated with antibiotics 
for a longer time period (median 75 vs. 35 days). The duration of fever, the percentage of patients 
A B
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admitted to the ICU, and the duration of ICU stay, however, did not differ significantly between 
patients with and patients without metastatic complications. In the group with metastatic 
infection, five patients died of complicated infection and four patients had persisting infection 
(one patient with a mycotic aortic aneurysm with a follow-up of 36 months and three patients with 
infected vascular prostheses, who could not be treated surgically, with a follow-up of 3, 6, and 23 
months, respectively). One patient, who had been treated because of a S. aureus psoas abscess, was 
diagnosed with a relapse after discontinuation of antibiotic therapy. The cure rate was significantly 
lower in the group with metastatic infection than in patients without metastatic complications 
(67% vs. 100%). 
Table 6 Outcome of 40 patients suspected of metastatic infectious disease
Characteristic Total Metastatic foci
(n=40) Yes (n=30) No (n=10)
Duration of fever (days)# 18 ± 27 25 ± 30 7 ± 14
Duration of hospitalization (days)# 45 ± 25 47 ± 25† 23 ± 18†
Duration of antibiotic therapy (days)# 50 ± 266 75 ± 299† 35 ± 16†
Admission to ICU 7 (18%) 6 (20%) 1 (10%)
Duration of ICU stay (days)# 2 ± 6 2 ± 6 2
Cure 30 (75%) 20 (67%)† 10 (100%)†
Persisting infection 4 (10%) 4 (13%) 0
Relapse 1 (3%) 1 (3%) 0
Death 5 (13%) 5 (17%) 0
  # median ± SD
  † P <0.05
Discussion
In this study, the utility of FDG-PET in patients suspected of metastatic infectious disease was 
evaluated. Even after a median number of four conventional diagnostic tests, FDG-PET revealed 
clinically relevant new infectious foci in 45% of all patients. In these cases, the results of FDG-PET 
led to a change of treatment. This study represents the largest patient population ever screened for 
metastatic infectious foci by FDG-PET. No comparable studies are available at this time. In several 
previous studies, the accuracy of FDG-PET for diagnosing primary, mostly orthopedic, infections 
ranged from 80 to 100% [12-14]. Although FDG-PET is able to detect infection of joint prostheses, 
it is less accurate than, and is not a suitable replacement for, leukocyte imaging or labeled IgG 
for this indication [15,16]. In three prospective studies, FDG-PET enabled correct visualization of 
spondylodiscitis and proved to be superior to MRI, 67gallium-citrate scintigraphy and bone scan 
[17-19]. In two studies, FDG-PET reliably identified septic thrombophlebitis in cancer patients with 
CVCs suspected of infection and was able to distinguish septic thrombophlebitis from deep venous 
thrombosis leading to significant therapeutic changes [20,21]. PET revealed increased FDG-uptake 
at the site of the CVC even in patients without signs of infection and in several patients with severe 
neutropenia. It is obviously impossible to compare these studies because of different study designs 
and different patient characteristics, but the results of these studies and our results suggest that 
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FDG-PET is a sensitive method to detect various infectious foci in different organ systems with a 
reasonable specificity. 
A weakness of this study is its retrospective nature. A high percentage of patients had metastatic 
disease, underscoring that this group of patients had been selected on the basis of their high risk of 
metastatic complications. The results of this study, therefore, should not be applied to all patients 
with blood stream infection. Furthermore, since a rigid investigation protocol for the diagnostic 
work-up of these patients was not applied, the number and the kind of diagnostic tests performed 
differed considerably between individual patients. For a period of at least three months after 
admission, follow-up data were available from the medical charts of all patients. However, it cannot 
be excluded that relapses have occurred, which remained unnoticed by the attending physicians. 
Calculation of sensitivity and specificity of FDG-PET in patients suspected of focal infection is 
difficult for several reasons. First, the interpretation of this procedure is hampered due to a lack of a 
gold standard, especially in case of a normal FDG-PET-scan. When additional diagnostic procedures 
were negative and a follow-up of at least three months did not reveal new infectious foci or a relapse 
after discontinuation of therapy, it was considered appropriate to presume that other infectious 
foci were indeed absent. Second, FDG-PET cannot exclude cerebral disease or meningitis, because 
physiologic uptake in the cerebral cortex in most cases obscures any pathological uptake. Besides 
physiologic uptake of FDG in the brain, normal activity in the heart, the kidneys and the bladder 
severely hampers the delineation of disease in these organs. Variable physiologic FDG-uptake in 
the bowel is possible [22] and can thus lead to a false positive interpretation, although this problem 
was not encountered in our group of patients. 
Detection of infectious foci by CT, MRI and ultrasonography is difficult in an early phase because 
of the lack of substantial anatomical changes at that time. Also, discrimination of active infectious 
lesions from residual changes due to cured processes or surgery remains difficult. FDG-PET shows 
functional changes caused by activation of inflammatory cells and does not depend on anatomical 
changes. In addition, advantages of FDG-PET in suspected metastatic infection, compared to CT 
and MRI, are whole body screening, high contrast resolution, absence of disturbance by metallic 
implants and absence of contrast-related side effects (CT). Conventional radiopharmaceuticals 
routinely used in clinical practice (67Ga-citrate and 111In-labeled or 99mTc-labeled leucocytes or 
IgG) have several disadvantages, such as normal accumulation in liver and spleen, handling of 
potentially infected blood products, and high radiation burden (67Ga) [23]. Advantages of FDG-PET 
are early imaging (one hour vs. up to 48 hours), higher resolution, high target-to-background ratio 
[24], sensitivity in chronic low-grade infections [25-27], high accuracy in the central skeleton, liver, 
spleen and vascular system, and high interobserver agreement [25]. Obvious disadvantages are the 
relatively high cost and the currently limited availability. However, when FDG-PET performance for 
this indication is confirmed in larger prospective studies and the number of PET-systems further 
increases, the high diagnostic yield of FDG-PET may well become a clinically significant and also 
cost-effective modality, since adequate early diagnosis limits the number of non-contributing 
(invasive) tests required and the time to diagnosis and thus facilitates adequate antibiotic and/
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or local (surgical) therapy. A further potential application, that needs to be investigated, is the 
contribution of FDG-PET in determining the duration of antimicrobial treatment in patients with 
metastatic infection.
Conclusion
FDG-PET is a valuable imaging technique in patients at high risk of metastatic infectious disease 
even when the results of other diagnostic procedures show no signs of infection. However, for a 
validation of FDG-PET for this indication and for determination of its exact position in the order of 
diagnostic tests, prospective studies in a larger number of patients are warranted.
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Abstract
Nowadays fever of unknown origin (FUO) is often defined as a fever higher than 38.3oC on several 
occasions during at least 3 weeks with uncertain diagnosis after a number of obligatory tests. 
Infection accounts for about one-third of cases of FUO, followed by neoplasm and non-infectious 
inflammatory diseases. No diagnosis is reached in 25 to 35% of cases. In patients with periodic fever, 
this percentage is even higher. A diagnostic algorithm is proposed in which the most important step 
is a history taking, physical examination and the obligatory investigations in a search for potentially 
diagnostic clues (PDCs). First, factitious fever and drug fever should be ruled out. Further diagnostic 
procedures should be guided by a list of most probable diagnoses. In patients without useful PDCs, 
certain diagnostic procedures, divided in first stage and second stage investigations should be 
performed. If no diagnosis is reached and the clinical condition is stable, waiting for new PDCs is 
recommended. In patients with recurrent fever, the diagnostic workup should consist only of the 
search for PDCs matching known recurrent syndromes. Scintigraphic methods, such as 67gallium 
citrate, labeled leukocytes, and 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), 
are often used in patients with FUO. Because of favorable characteristics of FDG-PET, conventional 
scintigraphic techniques may be replaced by FDG-PET in institutions where PET is available. If 
undiagnosed fever persists, supportive treatment with NSAIDs can be helpful. Most patients with 
undiagnosed FUO have benign self-limiting or recurrent fever. Only if patients deteriorate, other 
therapeutic trials should be considered. 
Definition
Despite recent advances in diagnostic techniques, fever of unknown origin (FUO) remains a 
formidable diagnostic challenge. In 1961, FUO was defined by Petersdorf and Beeson as an illness 
of more than three weeks duration, fever higher than 38.3oC (101oF) on several occasions, and 
diagnosis uncertain after one week of study in the hospital [1]. This definition has been modified 
by removing the requirement that the evaluation must take place in the hospital and by excluding 
immunocompromized patients, because these patients need an entirely different diagnostic 
and therapeutic approach. Recently it has been proposed to change the quantitative criterion 
(diagnosis uncertain after one week of study) to a qualitative criterion that requires a list of certain 
investigations to be performed in order to reduce selection bias. Defining the necessary initial 
investigations will remain a matter of debate, but it is generally agreed that the initial diagnostic 
protocol required for a case to qualify as FUO should at least include the following tests: a 
comprehensive history and physical examination, routine blood tests, antinuclear antibodies, 
rheumatoid factor, microscopic urinalysis, three blood cultures, a urine culture and other cultures if 
clinically indicated, chest X-ray, abdominal ultrasonography and a tuberculin skin test (Table 1).
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Table 1 Definition of fever of unknown origin
1. Fever higher than 38.3oC (101oF) on two occasions
2. More than three weeks duration
3. Exclusion of immunocompromized patients: neutropenia (leukocyte count < 1.0 x 109/l and/or granulocyte 
count < 0,5 x 109/l) during at least 1 week within the 3 months preceding the fever, known HIV-infection, known 
hypogammaglobulinemia (IgG < 50% of the normal value), use of the equivalent of more than 10 mg prednisone 
during at least 2 weeks in the previous 3 months
4. Diagnosis uncertain after thorough history-taking, physical examination and the following obligatory investigations: 
ESR or CRP, hemoglobulin, trombocyte count, leukocyte count and differentiation, electrolytes, kreatinine, total 
protein, protein electrophoresis, alkaline phosphatase, AST, ALT, LDH, creatine kinase, antinuclear antibodies, 
rheumatoid factor, urinalysis, blood cultures (n=3), urine culture, chest X-ray, abdominal ultrasonography and 
tuberculin skin test
Causes of FUO
Table 2 presents an overview of the differential diagnosis of FUO, which is probably the longest in 
medicine. In general, infection accounts for about one-third of cases of FUO, followed by neoplasm 
and non-infectious inflammatory diseases (NIID) [2]. The term NIID has replaced older terms such 
as rheumatic diseases, collagen diseases etc. The category NIID includes “collagen or rheumatic 
diseases”, vasculitis syndromes and granulomatous disorders. 
In recent series of FUO, no diagnosis could be reached in 25 to 35% of all cases. In patients with 
recurrent fever, often defined as repeated episodes of fever with fever-free intervals of at least 
two weeks and apparent remission of the underlying disease, the chance of reaching a diagnosis 
is less than 50%. 
Table 2 Possible causes of FUO
Infections
Bacterial, non-specific
Endocarditis, abdominal abscesses, appendicitis, diverticulitis, adnexitis, endometritis, renal abscess, xanthogranulomatous 
pyelonephritis, cholecystitis, cholangitis, bacterial hepatitis, prostatitis, urinary tract infections, apical granuloma, sinusitis, 
mastoiditis, intracranial abscess, epidural abscess, lung abscess, mediastinitis, mycotic aneurysm, infected vascular 
catheter, infected vascular prosthesis, septic phlebitis, osteomyelitis, spondylodiscitis, infectious arthritis, infected joint 
prosthesis, infective myonecrosis
Bacterial, specific
Actinomycosis, bartonellosis, brucellosis, campylobacteriosis, Chlamydia pneumoniae infection, chronic meningococcemia, 
ehrlichiosis, febris recurrens (Borrelia recurrentis), gonococcemia, legionellosis, leptospirosis, listeriosis, Lyme disease, 
melioidosis (Pseudomonas pseudomallei), Mycoplasma infection, psittacosis, Q-fever (Coxiella burnetii), rickettsiosis, 
salmonellosis, Spirillum minor infection, Streptobacillus moniliformis infection, syphilis, tularemia, tuberculosis, Whipple’s 
disease, yersiniosis
Viral
Cytomegalovirus infection, Coxsackievirus infection, dengue, Epstein Barr virus infection, hanta, hepatitis A, B or C, Herpes 
simplex, HIV infection, parvovirus infection
Fungal
Aspergillosis, candidiasis, cryptococcosis, histoplasmosis, malassezia furfur infection, Pneumocystis jiroveci pneumonia
Parasitic
Amoebiasis, babesiosis, schistosomiasis, echinococcosis, fascioliasis, leishmaniasis, malaria, toxocariasis, toxoplasmosis, 
trypanosomiasis, trichinosis
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Neoplasia
Hematological
Angio-immunoblastic lymphoma, Hodgkin’s disease, non-Hodgkin’s lymphoma, leukemia, malignant histiocytosis, multiple 
myeloma, myelodysplastic syndrome, myelofibrosis, lymphomatoid granulomatosis, systemic mastocytosis
Solid tumors
Most solid tumors and metastases can cause fever, the most common causes of FUO are: breast carcinoma, colon 
carcinoma, hepatocellular carcinoma, lung carcinoma, pancreatic carcinoma and renal cell carcinoma
Benign tumors
Angiomyolipoma, craniopharyngioma, cavernous hemangioma of the liver, necrosis in dermoid tumor in Gardner’s 
syndrome
Non-infectious inflammatory diseases
“Collagen diseases”
Acute rheumatic fever, ankylosing spondylitis, Behçet’s disease, cryoglobulinemia, dermatomyositis, Felty syndrome, mixed 
connective tissue disease, polymyositis, Reiter’s syndrome, rheumatoid arthritis, systemic lupus erythematosus, recurrent 
polychondritis, Sjögren’s syndrome, Still’s disease
Vasculitis syndromes
Allergic vasculitis, Churge-Strauss syndrome, giant cell vasculitis/polymyalgia rheumatica, hypersensitivity vasculitis, 
polyarteritis nodosa, Takayasu arteritis, urticarial vasculitis, Wegener’s granulomatosis
Granulomatous diseases
Crohn’s disease, granulomatous hepatitis, granulomatous myositis, sarcoidosis
Miscellaneous (in alphabetical order)
Adrenal insufficiency, amyloidosis, aneurysms, anhidrotic ectodermal dysplasia, anomalous thoracic duct, antiphospholipid 
syndrome, aortic dissection, aortic-enteral fistula, aseptic meningitis (Mollaret’s syndrome), atrial myxoma, auto-immune 
hemolytic anemia, auto-immune hepatitis, brewer’s yeast ingestion, Caroli’s disease, Castleman’s disease, cerebrovascular 
accident, cholesterol emboli, cirrhosis, complex partial status epilepticus, cyclic neutropenia, drug fever, Erdheim-
Chester disease, erythema multiforme, erythema nodosum, extrinsic allergic alveolitis, Fabry’s disease, factitious disease, 
familial Mediterranean fever, FAPA syndrome (fever, aphthous stomatitis, pharyngitis, adenitis), Gaucher’s disease, 
gout, habitual hyperthermia, Hamman-Rich syndrome (acute interstitial pneumonia), Hashimoto’s encephalopathy, 
hematoma, hemophagocytic syndrome, hyper IgD syndrome, hypersensitivity pneumonitis, hyperthyroidism, 
hypertriglyceridemia, hypothalamic hypopituitarism, idiopathic hypereosinophilic syndrome, idiopathic normal pressure 
hydrocephalus, inflammatory pseudotumour, Kawasaki’s syndrome, Kikuchi’s syndrome, linear IgA dermatosis, Loch Fyne 
fever, malacoplakia, mesenteric fibromatosis, metal fume fever, milk protein allergy, Muckle-Wells syndrome, myotonic 
dystrophy, pheochromocytoma, polymer fume fever, postmyocardial infarction syndrome, primary biliary cirrhosis, primary 
hyperpathyroidism, pseudogout, psychogenic fever, pulmonary embolism, retroperitoneal fibrosis, Schnitzler’s syndrome, 
sclerosing mesenteritis, sickle cell disease vaso-occlusive crisis, silicone embolisation, subacute thyroiditis (de Quervain’s), 
Sweet’s syndrome, Teflon embolisation, thrombosis, TRAPS (tumor necrosis factor receptor-associated periodic syndrome, 
formerly known as familial Hibernian fever), ulcerative colitis, vitamin B12 deficiency, Vogt-Koyanagi-Harada syndrome, 
Weber-Christian disease
Diagnosis
Because of the diversity of causes of longstanding fever, it is difficult to construct algorithms 
that cover the complete spectrum of FUO. The algorithm we propose is shown in Figure 1. The 
most important step in the diagnostic workup is a complete and repeated history taking, physical 
examination and the obligatory investigations in a search for potentially diagnostic clues (PDCs). 
PDCs are defined as all localizing signs, symptoms and abnormalities potentially pointing toward 
a diagnosis. Although often misleading, only with help of these PDCs a limited list of probable 
diagnoses can be made. 
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Figure 1 Diagnostic algorithm in patients with FUO
PDCs = potential diagnostic clues, NSAID = non-steroidal anti-inflammatory drug
(1) Obligatory tests for the definition of fever of unknown origin are shown in Table 1.
(2) First stage investigations are fundoscopy, serum for cryoglobulins, and temporal artery biopsy in patients older than 55 years
(3) 67gallium citrate, 111indium-labeled or 99mtechnetium-labeled leukocytes or 18F-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) can be used. Because of favorable characteristics of FDG-PET, we believe that conventional scintigraphic 
techniques may be replaced by FDG-PET in institutions where PET is available. In our hospital, FDG-PET is performed after 
the first stage investigations, but placing scintigraphic imaging after the second stage investigations is a common strategy.
(4) Second stage investigations are bone marrow biopsy, liver biopsy, abdominal CT and chest CT.
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History 
A thorough history should include information about alcohol intake, medications, occupational 
exposures, exposure to animals, travel, risk for venereal diseases, familial disorders, exposure to 
tuberculosis and previous illnesses. The most common PDCs are relevant past medical or social 
history, weight loss, headache, myalgia, arthralgia, skin lesions and diarrhea.
Physical examination 
Clinicians should perform a complete physical examination with special attention to the lymph 
nodes, temporal arteries, sites of previous surgery, the entire skin surface and mucous membranes. 
Specific findings leading to a diagnosis in FUO are numerous and diverse, but can often be 
detected only by a very careful examination and may be missed the first time. In the absence of 
PDCs, the physical examination should therefore be repeated regularly.
Clinical features 
One of the first steps should be to rule out factitious fever particularly in patients without signs 
of inflammation on laboratory tests. Also, all medications, including non-prescription drugs and 
nutritional supplements, should be discontinued early in the evaluation to exclude drug fever. The 
length of time of previous use is irrelevant since medications that a patient has consumed without 
problems for years can cause fever. If the fever persists beyond 72 hours after discontinuation of 
the suspected drug it is unlikely that this drug is causing the fever. 
Investigations
Continuous fever 
After identification of all PDCs retrieved from the history, physical examination and obligatory 
tests, a limited list of most probable diagnoses should be made. Since most investigations are 
helpful only when performed in patients with PDCs for the diagnoses searched for, further 
diagnostic procedures should be limited to specific investigations used to confirm or exclude 
diseases on this list. In patients without PDCs or only misleading PDCs, the following procedures 
were found to be useful in the early stage of the diagnostic workup: fundoscopy, cryoglobulins, and 
temporal artery biopsy in patients older than 55 years. In a later phase, bone marrow biopsy, liver 
biopsy, abdominal CT and chest CT are useful in patients without PDCs [3]. However, second stage 
investigations should also be determined by local epidemiological data and the diagnostic facilities 
available. In patients with unexplained fever at this point, the last step in the diagnostic workup 
comes at an extraordinary high cost and discomfort with a marginal diagnostic yield. Repeating a 
thorough history taking, physical examination and review laboratory results and imaging studies 
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including those from other hospitals is recommended. Delay often results from the failure to 
recognize helpful clues in available information. In these patients with persisting FUO, waiting for 
new PDCs to appear probably is better than ordering more screening investigations. Only in the 
rare patient who deteriorates without presenting new PDCs, a further diagnostic workup should 
be performed. 
Recurrent or episodic fever 
In patients with familial fever or recurrent fever for more than two years, it is very unlikely that the 
fever is being caused by infection or malignancy. In these patients, the diagnostic workup should 
consist only of the thorough history taking, physical examination and obligatory examinations. The 
search for PDCs should be directed to PDCs matching known recurrent syndromes (Table 3). Only 
when PDCs for infections, vasculitis syndromes or malignancy are present, or when the clinical 
condition is deteriorating, further diagnostic tests should be considered. Systemic examinations 
should only be performed during a symptomatic phase.
Table 3 Possible causes of periodic fever
Familial syndromes
Fabry’s disease, familial Mediterranean fever, Gaucher’s disease, hyper IgD syndrome, hypertriglyceridemia, Muckle-Wells 
syndrome, TRAPS (tumor necrosis factor receptor-associated periodic syndrome)
Infections
Bacterial, non-specific
Recurrent bacteremia caused by colonic neoplasia, prostatitis, apical granuloma, diverticulitis or other focal infections
Bacterial, specific
Brucellosis, chronic meningococcemia, febris recurrens (Borrelia recurrentis), melioidosis (Pseudomonas pseudomallei), Q-
fever (Coxiella burnetii), salmonellosis, Spirillum minor infection, Streptobacillus moniliformis infection, syphilis, tularemia, 
Whipple’s disease, yersiniosis
Parasitic
Babesiosis, malaria, toxoplasmosis, trypanosomiasis, visceral leishmaniasis (Kala Azar)
Neoplasia
Angio-immunoblastic lymphoma, Hodgkin’s disease, non-Hodgkin lymphoma, malignant histiocytosis, colon carcinoma, 
craniopharyngioma
Non-infectious inflammatory diseases
Ankylosing spondylitis, mixed cryoglobulinemia, recurrent polychondritis, Reiter’s syndrome, systemic lupus erythematosus, 
Still’s disease, Crohn’s disease, granulomatous hepatitis, sarcoidosis
Miscellaneous (in alphabetical order)
Aortic-enteral fistula, atrial myxoma, brewer’s yeast ingestion, Castleman’s disease, cholesterol emboli, cyclic neutropenia, 
drug fever, extrinsic allergic alveolitis, factitious disease, FAPA syndrome (fever, aphthous stomatitis, pharyngitis, adenitis), 
habitual hyperthermia, hypersensitivity pneumonitis, hypothalamic hypopituitarism, inflammatory pseudotumour, Loch 
Fyne fever, metal fume fever, milk protein allergy, polymer fume fever, psychogenic fever, pulmonary embolism, Schnitzler’s 
syndrome, sclerosing mesenteritis
Scintigraphic imaging
Although the diagnostic yield and the exact place in the order of diagnostic procedures remain 
unclear, scintigraphic methods play an important role in the diagnostic process of patients with 
FUO in clinical practice. Opinions differ on the type of scintigraphic method that should be 
used. Conventional radiopharmaceuticals routinely used in patients suspected of infectious or 
inflammatory disease, such as 67gallium citrate (67Ga) and 111indium-labelled or 99mtechnetium-
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labelled leukocytes (WBC), have disadvantages and limitations, such as handling of potentially 
infected blood products (WBC), high radiation burden (67Ga), and the long time span between 
injection and diagnosis (67Ga). 
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)
FDG-PET detects malignant processes as well as infectious and inflammatory disorders, but is not 
able to differentiate between those disorders. As a screening procedure in the investigation of 
patients with FUO, however, this appears to be an advantage rather than a drawback. Compared to 
conventional nuclear medicine techniques, other advantages of FDG-PET are early imaging (one 
hour), higher resolution, and sensitivity in chronic low-grade infections, infections of the central 
skeleton and vasculitis. Based on several studies [4-6] and resulting from favorable characteristics 
of FDG-PET, conventional scintigraphic techniques may be replaced by FDG-PET in institutions 
where this technique is available. When ordered early in the diagnostic workup, FDG-PET enables 
identifying the organ or tissue where the cause of the fever is likely to be found. Abnormal FDG-
PET results could then be used for guiding intelligent further testing. However, for determination 
of its exact position in the order of diagnostic tests, prospective studies of FDG-PET being part of 
a structured diagnostic protocol are needed.
Management
If the fever persists and the source remains elusive after completing the second stage investigations, 
supportive treatment with NSAIDs can be helpful. Therapeutic trials with antibiotics, steroids, or 
antituberculous agents should be avoided, except in patients whose condition is deteriorating.
Prognosis
The prognosis is determined primarily by the underlying disease and also by rapidity of diagnosis. 
Most patients with undiagnosed FUO, however, have benign self-limiting or recurrent fever. In two-
thirds of cases, fever will resolve by two years with 3% mortality in this group at five years [7].
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Abstract
Fever of unknown origin (FUO) and suspected focal infection or inflammation are challenging 
medical problems. The aim of this study was to assess the value of FDG-PET in patients with FUO and 
patients suspected of focal infection or inflammation. All FDG-PET scans ordered because of FUO or 
suspected focal infection or inflammation in the last four years were reviewed. These results were 
compared to the final diagnosis. Thirty-five FDG-PET scans were performed in 35 patients with FUO. 
A final diagnosis was established in 19 patients (54%). Of the total number of scans, 37% were clinically 
helpful. Positive predictive value of FDG-PET in these patients was 87% and negative predictive value 
was 95%. Fifty-five FDG-PET scans were performed in 48 patients with suspected focal infection or 
inflammation. A final diagnosis was established in 38 patients (82%). Of the total number of scans, 
65% were clinically helpful. Positive predictive value of FDG-PET in these 55 episodes of suspected 
infection or inflammation was 95% and negative predictive value was 100%. It is concluded that FDG-
PET appears to be a valuable imaging technique in evaluation of FUO and suspected focal infection 
or inflammation. Furthermore, FDG-PET could become a useful tool for evaluating the effect of 
treatment of infectious and inflammatory processes that cannot reliably be visualized by conventional 
techniques. However, to assess the additional diagnostic value of this technique, prospective studies 
of FDG-PET being part of a structured diagnostic protocol are warranted.
Introduction
Fever of unknown origin and suspected focal infection or inflammation are challenging medical 
problems. In 1961, fever of unknown origin was defined by Petersdorf and Beeson as an illness 
of more than three weeks duration, fever higher than 38.3oC (101oF) on several occasions, and 
diagnosis uncertain after one week of study in the hospital [1]. This definition has been modified by 
removing the requirement that the evaluation must take place in the hospital [2] and by excluding 
immunocompromized patients, because these patients need an entirely different diagnostic and 
therapeutic approach [2,3]. In general, infection accounts for about one-third of cases of FUO, 
followed by neoplasm and collagen vascular diseases, while in 25 to 36% of the cases no diagnosis 
can be made [2,4-6]. Timely identification and localization of infectious and inflammatory lesions 
is critical in appropriate treatment of patients. Focal infectious and inflammatory processes can be 
detected by several radiological techniques including computerized tomography (CT), magnetic 
resonance imaging (MRI) and ultrasonography. However, infectious and inflammatory foci cannot 
be detected by these techniques in an early phase because of the lack of substantial anatomical 
changes at this time. Also, discrimination of active infectious or inflammatory lesions from residual 
changes due to cured processes or surgery remains difficult. 
Scintigraphic imaging is a non-invasive method allowing delineation of both localization and number 
of foci in all parts of the body, based on functional changes of tissues. 18F-fluorodeoxyglucose (FDG) 
positron emission tomography (PET) has become an established imaging tool in oncology and is now 
entering the field of clinical infectious diseases [7]. FDG accumulates in organ tissues with a high rate 
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of glycolysis [8], which not exclusively occurs in neoplastic cells. Lesions with a high concentration of 
activated inflammatory cells also show increased uptake of FDG [9,10]. Since the first report on high 
FDG-uptake in a human abdominal abscess [11], there have been many reports of FDG accumulation 
in different infections and inflammatory lesions. To assess the role of FDG-PET imaging in the 
evaluation of patients with FUO or suspected localized infection or inflammation, we evaluated the 
results of FDG-PET scans ordered because of FUO or suspected infection or inflammation.
Materials and methods
Patients 
The results of all FDG-PET scans ordered for evaluation of FUO or suspected focal infection or 
inflammation from January 1999 to December 2002 in the Radboud University Nijmegen Medical 
Centre were analyzed retrospectively. The first group consisted of patients with FUO, which was 
defined as a febrile illness of >3 weeks duration, a temperature of >38.3°C on several occasions, 
and no diagnosis after one week of evaluation in the hospital or in the outpatient department. 
Recurrent fever was defined as repeated episodes of fever with fever-free intervals of at least 
two weeks and apparent remission of the underlying disease. A rigid investigation protocol for 
the diagnostic work-up of patients with FUO was not applied. First level diagnostic tests were 
defined as tests performed in almost every patient, such as routine laboratory tests, blood cultures, 
serology, chest radiograph and abdominal ultrasound. Second level tests were defined as tests 
performed after the first level tests proved to be normal, for example CT or MRI scans, endoscopy, 
biopsy, 67gallium-citrate (67Ga), 111indium-leukocyte (111In-WBC) or 111In-human immunoglobulin 
G scintigraphy (111In-HIG). Third level tests were defined as tests performed after a thorough 
diagnostic work-up including several second level tests, usually concerning patients referred to 
our hospital for a second opinion. The second group of patients was defined by suspected focal 
infection or inflammation being the reason for ordering FDG-PET. The suspicion of infection or 
inflammation was based on a combination of several of the following symptoms and signs: fever, 
localizing symptoms, leucocytosis, elevated CRP or positive blood cultures. Both patient groups 
were evaluated with other imaging modalities and laboratory tests as was considered clinically 
appropriate.
FDG-PET
A dedicated, full ring PET scanner (ECAT-EXACT, Siemens/CTI, Knoxville, TN., USA) was used for 
data acquisition. Prior to FDG injection patients had fasted for at least 6 hours. Intake of sugar-
free liquids was permitted. Immediately prior to the procedure, the patients were hydrated with 
500 ml of water. One hour after intravenous injection of 200-220 MBq FDG (Tyco Healthcare/
Mallinckrodt Medical, Petten, The Netherlands) and 10 to 15 mg furosemide, emission images or 
emission and transmission images of the area between the proximal femora and the base of the 
skull were acquired (10 minute per bed position). When only an emission study was recorded, the 
images were not corrected for attenuation and were reconstructed using filtered back-protection 
(Butterworth filter with a cut-off frequency of 0.4 Nyquist). When emission and transmission 
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studies were recorded, the images were corrected for attenuation and were reconstructed using 
the ordered subsets-expectation maximization (OSEM) algorithm. Reconstructed images were 
displayed in coronal, transverse and sagittal planes.
Interpretation
For this study, FDG-PET scans were interpreted by two staff members of the department of 
nuclear medicine without information of the results of the original interpretation of the FDG-
PET scan, other diagnostic tests or the final diagnosis. Results were judged to be abnormal if 
focal accumulation of the tracer was detected outside of the areas of physiological uptake. 
Disagreements were resolved by consensus.
Clinical assessment of test results and diagnosis
The results of FDG-PET were evaluated for their diagnostic contribution. Abnormal FDG-PET scans 
were categorized as “helpful in diagnosis” or “non-contributory to diagnosis”. They were regarded 
as helpful in diagnosis when abnormal FDG-uptake pointed to the organ or tissue where the cause 
of the symptoms was eventually found by additional conventional diagnostic techniques. Abnormal 
results were regarded as non-contributory to diagnosis when the detected abnormality was 
considered to be unrelated to the illness causing the symptoms or when no final diagnosis could 
be made. Results were considered to be true positive when abnormal FDG-uptake pointed to the 
organ or tissue where the cause of the symptoms was eventually found by additional conventional 
techniques, as mentioned above. Abnormal results were categorized as false positive when the 
abnormality was not related to the illness or when no final diagnosis could be made. A normal 
FDG-PET scan was called true negative when no cause of the symptoms was identified despite an 
extensive diagnostic work-up and clinical follow-up of at least six months. A normal FDG-PET scan 
was considered false negative when a focal infection, inflammation or neoplasm was diagnosed 
except for infection or inflammation in the brain (known low sensitivity of FDG-PET and brain not 
routinely imaged) or the legs (not routinely imaged). A final diagnosis was based on positive blood 
or tissue culture, biopsy, surgery or autopsy. When this was not possible, a probable diagnosis was 
made based on clinical follow up, serology, or conventional radiological studies. The final diagnosis 
was never based on FDG-PET results alone. This final or probable diagnosis served as a standard of 
reference and was used for the comparisons with the FDG-PET results.
Results
From January 1999 to December 2002, 84 patients were referred for a total of 91 FDG-PET scans 
because of FUO or suspected focal infection or inflammation. One patient had to be excluded 
because of insufficient clinical data other than FDG-PET results, so the results of 90 FDG-PET 
scans in 83 patients were evaluated. Thirty-five FDG-PET scans were performed in 35 patients with 
FUO and 55 FDG-PET scans were performed in 48 patients because of suspected focal infection or 
inflammation. 
120
_____  Chapter 7  _____________________________________________________________________________________________________________ __________________________________  Clinical value of FDG-PET in FUO and in suspected focal infection or inflammation  _____ 
121
FUO
Of the total number of 35 patients with FUO, 15 were male and 20 were female with a median age 
of 51 years (range 18 to 82 years). Twenty patients (57%) had already been investigated by internists 
in other hospitals and were referred for a second opinion. The median duration of fever before an 
FDG-PET scan was performed was two months (range 3 weeks to 14 years). Six patients (17%) had 
recurrent fever.
An infectious disease was the cause of the fever in six patients (17%), a neoplasm in four patients 
(11%), non-infectious inflammatory diseases in six patients (17%), drug fever in one patient and 
“miscellaneous diseases” in two patients (6%) (Table 1). In 16 patients (46%), the cause of the fever 
was not found. In five of the 15 patients who were directly referred to our hospital (33%), no diagnosis 
could be reached. In 11 (55%) of the 20 patients who were referred for a second opinion, no cause of 
the fever was found. Six of 16 patients, in whom no diagnosis could be reached, had recurrent fever. 
In four patients, the fever subsided spontaneously after 3 months, 13 months, 3 years and 5 years, 
respectively. In one patient, the fever subsided after treatment with non-steroidal anti-inflammatory 
drugs after a duration of fourteen years and in two patients the fever disappeared upon treatment 
with prednisone after a duration of two and five years. One patient with a history of short bowel 
syndrome and chronic total parenteral nutrition recovered with antibiotic treatment after a total 
duration of fever of five weeks. In two patients the fever still persists for 18 months and 5 years.
Table 1 Final diagnoses in patients with FUO and classification of the results of FDG-PET for each category
Category No. of cases True positive
True 
negative
False 
positive
False 
negative
Infection  6  (17%) 4  2 - -
Persistent Yersiniosis  1 1  - - -
Septic thrombophlebitis of the portal vein  1 1  - - -
Pelvic abscess  1 1  - - -
Prostatitis  1 1  - - -
Generalized Bartonella infection  1 -  1 - -
Viral meningitis  1 -  1 - -
Neoplasm  4  (11%) 4  - - -
Metastatic gastric carcinoma  1 1  - - -
Malignant lymphoma  2 2  - - -
Soft tissue leiomyoma  1 1  - - -
Non-infectious inflammatory disease  6  (17%) 4  1 - 1
Polymyalgia rheumatica  1 1  - - -
Cryoglobulinemia  1 -  1 - -
Adult-onset Still’s disease  1 1  - - -
Polyarteritis nodosa  1 1  - - -
Sarcoidosis  1 1  - - -
Crohn’s disease  1 -  - - 1
Drug fever  1  (3%) -  - 1 -
Miscellaneous  2  (6%) 1  1 - -
Hemophagocytic syndrome  1 1  - - -
Chronic non-infectious meningitis  1 -  1 - -
No diagnosis  16  (46%) -  15 1 -
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Table 2  Second and third level diagnostic tests performed in 35 patients with FUO
Diagnostic method No. of cases 
Radiology
Sinus radiography  13
Small bowel follow through  9
Barium enema  6
Mammography  2
Intravenous pyelography  3
Echocardiography  14
Thoracic CT  16
Abdominal CT  30
Cerebral CT  5
Other CT  3
Cerebral MRI  5
Other MRI  5
Endoscopy
Gastroscopy  11
Colonoscopy  14
ERCP  1
Bronchoscopy  6
Scintigraphy
99mTc-leukocyte scan  4
67Ga-citrate scan  5
99mTc-human immunoglobulin scan  8
Ventilation/perfusion lung scan  6
Bone scan  7
Biopsy
Bone marrow  15
Liver  4
Lymph node  6
Skin/muscle  9
Other  3
Surgery
Mediastinoscopy  2
Laparotomy  5
  ERCP = endoscopic retrograde cholangiopancreaticography.
In all of the patients with FUO, the following diagnostic procedures were performed: history, 
clinical examination, routine laboratory tests, blood cultures, chest radiograph and abdominal 
ultrasound. In most patients subsequent diagnostic studies were performed (Table 2). In some 
cases one or more of these studies were done to further evaluate the results of FDG-PET. When 
patients were directly referred to our hospital, an FDG-PET scan was ordered after a median 
duration of the fever of five weeks (range 3 weeks to 5 years) as a second level test after the basic 
diagnostic work-up in most cases. In the remaining patients, an FDG-PET scan was ordered after a 
median duration of fever of nine months (range one month to 14 years) as a third level test after 
a very extensive diagnostic work-up in the referring hospital. Fifteen (43%) of 35 FDG-PET scans 
were considered abnormal (Table 3). Of these abnormal FDG-PET scans, 13 correctly pointed to the 
source of the fever. In one patient, without evidence of colonic disease confirmed by colonoscopy 
and eventually diagnosed with drug fever, abnormal FDG-uptake in the colon was found. In 
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another patient, increased FDG-uptake in multiple lymph nodes was shown, but lymph node biopsy 
and two bone marrow biopsies were normal. Six months after FDG-PET, no diagnosis has been 
made and the fever has disappeared. The results of these two FDG-PET scans were considered 
false positive (Table 1). FDG-PET results were considered to be true negative in the patients with 
viral encephalitis, chronic meningitis, systemic Bartonella infection without focal infection, 
cryoglobulinemia without focal inflammation, and in 15 patients (94%) without a known cause of 
the fever. In one patient with Crohn’s disease, FDG-PET was normal and this was considered to 
be false negative. Thus, 87% of the abnormal FDG-PET scans were clinically helpful and FDG-PET 
contributed to the eventual diagnosis in 37% of all patients with FUO in whom the probability of 
a diagnosis was only 54%. Sensitivity of FDG-PET in these FUO patients was 93%, specificity was 
90%, positive predictive value was 87% and negative predictive value was 95%. Table 4 shows the 
diagnostic methods that established the cause of the fever in 19 patients with a final diagnosis. The 
abnormal FDG-PET results were confirmed by biopsy in 11 cases (85%).
Figure 1 This 70-year-old female presented with fever, fatigue and weight loss of three weeks duration. Physical 
examination was normal. The erythrocyte sedimentation rate was 67 mm/h (normal 2-12 mm/h) with normal 
leukocytes, creatinine, liver function tests, and normal angiotensin converting enzyme. A chest X-ray, 
abdominal ultrasound and tuberculin skin test were normal. A temporal artery biopsy was also normal. PET 
revealed pathological FDG-uptake in pretracheal, hilar and mediastinal lymph nodes (arrow). Subsequent 
abdominal and thoracic CT showed slightly enlarged lymph nodes pretracheally and in the mediastinum. A 
lymph node biopsy obtained by mediastinoscopy demonstrated granulomatous inflammation confirming a 
diagnosis of sarcoidosis. Her symptoms resolved upon treatment with corticosteroids.
Table 3 Results of FDG-PET in patients with FUO
FDG-PET abnormal FDG-PET normal No. of patients
Contributory Non-contributory
Infection  4  0  2  6
Neoplasm  4  0  0  4
NIID  4  0  2  6
Drug fever  0  1  0  1
Miscellaneous  1  0  1  2
No diagnosis  0  1  15  16
Total  13 (37%)  2 (6%)  20  (57%)  35
NIID = non-infectious inflammatory diseases.
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Table 4 Diagnostic methods establishing the final diagnosis in 19 patients with FUO in whom a cause of the fever was 
found
Diagnostic method No. of patients
FDG-PET abnormal FDG-PET normal
Non-invasive   
Culture or serology  0  2
Radiology  0  1
Clinical criteria or clinical course  3  2
Invasive  
Biopsy  11  0
Suspected focal infection or inflammation
Of the total number of 48 patients with suspected focal infection or inflammation, 20 were 
male and 28 were female with a median age of 61 years (range 18 to 85 years). In three patients, 
the second FDG-PET scan was ordered for follow-up of a known infection. In two patients with 
autosomal dominant polycystic kidney disease, multiple FDG-PET scans (2 and 4, respectively) 
were performed because of new episodes with complaints suggesting newly infected renal or 
hepatic cysts. 
An infection was the cause of the symptoms in 32 episodes (58%), a neoplasm in three patients 
(5%), and non-infectious inflammatory diseases in four patients (7%). Three FDG-PET scans were 
performed for follow-up of a known infection and in three patients (5%) the final diagnosis was 
categorized as miscellaneous (Table 5). In 10 patients (18%) the cause of the symptoms was not 
found. In six of these patients the symptoms disappeared spontaneously after a median duration of 
six weeks. In the remaining four patients the symptoms persisted and no diagnosis could be made 
after a median follow-up of 22 months. 
The median duration of the illness before the first FDG-PET scan in each patient was performed 
was three weeks (range 4 days to 30 months). Table 6 shows the results of FDG-PET in the different 
diagnostic categories of 55 episodes of suspected localized infection or inflammation in 48 
patients. Of the total number of 55 FDG-PET scans, 38 (69%) were considered abnormal. Of these 
abnormal scans, 36 (95%) correctly pointed to the cause of the symptoms. In one patient, increased 
FDG-uptake in the upper lobe of the right lung was demonstrated. Subsequent chest X-ray and 
CT scanning were both normal and no diagnosis could be made, so the FDG-PET results were 
considered false positive (Table 5). In another patient with fever and abdominal pain with normal 
abdominal CT and colonoscopy, increased FDG-uptake in the entire colon was considered false 
positive. No diagnosis could be reached and her symptoms disappeared. FDG-PET was considered 
true negative in the patients with cerebral Candida abscess, Candida sepsis without focal infection 
(n=2), cystitis (n=2), myelodysplastic syndrome, non-infected hematoma, and in eight patients 
(80%) without a known cause of their symptoms. In two cases, FDG-PET performed for follow-
up of a known infection was normal, which was supported by clinical follow-up, so these results 
were considered true negative. Persisting high FDG-uptake on FDG-PET performed for follow-up 
of a mycotic aortic aneurysm was in line with clinical follow-up and increasing wall thickness of 
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the aorta on CT, so the results were considered true positive. The history of this patient has been 
published as a case report [12]. Thus, 95% of the abnormal FDG-PET scans were clinically helpful 
and FDG-PET contributed to the final diagnosis in 65% of all 55 episodes of suspected localized 
infection or inflammation in which the probability of a diagnosis was 82%. Sensitivity of FDG-PET 
in these 55 episodes was 100%, specificity was 89%, positive predictive value was 95% and negative 
predictive value was 100%. Table 7 shows the diagnostic methods used to establish a final diagnosis 
in 45 episodes in which the cause of the symptoms was found.
Table 5 Final diagnoses in 55 episodes with symptoms suggesting a focal infection or inflammatory process in 48 
patients and classification of the results of FDG-PET for each category
Category No. of cases True positive
True 
negative
False 
positive
False 
negative
Infection  32 (58%)  27 5 - -
Soft tissue/skin infection  3  3 - - -
Septic arthritis  2  2 - - -
Spondylodiscitis  6  6 - - -
Infected vascular prosthesis  3  3 - - -
Mycotic aneurysm  2  2 - - -
Infected cyst in ADPKD  5  5 - - -
Abdominal abscess  2  2 - - -
Echinococcus infection liver  1  1 - - -
Prostatitis  1  1 - - -
Cystitis  2  - 2 - -
Pneumonia  1  1 - - -
Cerebral abscess  1  - 1 - -
Endophthalmitis  1  1 - - -
Candida sepsis without focus  2  - 2 - -
Neoplasm  3 
(5%)
 3 - - -
ACUP  1  1 - - -
Pelvic squamous cell carcinoma  1  1 - - -
Malignant lymphoma  1  1 - - -
Non-infectious inflammatory disease  4  
(7%)
 4 - - -
Polymyalgia rheumatica  1  1 - - -
Giant-cell arteritis  1  1 - - -
Crohn’s disease  1  1 - - -
Chronic granulomatous disease rectum  1  1 - - -
Follow-up of known infection  3 
(5%)
 1 2 - -
Miscellaneous  3 
(5%)
 1 2 - -
Amyloidosis  1  1 - - -
Hematoma  1  - 1 - -
Myelodysplastic syndrome  1  - 1 - -
No diagnosis  10 
(18%)
 - 8 2 -
  ADPKD = autosomal dominant polycystic kidney disease, ACUP = adenocarcinoma with unknown primary.
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Figure 2 This 76-year-old woman presented with fever and weight loss. Physical examination was normal. The erythrocyte 
sedimentation rate was 143 mm/h (normal 2-12 mm/h), a severe microcytic anemia was present and alkaline 
phosphatase was 250 U/l (normal <120 U/l). A tuberculin skin test was positive. Blood, urine, bronchoalveolar 
lavage fluid and bone marrow cultures were negative. Chest X-ray, abdominal and thoracic CT-scans, MRI of 
the spine, bone scan, lung perfusion scintigraphy, 111indium-leukocyte scan, gastroscopy, colonoscopy and 
bronchoscopy were all normal. Duodenum, liver, bone and temporal artery biopsies were normal. Her condition 
progressively deteriorated and she was referred to our hospital. PET demonstrated increased FDG-uptake in 
several areas in the spleen and para-aortal lymph nodes suggestive of malignant lymphoma. The patient refused 
further diagnostic tests or treatment and she died four weeks later. Autopsy revealed enlarged para-aortal 
lymph nodes and splenomegaly due to localization of malignant B-cell lymphoma.
Table 6 Results of FDG-PET in 55 episodes with symptoms suggesting a focal infection or inflammatory process in 48 
patients 
FDG-PET abnormal FDG-PET normal No. of patients
Contributory Non-contributory
Infection  27 0  5  32
Neoplasm  3 0  0  3
NIID  4 0  0  4
Follow-up  1 0  2  3
Miscellaneous  1 0  2  3
No diagnosis  0 2  8  10
Total (%)  36 (65) 2  (4)  17 (31)  55
NIID = non-infectious inflammatory diseases.
Table 7 Diagnostic methods establishing the final diagnosis in 45 episodes of suspected focal infection or inflammation 
in which a cause of the symptoms was found
Diagnostic method
No. of patients
FDG-PET abnormal FDG-PET normal
Non-invasive
Culture or serology  5  3
Radiology  10  4
Clinical criteria or clinical course  7  0
Invasive
Biopsy  7  1
Surgery  4  1
Autopsy  3  0
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Discussion
The utility of FDG-PET in patients with FUO and in patients suspected of focal infection or 
inflammation was retrospectively evaluated. In all patients with FUO, 37% of the FDG-PET scans 
were helpful in the diagnostic process while the probability of a diagnosis was only 54% in these 
patients. The percentage of FDG-PET scans helpful in the diagnostic process in patients with FUO, 
as reported in the literature, varied from 41% to 69% [6,13,14]. In a retrospective study of 16 patients 
with FUO in whom conventional diagnostics had not been conclusive, Lorenzen et al. found that 
FDG-PET was helpful in 69% [14]. Meller et al. prospectively studied the utility of FDG coincidence 
imaging in 20 patients with FUO. In 55% of these patients FDG-PET was helpful in establishing a 
final diagnosis. Positive predictive value was 90% and negative predictive value was 75% compared 
to a positive predictive value of 67Ga scintigraphy in the same patients of 75% and a negative 
predictive value of 70% [13]. In a prospective study of 58 patients with FUO, Blockmans et al. 
demonstrated that FDG-PET was helpful in 41% of the patients. 67Ga scintigraphy was only helpful 
in 25% of a subgroup of 40 patients in the same study [6]. Comparing these studies is difficult. The 
definition of FUO differed slightly, FDG-PET was performed at different stages of the diagnostic 
process, no structured diagnostic protocol was used and the FDG-PET technique differed between 
the studies, resulting in considerable selection bias. The percentage of patients in whom no 
diagnosis could be made varied from 10 to 36% and even 46% in our study, suggesting very 
different patient characteristics. The unusually high percentage of patients in whom no diagnosis 
could be made in our study can probably be explained by the high number of patients referred for 
a second opinion (57%) in whom the chance of finding a cause of the fever was only 45% compared 
to 67% in the patients who were directly referred to our clinic. The referred patients most probably 
represent a selected group of FUO cases, which have a lower chance of reaching a final diagnosis 
[5]. Furthermore, a high number of patients without a final diagnosis had recurrent fever (6/16). 
Infections, malignancies and inflammatory diseases represent only 20% of the causes of recurrent 
fever and in about half, the cause of the fever is never found [3,15].
In the patients suspected of focal infection or a localized inflammatory process, 65% of all FDG-PET 
scans were clinically helpful. In a prospective study of 11 patients suspected of various infections 
by Sugawara et al. [16], FDG-PET correctly diagnosed the presence or absence of active infection 
in 10 of 11 patients. Stumpe et al. [17] studied the results of 45 FDG-PET scans in 39 patients with 
suspected infectious foci, which were true positive in 40 cases, false positive in four and false 
negative in one patient. In a retrospective study, Chacko et al. [18] reviewed the results of 167 FDG-
PET scans in patients suspected of various, but mostly orthopedic, infections. Accuracy of FDG-
PET in 97 cases of suspected complicated orthopedic hardware was 96% for hip prosthesis, 81% 
for knee prosthesis, and 100% for other orthopedic devices. Accuracy of FDG-PET in 56 patients 
suspected of chronic osteomyelitis was 91%. FDG-PET was accurate in three out of six cases of 
FUO and in eight cases of vascular graft and soft tissue infections [18]. It is even more difficult to 
compare these studies because of different study designs and different patient characteristics, but 
the results of these three studies and our results suggest that FDG-PET is a very sensitive method 
to detect infectious and inflammatory foci with a reasonable specificity. Calculation of sensitivity 
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and specificity of FDG-PET in patients with FUO or suspected focal infection or inflammation 
is difficult for several reasons. First, since a final diagnosis is not established in all patients, the 
interpretation of this procedure is hampered due to a lack of a gold standard. When additional 
diagnostic procedures are negative and long-term follow-up does not reveal a diagnosis, it is 
probably legitimate to presume that focal infection or inflammation or malignancy is not the cause 
of the symptoms in these patients. Second, in patients with negative FDG-PET, a variety of diseases 
were found that could not be diagnosed with FDG-PET. FDG-PET cannot exclude cerebral disease 
or meningitis, because physiologic uptake in the cerebral cortex in most cases obscures any 
pathological uptake. Therefore, cerebral infection or meningitis was not scored as false negative. 
Besides physiologic uptake of FDG in the brain, normal activity in the kidneys and the bladder 
severely hamper the delineation of disease in these organs. Variable physiologic FDG-uptake in 
the bowel is possible and can thus lead to a false positive interpretation, as illustrated by two of 
our patients.
Conventional radiopharmaceuticals routinely used in clinical practice (67Ga and 111In-labeled or 
99mtechnetium-labeled leukocytes (WBC)) have disadvantages and limitations, such as handling of 
potentially infected blood products (WBC), high radiation burden (67Ga), instability of the labeling 
(99mTc-WBC), and the long time span between injection and diagnosis (67Ga) [19]. Compared 
to conventional nuclear medicine techniques, advantages of FDG-PET are early imaging (one 
hour) [16], higher resolution, high target-to-background ratio [20], sensitivity in chronic low-
grade infections [21-23], high accuracy in the central skeleton [21,22,24], and high inter observer 
agreement [21,24]. Another major advantage of FDG-PET in the work-up of FUO is the vascular 
FDG-uptake in patients with vasculitis [13,25]. Obvious disadvantages are the relatively high cost 
and the currently limited availability. However, when FDG-PET performance for this indication is 
confirmed in larger prospective studies and the number of PET systems further increases, the high 
diagnostic yield of FDG-PET may very well become a clinically significant and also cost-effective 
modality, since adequate early diagnosis limits the number of other non-contributing (invasive) 
tests required and the time to diagnosis and thereby the duration of hospitalization for diagnostic 
purposes. Further positive aspects of FDG-PET imaging in FUO and suspected infectious or 
inflammatory diseases compared to CT and MRI are absence of disturbance by metallic implants, 
whole body screening and absence of contrast-related side effects. A negative aspect of FDG-PET 
when compared to CT is the limited anatomic information. In addition, differentiation between 
malignancy and infection or inflammation is not possible, but in the investigation of patients with 
FUO this appears to be an advantage rather than a drawback. 
In conclusion, FDG-PET is a valuable new imaging technique in patients with FUO and patients 
suspected of focal infection or inflammation. Based on previous studies comparing 67Ga and 
FDG-PET in patients with FUO [6,13] and resulting from favorable characteristics of FDG-PET, 
conventional scintigraphic techniques may be replaced by FDG-PET in institutions where PET is 
available. When ordered early in the diagnostic work-up, FDG-PET enables identifying the organ or 
tissue where the cause of the fever is likely to be found. Abnormal FDG-PET results could then be 
used for guiding intelligent further testing. Furthermore, FDG-PET could become a useful tool for 
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evaluating the effect of treatment of infectious and inflammatory processes that cannot reliably be 
visualized by conventional techniques. However, for a final validation of FDG-PET in patients with 
FUO and suspected infection or inflammation and for determination of its exact position in the 
order of diagnostic tests, especially in the work-up of FUO, prospective studies of FDG-PET being 
part of a structured diagnostic protocol are needed.
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Abstract
Since 18F-fluorodeoxyglucose (FDG) accumulates in neoplastic cells and in activated inflammatory 
cells, positron emission tomography (PET) with FDG could be valuable in diagnosing patients with 
fever of unknown origin (FUO). The aim of this study was to validate the use of FDG-PET as part of 
a structured diagnostic protocol in the general patient population with FUO.
Methods: From December 2003 to July 2005, 70 patients with FUO were recruited from one university 
hospital (n=38) and five community hospitals (n=32). A structured diagnostic protocol including FDG-
PET was used. A dedicated, full ring PET-scanner was used for data acquisition. FDG-PET scans were 
interpreted by two staff members of the department of nuclear medicine without further clinical 
information. The final clinical diagnosis was used for comparison with the FDG-PET results.
Results: Of all scans, 33% were clinically helpful. Contribution of FDG-PET to the final diagnosis 
did not differ significantly between patients diagnosed in the university hospital and patients in 
the community hospitals. FDG-PET contributed significantly more often to the final diagnosis in 
patients with continuous fever than in patients with periodic fever. FDG-PET was not helpful in any 
of the patients with normal erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
Conclusion: FDG-PET is a valuable imaging technique as part of a diagnostic protocol in the 
general patient population with FUO and a raised ESR or CRP. 
Introduction
Despite modern diagnostic techniques, no diagnosis can be reached in up to 53% of all patients with 
fever of unknown origin (FUO) [1-9]. Since 18F-fluorodeoxyglucose (FDG) accumulates in cells with a 
high rate of glycolysis [10], such as neoplastic cells and activated inflammatory cells [11,12], positron 
emission tomography (PET) with FDG could be valuable in diagnosing patients with FUO. In previous 
studies, the percentage of FDG-PET scans helpful in the diagnostic process in patients with FUO 
varied from 16% to 69% [13-18]. All previous studies have been performed in tertiary care or university 
hospitals and it is unknown whether these results can also be applied to FUO patients who are being 
diagnosed in community hospitals. Furthermore, in none of these studies a structured diagnostic 
protocol was used. The aim of this prospective multi-center study was to validate the use of FDG-PET 
as part of a structured diagnostic protocol in a general population of patients with FUO.
Materials and methods
Hospitals
From December 2003 to July 2005, patients with FUO were prospectively recruited from the 
Radboud University Nijmegen Medical Centre (RUNMC), a 950-bed university hospital and tertiary 
referral center for patients with classical FUO and periodic fever. Patients were also recruited from 5 
community hospitals: Canisius Wilhelmina Hospital Nijmegen (650 beds), Jeroen Bosch Hospital ’s-
Hertogenbosch (450 beds), Rijnstate Hospital Arnhem (750 beds), Slingeland Hospital Doetinchem 
134
_____  Chapter 8  _____________________________________________________________________________________________________________ _____________________________________________  The value of FDG-PET as part of a structured diagnostic protocol in FUO  _____ 
135
(450 beds) and Maxima Medical Center Veldhoven (500 beds). The study was approved by all local 
ethical committees and all patients provided written informed consent. 
Patients
FUO was defined as a febrile illness of >3 weeks duration, a temperature of >38.3°C on at least 
two occasions, and diagnosis uncertain after thorough history-taking, physical examination and 
certain obligatory investigations (Figure 1). Periodic fever was defined as repeated episodes of 
fever with fever-free intervals of at least two weeks and apparent remission of the underlying 
disease. Immunocompromized patients, defined as patients with neutropenia (leukocyte count <1.0 
x 109/l and/or granulocyte count <0.5 x 109/l) during at least 1 week within 3 months preceding the 
fever, known HIV-infection, known hypogammaglobulinemia, use of the equivalent of more than 
10 mg prednisone during at least 2 weeks in the previous 3 months, were excluded. All records of 
non-immunocompromized patients with fever on the internal medicine wards and out patient 
departments aged 18 years or older were reviewed at least weekly for the criteria for FUO by the first 
author or the local investigator. In a retrospective study of patients with FUO previously performed in 
our university hospital, it was observed that blood cultures were performed in all patients with FUO 
[4]. Because of the size of the university hospital, records of all patients in whom blood cultures were 
performed were reviewed weekly for the criteria of FUO by the first author as a second check. 
Diagnostic work-up
In all patients primarily referred to one of the participating hospitals, a structured diagnostic 
protocol was used (Figure 1). The maximum time interval between the obligatory tests and the FDG-
PET scan was one week in hospitalized patients and 2 weeks in the remaining patients. In patients 
with periodic fever, FDG-PET was performed during a symptomatic phase (within 3 days after the 
beginning of the fever). In these patients, second level diagnostic tests were only recommended 
when potential diagnostic clues for infectious diseases, vasculitis syndromes or malignancy were 
present, or when the clinical condition was deteriorating. 
FDG-PET
A dedicated, full ring PET-scanner (Philips Allegro, Philips, Eindhoven, The Netherlands for patients 
recruited in Rijnstate Hospital in Arnhem, ECAT-EXACT, Siemens/CTI, Knoxville, TN, USA for all 
other patients) was used for data acquisition. Prior to FDG-injection, patients had fasted for at 
least 6 hours. Immediately prior to the procedure, the patients were hydrated with 500 ml of 
water. One hour after intravenous injection of 200-220 MBq FDG (Tyco Healthcare/Mallinckrodt 
Medical, Petten, The Netherlands) and 10 to 15 mg furosemide, emission and transmission images 
of the area between the proximal femora and the base of the skull were acquired (10 minute per 
bed position). Performing total body FDG-PET including the legs was not possible because of the 
long duration of the procedure expected to cause patient compliance problems and because this 
would have significantly decreased PET capacity. Scanning of the legs was performed when PDCs 
for diseases occurring in the legs were present. The images were corrected for attenuation and 
were reconstructed using the ordered subsets-expectation maximization (OSEM) algorithm. FDG-
PET scans were interpreted by two staff members of the department of nuclear medicine without 
information of the results of other diagnostic tests or the final diagnosis. All abnormalities, no 
matter how subtle, were reported. Disagreements were resolved by consensus.
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Figure 1  This figure shows the diagnostic protocol that was used in all participating patients.
  PDCs = potentially diagnostic clues. Obligatory tests: erythrocyte sedimentation rate or C-reactive protein, 
hemoglobin, platelet count, leukocyte count and differentiation, electrolytes, creatinine, total protein, protein 
electrophoresis, alkaline phosphatase, ALAT, LDH, creatine kinase, antinuclear antibodies, rheumatoid factor, 
urinalysis, blood cultures (n=3), urine culture, chest X-ray, abdominal ultrasonography (or CT) and tuberculin 
skin test. Second level investigations: bone marrow biopsy, temporal artery biopsy in patients older than 55 
years, fundoscopy, abdominal CT and chest CT
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Diagnosis and assessment of FDG-PET results
The final diagnosis, established by the attending physician and the first author, was used for 
comparison with FDG-PET results. A definite diagnosis was based on biopsy, positive serology, or 
positive cultures. Yersinia serology was considered positive in case both IgA and IgG immunoblots 
were repeatedly positive for at least 2 bands and other diagnoses were excluded. When patients 
fulfilled generally accepted clinical criteria, the diagnosis was also considered definite. In this study, 
the following criteria were used: American College of Rheumatology revised criteria (ARA-criteria) 
for systemic lupus erythematosus (SLE) [19], American College of Rheumatology criteria for giant 
cell vasculitis [20], American College of Rheumatology criteria for Henoch Schonlein purpura [21], 
criteria by Fautrel et al. for adult onset Still’s disease [22], and the Moll and Wright criteria for psoriatic 
arthritis [23]. Polymyalgia rheumatica was diagnosed in case the patient (1) was 50 years or older at 
onset, (2) had bilateral aching and morning stiffness (lasting 30 minutes or more) persisting for at least 
one month, with involvement of at least two of the following three areas: neck or torso, shoulders or 
proximal regions of the arms, and hips or proximal aspects of the thighs, and (3) when erythrocyte 
sedimentation rate (ESR) was elevated to 40 mm/h or more. A diagnosis was never based on the FDG-
PET results alone. Abnormal FDG-PET scans were considered helpful in establishing the diagnosis or 
true positive when abnormal FDG-uptake pointed to the organ or tissue where the cause of the fever 
was found by additional diagnostic techniques. Abnormal results were regarded as non-contributory to 
diagnosis or false positive when the detected abnormality was considered to be unrelated to the illness 
causing the fever or when no final diagnosis could be made. A normal FDG-PET scan was considered 
true negative when no cause of the symptoms was identified despite an extensive diagnostic work-up 
and clinical follow-up of at least 3 months after FDG-PET. A normal FDG-PET scan was considered false 
negative when a focal infection, a focal inflammatory process or neoplasm was diagnosed. 
Statistical analysis
Descriptive statistics for continuous variables are represented as means ± standard deviations. 
Categorical variables are reported in terms of the number and percentage of patients affected. 
Differences between the patient groups were tested with Fisher’s exact tests for categorical 
variables. Differences were considered to be statistically significant at P <0.05.
Results
Between December 2003 and July 2005, 75 patients with FUO were identified. No additional 
patients were identified through review of the records of all patients in whom blood cultures were 
requested. Two patients refused participation and 3 patients had to be excluded (Figure 2). The 
results of 70 patients (32 males and 38 females) with a mean age of 53 years (range 26 to 87 years) 
were evaluated: 38 patients were recruited from RUNMC and 32 from the other hospitals. Twenty-
four patients (34% of all patients, 63% of patients recruited from RUNMC) were referred to RUNMC 
for a second opinion after previous extensive investigation elsewhere. All patients recruited from 
the community hospitals were referred by their general practitioner. Twenty-six patients (37%) 
had periodic fever: 20 of these patients (77%) were enrolled in RUNMC and 6 in other hospitals 
(P <0.01).
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Figure 2 Three patients had to be excluded: all symptoms resolved before FDG-PET was performed in one patient, in 
another patient, it proved to be impossible to obtain a reliable FDG-PET scan due to severe contractures of the 
extremities, and one patient died before FDG-PET was performed.
An infectious disease was the cause of the fever in 12 patients (17%), a neoplasm in 5 patients (7%), 
non-infectious inflammatory diseases (NIID) in 16 patients (23%), and hypertriglyceridemia and 
drug fever in one patient each (Table 1). In 35 patients (50%), the cause of the fever was not found. 
Obligatory laboratory tests, other chemical tests, immunological serology, and endocrinological 
investigations never directly revealed the diagnosis. The presence of antinuclear antibodies was 
helpful in diagnosing SLE in all 4 patients diagnosed with this disease, but showed false positive 
results in 8 patients. In one patient with microscopic polyangiitis, the presence of anti neutrophil 
cytoplasmic antibodies (ANCA) was helpful while ANCA were also present in 5 patients without 
vasculitis. In 53 patients, 509 microbiological serologic tests were performed (repeated measurements 
of the same parameter were not counted). Except for Yersinia enterocolitica serology, these tests were 
never helpful in establishing a diagnosis. Positive results (IgA and IgG repeatedly positive for at least 
2 bands) were obtained in 4 patients who were diagnosed with chronic persistent yersiniosis as cause 
of the fever. In three patients, all symptoms disappeared after antibiotic treatment and in one patient, 
symptoms disappeared and inguinal lymphadenopathy markedly decreased without treatment. 
Except for Yersinia serology there were no significant differences in the number of abnormal results 
of biochemical or serological tests between the different diagnostic categories and patients without 
a final diagnosis. In none of the 11 patients with normal C-reactive protein (CRP) and normal ESR, 
FDG-PET contributed to the final diagnosis compared to 39% in patients with either elevated CRP or 
ESR (P=0.01). None of the other biochemical or serological tests were helpful in predicting whether 
FDG-PET would be helpful in establishing a final diagnosis. 
Thirty-three (47%) of 70 FDG-PET scans were considered abnormal (Table 2). Of these abnormal 
FDG-PET scans, 23 correctly pointed to the source of the fever and were thus true positive (Figures 
2-4). FDG-PET was considered true negative in 7 patients with NIID (polymyalgia rheumatica, adult 
onset Still’s disease, Henoch Schonlein and microscopic polyangiitis, respectively) without any 
focal symptoms of disease, arthritis or signs of large vessel vasculitis (Table 1, in the patient with 
73 patients included 
75 eligible for inclusion
2 declined participation 
3 patients excluded 
70 FDG-PET
23 true positive 10 false positive  34 true negative 3 false negative
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adult onset Still’s disease with palpable lymphadenopathy, abnormal FDG-uptake in multiple lymph 
nodes was considered true positive). Normal FDG-PET results were also considered true negative 
in one patient with hypertriglyceridemia. In 26 patients without a final diagnosis, a normal FDG-
PET scan was classified as true negative, so in total there were 34 true negative FDG-PET-scans. 
FDG-PET was considered false negative in two patients with small pleural effusions who were 
eventually diagnosed with SLE and one patient with pyelonephritis. FDG-PET was classified as 
false positive in 10 cases (Table 3). In these patients, 12 diagnostic procedures were performed as 
a result of FDG-PET. Following the diagnostic protocol, 5 of these diagnostic tests would also have 
been performed in case the FDG-PET results had been negative. So false positive FDG-PET results 
generated 7 unnecessary diagnostic procedures: 3 invasive procedures (2 lymph node biopsies and 
1 gastroscopy) and 4 non-invasive procedures (consultation of another specialty: n=3 and 1 MRI). In 
comparison, 16 false positive abdominal CT scans (performed in a total of 60 patients) generated 22 
unnecessary investigations: 15 non-invasive procedures and 7 invasive procedures. In all patients, a 
total of 997 diagnostic procedures not including laboratory tests or cultures were performed before 
a cause of the fever was found or until the end of follow-up in patients with unexplained fever. So 
false-positive FDG-PET results were responsible for only 0.7% of all diagnostic procedures.
Table 1 Final diagnoses in patients with FUO and classification of the results of FDG-PET for each category 
Category No. of cases 
True
positive
True
negative
False
positive
False 
negative
Infection 12 (17%) 11 - - 1
Bronchiectasia/pneumonia 2 2 - - -
Diverticulitis 1 1 - - -
Pyelonephritis 1 - - - 1
Abdominal abscesses 1 1 - - -
Osteomyelitis 2 2 - - -
Tonsillitis 1 1 - - -
 Chronic persistent Yersiniosis 4 4 - - -
Neoplasm 5 (7%) 5 - - -
Non-Hodgkin’s lymphoma 3 3 - - -
Metastatic breast cancer 1 1 - - -
Adenocarcinoma with unknown primary 1 1 - - -
Non-infectious inflammatory disease 16 (23%) 6 7 1 2
Large vessel vasculitis 2 2 - - -
Polymyalgia rheumatica 3 - 3 - -
Henoch Schonlein purpura 1 - 1 - -
Microscopic polyangiitis 1 - 1 - -
Psoriatic arthritis 1 1 - - -
Adult onset Still’s disease 3 1 2 - -
Systemic lupus erythematosus 4 2 - - 2
Cryoglobulinemia 1 - - 1 -
Miscellaneous 2 (3%) 1 1 - -
Drug fever 1 1 - - -
Hypertriglyceridemia 1 - 1 - -
No diagnosis 35 (50%) - 26 9 -
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Table 2 Results of FDG-PET in patients with FUO
FDG-PET abnormal FDG-PET normal
Contributory Non-contributory
Infection 11 - 1
Neoplasm 5 - -
NIID 6 1 9
Miscellaneous 1 - 1
No diagnosis - 9 26
Total 23 (33%) 10 (14%) 37 (53%)
NIID = non-infectious inflammatory diseases. 
Table 3 Final diagnosis in patients with false-positive FDG-PET results (n=10)
Patient FDG-PET result 
Investigation guided by 
FDG-PET Final diagnosis
Follow-up
(duration months)
F, 29 yr Right lower quadrant 
abdomen
Gynecological examination: normal No diagnosis Persisting FUO (20)
M, 61 yr Supraclavicular lymph 
node
Lymph node biopsy: reactive No diagnosis Persisting FUO (10)
M, 45 yr Supraclavicular lymph 
node
Lymph node biopsy: reactive No diagnosis Persisting FUO (13)
M, 29 yr Vertebra Th10 MRI: impression fracture Th10 No diagnosis Recovery (6)
F, 27 yr Focal mediastinal 
FDG-uptake
Thoracic CT: normal No diagnosis Persisting FUO (7)
F, 26 yr FDG-uptake above 
bladder
Abdominal CT, gynecological 
examination: normal
No diagnosis Persisting FUO (11)
M, 60 yr Focal mediastinal 
FDG-uptake
Thoracic CT: enlarged subcarinal 
lymph node (no biopsy)
No diagnosis Recovery (6)
M, 71 yr Large vessel vasculitis - No diagnosis Recovery (7)
M, 42 yr FDG-uptake upper 
abdomen
Abdominal CT/gastroscopy: normal No diagnosis Recovery (6)
M, 69 yr Right lung, both hips Thoracic CT: previous bilobectomy, 
Consultation pulmonary medicine: 
recurrence of lung cancer unlikely
Cryoglobulinemia Recovery (4)
Thus, 70% of the abnormal FDG-PET scans were clinically helpful and FDG-PET contributed to the 
ultimate diagnosis in 33% of all patients. FDG-PET was considered helpful in 66% of all patients with 
a final diagnosis. Sensitivity of FDG-PET was 88%, specificity was 77%, positive predictive value was 
70% and negative predictive value was 92%. In a subgroup of 43 patients, both abdominal and chest 
CT was performed. In these 43 patients, a combination of abdominal and chest CT had a positive 
predictive value of 48% and a negative predictive value of 86%. In the same 43 patients, positive 
predictive value of FDG-PET was 65% with a negative predictive value of 90%.
True positive FDG-PET results were definitely confirmed by biopsy (n=8), culture (n=3), serology 
(n=4) or generally accepted clinical criteria (n=16) [19-23] in 31 cases (89%) and a probable 
confirmation was reached in the remaining 4 cases (11%) through radiology  (n=3) or the clinical 
course (n=1). Median duration of follow-up was 10 months (range 4 to 22 months, >6 months in 93% 
of all patients). Contribution of FDG-PET to the final diagnosis did not differ significantly between 
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patients referred after investigation in another hospital and patients who were directly referred 
(25% vs. 39%) or between patients diagnosed in RUNMC and patients in the other hospitals (26% 
vs. 41%). FDG-PET contributed significantly more often to the final diagnosis in patients with 
continuous fever than in patients with periodic fever (45 vs. 12%, P <0.005). Although a diagnosis 
was reached in only 6 out of 26 patients with periodic fever, FDG-PET contributed to the diagnosis 
in 3 of these cases (50%) and was considered true negative in the other 3 patients with adult onset 
Still’s disease without localizing symptoms or focal abnormalities, Henoch Schonlein purpura and 
hypertriglyceridemia. In none of the 3 cases with true positive FDG-PET results, the final diagnosis 
was suspected before FDG-PET was performed despite extensive previous diagnostic tests. 
Discussion
In this multi-center prospective clinical study, 33% of all FDG-PET scans contributed to the final 
diagnosis while the probability of reaching a diagnosis was only 50%. Since significant differences 
in the contribution of FDG-PET between patients diagnosed in the university hospital and the 
community hospitals or between patients who were directly referred and patients referred after 
investigation in another hospital were absent, FDG-PET as part of the structured diagnostic 
protocol used in this study is valuable in the general population of patients with FUO. The 
contribution of FDG-PET in patients with periodic fever was low. It is very unlikely, however, that 
any of the conditions diagnosed after abnormal FDG-PET results in these patients would have 
been found without FDG-PET since these diagnoses were not suspected after a previous very 
extensive diagnostic workup. In none of the patients with periodic fever, a diagnosis with focal 
abnormalities was reached in case FDG-PET was normal (negative predictive value 100%) and FDG-
PET was helpful in 50% of patients with a final diagnosis. We believe that by adding FDG-PET to the 
diagnostic protocol in these patients and by avoiding any follow-up tests in case of normal FDG-
PET results in the absence of potential diagnostic clues or clinical deterioration, the number of 
unnecessary tests can be significantly reduced. In patients with periodic fever, sensitivity of FDG-
PET is probably highest when performed during a fever episode (Figure 3). Since FDG-PET did not 
contribute in any of the patients with normal CRP and ESR, it is not indicated in these patients.
Figure 3 This 61-year-old woman with periodic fever was referred after a very extensive diagnostic workup in another 
university hospital. A previous abdominal CT, performed at the end of a fever episode, was normal. Her first 
FDG-PET scan, performed in another hospital before inclusion in the present study between fever episodes, was 
normal (Figure 3A). When FDG-PET was repeated during a fever episode after inclusion, however, clearly abnormal 
FDG-uptake was seen in the left lower abdomen (Figure 3B). The next day abdominal CT showed diverticulitis. 
A B
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Including the patients in the present study, the value of FDG-PET has been studied in 2 retrospective 
and 5 prospective studies in 292 patients with FUO [13-18] (Table 4) showing an overall helpfulness 
of FDG-PET corrected for study population of 36%. Comparing these studies, however, is difficult. 
First of all, the definition of FUO was different in each study. In 3 studies, patients were not 
recruited from all patients with FUO presenting at the hospital, but from patients referred to 
the nuclear medicine department [14], from patients referred for 111In-granulocyte scintigraphy 
because of FUO by the department of infectious diseases [24] and from patients referred for 
FDG-PET because of FUO by the department of internal medicine [18], respectively. Second, the 
FDG-PET technique in the study by Meller et al. [14] is inferior to the FDG-PET technique in the 
other studies. Furthermore, FDG-PET was performed at different stages of the diagnostic process 
and a structured diagnostic protocol was never used. The use of a structured diagnostic protocol 
including FDG-PET has reduced the chance of selection bias in our study. To further reduce the 
chance of unintended selection bias, a broad initial selection criterion was used: reviewing of 
all records of non-immunocompromized patients with fever on the internal medicine wards and 
out patient clinics in all hospitals for the criteria for FUO. No further patients were identified by 
checking the records of patients in whom blood cultures were ordered during the study period. 
Since blood cultures were ordered in all patients with FUO in previous studies in the Netherlands 
[4,16], this indicates that all patients with FUO were identified by the first selection criterion.
Calculation of sensitivity and specificity of FDG-PET in patients with FUO is difficult, because a 
final diagnosis is not established in all patients. When additional diagnostic procedures, performed 
according to the diagnostic protocol, are negative and long-term follow-up does not reveal a 
diagnosis, it is probably legitimate to presume that focal infectious disease, inflammation or 
malignancy is not the cause of the symptoms in these patients. Second, in patients with negative 
FDG-PET, a variety of diseases were found that could not be diagnosed with FDG-PET. The way we 
perform FDG-PET does not allow to draw conclusions about the lower legs. Besides physiological 
uptake of FDG in the brain and the heart, physiological activity in the kidneys and the bladder 
severely hampers the delineation of disease in these organs. This hampers the classification of 
PET-scans as true negative. However, in our series we have obtained no evidence of infectious 
or inflammatory foci in the brain, the heart, or the bladder despite intensive searching. In one 
patient, pyelonephritis was diagnosed. This patient’s normal FDG-PET scan has been categorized 
as false negative. Variable physiologic FDG-uptake in the bowel is possible [25] and may lead to 
a false positive interpretation, although this problem was not encountered in the present study. 
Also, diseases without focal abnormalities (for example polymyalgia rheumatica without signs 
of large vessel vasculitis) or diseases with focal abnormalities smaller than 0.5 cm (for example 
microscopic polyangiitis) cannot be detected by FDG-PET. Therefore, normal FDG-PET results were 
not scored as false negative when such diseases were diagnosed. In all large series of FUO patients, 
simple diagnoses will eventually be established in a few patients when symptoms and signs are not 
specific as is illustrated in this study in the patients with tonsillitis and pyelonephritis, for example, 
and in the patient with diverticulitis described in Figure 3.
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Table 4 Review of the literature on the utility of FDG-PET in patients with FUO and comparison to the present study
First author (year) Study design FUO-definition FDG-PET technique Conclusions
Meller (2000) [14] Prospective (n=20): 
comparison FDG-PET 
and 67Ga-citrate (n=18)
- Temp. >38.3oC during 
>3 weeks
- no diagnosis after 1 
week of diagnostic 
work-up
-  AND referral to nuclear 
medicine department
Dual-headed coincedence 
camera
FDG-PET helpful in 55%, 
PPV* 92%, †NPV 75%, 
FDG-PET superior to 
67Ga-citrate
Blockmans (2001) [13] Prospective (n=58): 
comparison to 67Ga-
citrate (n=40)
-  Temp. >38.3oC during 
>3 weeks
-  no diagnosis after 
3 days in-hospital 
investigation
Full ring PET scanner FDG-PET helpful in 41%, 
FDG-PET superior to 
67Ga-citrate
Lorenzen (2001) [15] Retrospective (n=16) - Temp. >38.0oC during 
>3 weeks 
-  increased ‡ESR and 
§CRP
-  inconclusive diagnostic 
tests
Full ring PET scanner FDG-PET helpful in 69%, 
PPV 92%, NPV 100%
Bleeker-Rovers (2004) 
[16]
Retrospective (n=35) - Temp. >38.3oC during 
>3 weeks
-  no diagnosis after one 
week of evaluation in 
the hospital or in the 
outpatient department
Full ring PET scanner FDG-PET helpful in 37%, 
PPV 87%, NPV 95%
Kjaer (2004) [17] Prospective (n=19): 
comparison to 
111In-granulocyte 
- Temp. >38.3oC during
>3 weeks
-  no diagnosis after one 
week of evaluation in 
the hospital or in the 
outpatient department
-  AND referral for 
111In-granulocyte 
scintigraphy
Full ring PET scanner FDG-PET helpful in 16%, 
PPV 30%, NPV 67%, 111In-
granulocyte scintigraphy 
helpful in 26%, 
Buysschaert (2004) [18] Prospective (n=74) - Temp. >38.3oC during 
>3 weeks
-  no diagnosis after 3 
days in hospital or 3 
outpatient visits
-  AND referral for FDG-
PET
Full ring PET scanner FDG-PET helpful in 26%
Bleeker-Rovers 
(present study)
Prospective, multicenter 
(n=70)
-  Temp. >38.3oC during 
>3 weeks
-  no diagnosis after 
certain obligated initial 
investigations
Full ring PET scanner FDG-PET helpful in 33%, 
PPV 70%, NPV 92% 
*PPV = positive predictive value, †NPV = negative predictive value, ‡ESR = erythrocyte sedimentation rate, §CRP = C-reactive protein
No systematic research studying the use of CT or magnetic resonance imaging (MRI) in patients 
with FUO is available. Advantages of FDG-PET are absence of disturbance by metallic implants, 
whole body screening and absence of contrast-related side effects. The more limited anatomic 
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information will be overcome in the future as integrated PET-CT scanners become increasingly 
available. In a subgroup in our study in whom both abdominal and chest CT were performed as 
well as FDG-PET, positive and negative predictive values of FDG-PET were higher than those of 
abdominal and chest CT combined.
The conventional radiopharmaceuticals routinely used in clinical practice, 67Ga and 111In-labelled 
or 99mTc-labeled leukocytes, have disadvantages, such as handling of potentially infected blood 
products, high radiation burden, and the long time span between injection and diagnosis. 
Advantages of FDG-PET are higher resolution, sensitivity in chronic low-grade infections, and 
high accuracy in the central skeleton [26]. Another major advantage of FDG-PET in the work-up 
of FUO is the vascular FDG-uptake in patients with vasculitis [14,27]. A theoretical disadvantage is 
the impossibility to differentiate between malignancy and infectious diseases or inflammation. In 
patients with FUO, however, this appears to be an advantage rather than a drawback since all of 
these disorders are represented in this patient group and additional diagnostic tests are needed 
in most cases anyhow. Obvious disadvantages are the relatively high cost and the currently limited 
availability. However, when the number of PET systems further increases, the high diagnostic yield 
of FDG-PET may very well become a cost-effective modality, since adequate early diagnosis limits 
the number of other non-contributing (invasive) tests required and the time to diagnosis and 
thereby the duration of hospitalization for diagnostic purposes. 
From two prospective studies comparing FDG-PET with 67Ga-citrate scintigraphy in a total of 
58 patients with FUO, it was concluded that FDG-PET was superior to 67Ga-citrate scintigraphy 
because the diagnostic yield is at least comparable to that of 67Ga-citrate scintigraphy and 
the results are available within hours instead of days [13,14]. Kjaer et al. [17] conclude in their 
prospective study comparing FDG-PET with 111In-granulocyte scintigraphy in 19 patients with FUO 
that 111In-granulocyte scintigraphy is superior to FDG-PET, because of the high percentage of false 
positive FDG-PET scans (37%). Although unnecessary tests should, of course, be prevented if 
possible, it is very questionable if a relatively high percentage of false positive results is sufficient 
reason to reject FDG-PET as a valuable diagnostic method in patients with FUO. In our study, 
despite the fact that FDG-PET was read very sensitive with the inherent risk of over reporting, false 
positive FDG-PET results were responsible for less than 1% of all diagnostic studies performed in 
these patients. On the other hand, an abnormal FDG-PET scan leading to the underlying cause of 
the fever, prevents at least the tests that are advised in the diagnostic protocol as second level 
investigations. Furthermore, FDG-PET has a very high sensitivity for most malignant tumours while 
111In-granulocyte scintigraphy does not have a similar sensitivity. In addition, the therapeutic and 
prognostic consequences of a delay in diagnosing malignancy, responsible for FUO in 7 to 28% of 
cases [1-9], are clinically very important. Therefore, we believe that high accuracy in diagnosing 
malignant disease should be an important characteristic of the recommended nuclear medicine 
technique in FUO patients.
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Conclusion
FDG-PET is a valuable imaging technique as part of a structured diagnostic protocol in patients 
with FUO with a raised ESR or CRP, either referred to a university hospital or to a community 
hospital. Because reaching a diagnosis is extremely difficult in patients with periodic fever and 
FDG-PET offers a contribution (albeit small) and a very high negative predictive value, it is advised 
that FDG-PET is also added to the diagnostic protocol in these patients. 
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Abstract
This prospective study was performed to update our knowledge of FUO and to explore the utility 
of a structured diagnostic protocol. From December 2003 to July 2005, 73 patients with FUO were 
recruited from one university hospital (n=40) and 5 general hospitals (n=33) in the same region 
in The Netherlands. FUO was defined as a febrile illness of >3 weeks duration, a temperature of 
>38.3°C on several occasions without a diagnosis after standardized history-taking and physical 
examination and certain obligatory investigations. Immunocompromized patients were excluded. A 
structured diagnostic protocol was used. Patients from the university hospital were characterized by 
more secondary referrals and a higher percentage of periodic fever than those referred to general 
hospitals. Infection was the cause in 16%, a neoplasm in 7%, non-infectious inflammatory diseases 
in 22%, miscellaneous causes in 4%, and in 51%, the cause of fever was not found (no differences 
between university and general hospitals). There were no differences regarding the number and 
type of investigations between university and general hospitals. Significant predictors for reaching 
a diagnosis included: continuous fever, fever present for <180 days, elevated ESR, CRP, or LDH, 
leucopenia, thrombocytosis, abnormal chest CT and abnormal 18F-fluorodeoxyglucose positron 
emission tomography (FDG-PET). For future FUO studies, inclusion of out-patients and the use of a 
set of obligated investigations instead of a time-related criterion are recommended. Except for tests 
from the obligatory part of our protocol and cryoglobulins in an early stage, followed by FDG-PET, 
and in a later stage by abdominal and chest CT, temporal artery biopsy in patients of 55 years or older 
and possibly bone marrow biopsy, other tests should not be used as screening investigations. 
Introduction
Despite recent advances in diagnostic techniques, fever of unknown origin (FUO) remains a 
formidable challenge. Since the 1961 definition of FUO as an illness of more than three weeks 
duration, fever >38.3oC (101oF) on at least two occasions, and diagnosis uncertain after one week 
of hospitalization [1], this definition has been modified by removing the requirement that the 
evaluation must take place in the hospital [2]. Also, immunocompromized patients have been 
excluded, because these patients require an entirely different approach [2-4]. To reduce selection 
bias, it has been proposed to change the quantitative criterion (diagnosis uncertain after one week 
of study) to the qualitative requirement that certain investigations have to be performed [2,4,5].
The differential diagnosis of FUO is the most extensive in medicine and construction of algorithms 
covering all possible causes is difficult. In general, infectious diseases explain about one-third of 
cases of FUO, followed by neoplasms and non-infectious inflammatory diseases (NIID) [6]. In the 
vast literature on FUO, no controlled trials or meta-analyses are available. In recent series from 
Europe and the USA, the percentage of patients with unexplained FUO varied from 7 to 53% [4,7-14]. 
This variation is partly due to geographical factors and different definitions of FUO used. In addition, 
few studies have used uniform epidemiological entry criteria or a structured diagnostic protocol, 
which causes unintended selection bias and differences in diagnostic work-up. Moreover, results of 
those studies cannot easily be extrapolated to an individual patient presenting with FUO.
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This prospective study of patients with FUO recruited from one university hospital and 5 general 
hospitals in The Netherlands was performed to update information on FUO using the revised 
definition of FUO. Since there are only two older studies that included patients from general hospitals 
[15,8], the second aim was to compare the number and sort of additional diagnostic tests that were 
used and causes of fever between patients with FUO referred to a university hospital and patients 
referred to general hospitals. To minimize diversity in diagnostic management, a standardized 
diagnostic protocol was used, which was based on a previously performed in-depth inquiry into 
diagnostic management of FUO among Dutch internists [16], on retrospective analysis of diagnostic 
management of patients with FUO in our university hospital [10,17] and, most importantly, on the 
large prospective Dutch FUO studies of De Kleijn et al. [4,18]. Based on previous studies, showing that 
18F-fluorodeoxyglucose positron emission tomography (FDG-PET) contributed to the final diagnosis 
in 16 to 69% of all patients with FUO [17,19-23], FDG-PET was added to this protocol. 
Patients and methods
Hospitals
From December 2003 to July 2005, patients with FUO were recruited from the Radboud University 
Nijmegen Medical Center (RUNMC), a 950-bed university hospital and tertiary referral center 
for patients with classical FUO and periodic fever. Patients were also recruited from five general 
hospitals: Canisius Wilhelmina Hospital Nijmegen (CWH, 650 beds), Jeroen Bosch Hospital 
’s-Hertogenbosch (JBH, 450 beds), Rijnstate Hospital Arnhem (RH, 750 beds), Slingeland Hospital 
Doetinchem (SH, 450 beds) en Maxima Medical Center Veldhoven (MMC, 500 beds). The study 
was approved by all local ethic committees. 
Patients
FUO was defined as a febrile illness of >3 weeks duration, a temperature >38.3°C on at least two 
occasions, without a diagnosis after standardized history-taking, standardized physical examination 
and the following obligatory diagnostic investigations: erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), hemoglobin, platelet count, leukocyte count and differentiation, electrolytes, 
creatinine, total protein, protein electrophoresis, alkaline phosphatase, AST, ALT, LDH, creatine 
kinase, antinuclear antibodies, rheumatoid factor, urinalysis, at least 3 blood cultures, urine culture, 
chest X-ray, abdominal ultrasonography (or CT) and tuberculin skin test. Periodic fever was defined 
as repeated episodes of fever with fever-free intervals of at least two weeks and apparent remission 
of the underlying disease. Immunocompromized patients, defined as patients with neutropenia 
(leukocyte count <1.0 x 109/l and/or granulocyte count <0.5 x 109/l) during at least 1 week within 
the 3 months preceding the fever, known HIV-infection, known hypogammaglobulinemia (IgG 
<50% of the normal value), use of the equivalent of more than 10 mg prednisone during at least 2 
weeks in the previous 3 months, were excluded. All patients with FUO aged 18 years or older in the 
participating hospitals were eligible for inclusion. To minimize the chance of unintended selection 
bias, broad initial selection criteria were used. All records of non-immunocompromized patients 
with fever on the internal medicine wards and out-patient clinics in all hospitals were reviewed for 
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the criteria for FUO by either the first author or the local investigator. In a retrospective study of 
patients with FUO previously performed in our university hospital, it was found that blood cultures 
were performed in all patients with FUO [10]. Therefore, in the university hospital, records of all 
patients in whom blood cultures were performed were reviewed weekly for the criteria of FUO by 
the first author. All patients provided written informed consent.
Diagnostic work-up
In all patients primarily referred to one of the participating hospitals, a structured diagnostic 
protocol was used (Figure 1). In patients referred after investigations in another hospital, this 
diagnostic protocol was followed directly after referral. First, a complete and repeated history was 
taken, a complete physical examination was performed followed by the obligatory investigations in 
a search for potentially diagnostic clues (PDCs). PDCs are defined as all localizing signs, symptoms 
and abnormalities potentially pointing toward a diagnosis [4]. With help of these PDCs a limited 
list of probable diagnoses was made. After identification of all PDCs retrieved from the history, 
physical examination and obligatory tests, further diagnostic procedures were recommended to be 
guided by this list. Misleading PDCs are defined as PDCs not leading to the eventual diagnosis. In 
patients without PDCs or only misleading PDCs, cryoglobulins were determined. When diagnosis 
was still uncertain, FDG-PET was performed. In patients with continuous fever with normal or false 
positive FDG-PET results, bone marrow biopsy, temporal artery biopsy in patients older than 55 
years, fundoscopy, abdominal CT and chest CT were performed. In patients with periodic fever, 
FDG-PET was performed during a symptomatic phase. In these patients, second level diagnostic 
tests were only recommended when PDCs for infections, vasculitis syndromes or malignancy were 
present, or when the clinical condition was deteriorating. In all patients with unexplained fever 
at this point, repeating a thorough history taking, physical examination and reviewing laboratory 
results and imaging studies including those from other hospitals was recommended. Only in 
patients deteriorating without presenting new PDCs, a further diagnostic workup or therapeutic 
trial with antibiotics, steroids, or antituberculous agents was recommended.
Assessment of diagnostic results
The results of diagnostic investigations were evaluated for their diagnostic contribution. Abnormal 
test results were categorized as “helpful in diagnosis” or “non-contributory to diagnosis”. They were 
regarded as helpful in diagnosis or true positive when abnormal test results pointed to the cause of 
the fever. Abnormal results were regarded as non-contributory to diagnosis or false positive when 
the detected abnormality was considered to be unrelated to the illness causing the fever or when 
no final diagnosis could be made. Since in most cases a gold standard is not available, specificity 
and sensitivity could only be calculated assuming that negative results were true negative when 
further investigations or the final diagnosis did not contradict these results. Normal test results 
were categorized as true negative when no cause of the symptoms was identified despite an 
extensive diagnostic work-up and clinical follow-up of at least 3 months. Normal test results were 
considered false negative when a disease was diagnosed that would usually cause positive test 
results. Most investigations were performed in each hospital according to local standards, because 
the scale of this study did not allow us to centralize these measurements and investigations.
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Figure 1  This figure shows the diagnostic protocol that was used in all participating patients.
  PDCs = potentially diagnostic clues
  Obligatory tests: erythrocyte sedimentation rate or C-reactive protein, hemoglobin, platelet count, leukocyte 
count and differentiation, electrolytes, creatinine, total protein, protein electrophoresis, alkaline phosphatase, 
ALAT, LDH, creatine kinase, antinuclear antibodies, rheumatoid factor, urinalysis, blood cultures (n=3), urine 
culture, chest X-ray, abdominal ultrasonography (or CT) and tuberculin skin test.
  Second level investigations: bone marrow biopsy, temporal artery biopsy in patients older than 55 years, 
fundoscopy, abdominal CT and chest CT
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Diagnosis and follow up
The final diagnosis was established by the attending physician and the first author. A definite 
diagnosis was based on positive cultures, serology, histology, or internationally accepted criteria 
for certain diseases. When this was not possible, a probable diagnosis was made based on a 
combination of clinical follow-up, response to specific therapy and conventional imaging studies. 
Follow up was performed by the first author by analysis of the patient’s record, and, in case no 
diagnosis was reached at the end of the study, also by telephone calls to the attending physicians 
and, in some cases, to the patients after a follow-up of at least 3 months, and again after at least 6 
months.
Data collection and statistical analysis
Of all patients, epidemiological data, number, sort and results of all diagnostic tests that were 
performed, the final diagnosis, treatment data, and follow-up data were registered in a structured 
database. Descriptive statistics for continuous variables are represented as means ± standard 
deviations. Categorical variables are reported in terms of the number and percentage of patients 
affected. Differences between the patient groups were tested with unpaired student t-tests for 
continuous variables and with Fisher’s exact tests for categorical variables. Differences were 
considered to be statistically significant at P <0.05. Sensitivity and specificity were calculated with 
95% confidence intervals. All potential predicting factors for reaching a diagnosis (all parameters 
derived from the standardized history and physical examination and the obligatory diagnostic tests 
and also for results of FDG-PET, abdominal and chest CT) were dichotomized. Patients with a final 
diagnosis were compared to patients without a final diagnosis using a Fisher’s exact test. Relative 
risks were calculated with 95% confidence intervals. A parameter was considered as a significant 
predicting factor when the 95% confidence interval of the relative risk was >1.
Results
Clinical features
Between December 2003 and July 2005, 75 patients with FUO were identified by review of patient 
records or through direct report by treating physicians (Figure 2). No additional patients were 
identified through review of the records of all patients in whom blood cultures were performed 
during the study period. Two patients refused participation, so a total number of 73 patients were 
enrolled. The results of 73 patients (33 males and 40 females) with a mean age of 54 years (range 
26 to 87 years) were evaluated: 40 patients were recruited from the university hospital (RUNMC) 
and 33 from the other hospitals (Table 1). Twenty-five patients (34% of all patients, 63% of patients 
recruited from RUNMC) were referred to RUNMC after extensive investigation in another 
hospital. 
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Figure 2 This figure shows the numbers of patients that were included in the different stages of the diagnostic protocol. 
It also shows the numbers of patients in whom a diagnosis was reached after every level of diagnostic tests and, 
for the remaining patients, the reasons for not participating in the next step of the diagnostic protocol.
 Table 1  Epidemiological data of all patients with FUO
Characteristic Total (n=73)
University hospital 
(n=40)
General hospitals 
(n=33)
Patients per hospital – No. (%)
 RUNMC 40 (55%) 40 -
 CWH 11 (15%) - 11 (33%)
 JBH 5 (7%) - 5 (15%)
 RH 4 (5%) - 4 (12%)
 SH 11 (15%) - 11 (33%)
 MMC 2 (3%) - 2 (6%)
Age – yr
 Mean ± SD 54 ± 16 51 ± 16 57 ± 16
 Range 26-87 26-82 31-87
Male sex – No. (%) 33 (45%) 16 (40%) 17 (52%)
Secondary referral – No. (%) 15 (21%) 15 (38%)‡ 0‡
Periodic fever 25 (34%) 20 (50%)‡ 5 (15%)‡
Duration of fever before present analysis - days
 Median ± SD 53 ± 890 348 ± 1106‡ 15 ± 200‡
 Range 1-4197 1-4197 1-1144
Hospitalization – No. (%) 62 (85%) 33 (83%) 29 (88%)
 Median duration ± SD 29 ± 32 32 ± 40 28 ± 18
 Range 3-177 3-177 3-77
‡P <0.05
73 obligatory tests
75 eligible for inclusion
2 declined participation
47 eligible for second
level tests
71 first level tests and
FDG-PET
24 diagnosis
9 fever subsided without diagnosis
16 periodic fever without diagnosis 
12 second level tests
1 died without diagnosis1 drug fever
10 diagnosis
11 no diagnosis1 diagnosis
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All patients recruited from the general hospitals were referred by a general practitioner (P <0.0001). 
Twenty-five patients (34%) had periodic fever: 20 of these patients (80%) were enrolled in RUNMC 
and 5 in general hospitals (P <0.005). The patient group from RUNMC was thus characterized by a 
higher percentage of secondary referrals and significantly more patients with periodic fever when 
compared to the patient group recruited from the general hospitals. Of all FUO patients, 85% were 
hospitalized for a median duration of 32 days (range 3-177 days). Significant differences between 
the university hospital and the general hospitals regarding the percentage of patients hospitalized 
or duration of hospitalization were absent.
Diagnosis and outcome
An infectious disease was the cause of the fever in 12 patients (16%), a neoplasm in 5 patients 
(7%), non-infectious inflammatory diseases (NIID) in 16 patients (22%), and miscellaneous causes 
in 3 patients (4%) (Table 2). The proportion of patients in each diagnostic category did not differ 
significantly between RUNMC and the general hospitals. In patients who were directly referred, 
NIID were significantly more often diagnosed than in patients referred for a second opinion (41% 
vs. 9%, P=0.04). Diagnoses were definitely confirmed by biopsy, microbiology or generally accepted 
clinical criteria [24-27] in 31 cases (86%). A probable confirmation was reached in the remaining 5 
cases (14%) through radiology and clinical follow-up. In 37 patients (51%), the cause of the fever was 
not found. The percentage of patients without a final diagnosis did not differ significantly between 
RUNMC and the general hospitals (55% vs. 45%). In 19 of all 25 patients with periodic fever (76%), 
no cause of the fever was found. Of the remaining 48 patients with continuous fever, no diagnosis 
was established in 15 cases (31%, P <0.005). In patients referred for a second opinion, no diagnosis 
was reached in 17 of 25 patients (68%) compared to no diagnosis in 20 of 48 patients (42%) who 
were directly referred (P=0.05).
After a median follow-up of 12 months (range 6 to 23 months), the fever subsided spontaneously 
in 16 of all 37 patients without a final diagnosis, in 5 patients the fever subsided after empirical 
treatment with a non-steroidal anti-inflammatory drug (NSAID) or corticosteroids, and in 15 
patients, the fever persisted. Of these 15 patients with persisting fever after a median follow-up 
of 15 months (7 to 23 months), 10 had periodic fever. One patient died before a diagnosis was 
reached. Duration of follow-up exceeded 6 months in all surviving patients without a diagnosis. 
In 36 patients with an explanation for the fever and a median follow-up of 11 months (range 4 to 
23 months for surviving patients, >6 months in 88%), the fever subsided either spontaneously or 
after specific treatment in 22 patients and in 10 patients the fever persisted. Despite appropriate 
treatment, 4 patients died due to the underlying disease causing the fever (pulmonary infection 
with bronchiectasis, abdominal abscesses, non-Hodgkin’s lymphoma (NHL) and metastatic 
adenocarcinoma). 
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Table 2 Final diagnoses in 73 patients with FUO
Category Total (n=73) University hospital (n=40) General hospitals (n=33)
Infection 12 (16%) 7 (18%) 5 (15%)
Bronchiectasia/pneumonia 2 1 1
Diverticulitis 1 1 -
Pyelonephritis 1 - 1
Abdominal abscesses 1 1 -
Osteomyelitis 2 1 1
Tonsillitis 1 - 1
Chronic persistent Yersiniosis 4 3 1
Neoplasm 5 (7%) 2 (5%) 3 (9%)
Non-Hodgkin’s lymphoma 3 2 1
Breast carcinoma with metastases 1 - 1
Adenocarcinoma with unknown primary 1 - 1
Non-infectious inflammatory disease 16 (22%) 8 (20%) 8 (24%)
Large vessel vasculitis 2 - 2
Polymyalgia rheumatica 3 1 2
Henoch Schonlein purpura 1 1 -
Microscopic polyangiitis 1 1 -
Psoriatic arthritis 1 - 1
Adult onset Still’s disease 3 2 1
Systemic lupus erythematosus 4 2 2
Cryoglobulinemia 1 1 -
Miscellaneous 3 (4%) 0 3 (9%)
Drug fever 2 - 2
Hypertriglyceridemia 1 - 1
No diagnosis 37 (51%) 22 (55%) 15 (45%)
Spontaneous recovery 16 6 10
Recovery with NSAID or corticosteroids 5 3 2
Persistent fever 15 12 3
Death 1 1 -
Potentially diagnostic clues (PDCs)
After the standardized history, physical examination, and obligatory tests, PDCs were present in 
all patients (Table 3). On average, 15 PDCs were identified per patient of which 81% proved to be 
misleading. In the remaining 19%, PDCs contributed to the final diagnosis, but in none of these 
patients, PDCs alone directly led to a diagnosis. In all patients with PDCs contributing to the final 
diagnosis, misleading PDCs were also present. The PDCs most often leading to a diagnosis (<75% 
misleading, present in at least 10 patients) were weight loss, muscle weakness, skin changes, 
previous medical history, shortness of breath, chest pain, abdominal pain, arthralgia, morning 
stiffness, abnormal pulmonary auscultation, elevated lactate dehydrogenase (LDH), anemia, 
leukocytosis, abnormal urinalysis and abnormal chest X-ray. There was no significant difference 
between patients with a diagnosis and patients without a diagnosis or between patients from 
RUNMC and patients from the general hospitals regarding the number of PDCs present.
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Table 3 Numbers of PDCs derived from the standardized history, physical examination and obligatory tests in 73 
patients with FUO
PDCs – Total No. (%) Total (n=73) University hospital (n=40) General hospitals (n=33)
History 649 354 295
  Misleading 540 (83%) 297 (84%) 243 (82%)
Physical examination 128 64 64
 Misleading 92 (72%) 45 (70%) 47 (73%)
Obligatory tests 287 140 147
 Misleading 225 (78%) 108 (77%) 117 (80%)
Total 1064 558 506
 Misleading 857 (81%) 450 (81) 407 (80%)
PDCs = potentially diagnostic clues
Adherence to the diagnostic protocol
A total number of 5331 investigations were performed in these 73 patients. Adherence to the 
diagnostic protocol did not differ significantly between the university hospital and the general 
hospitals except for measurement of cryoglobulins, which was significantly more often performed 
in the university hospital than in the general hospitals (95% vs. 52%). The obligatory investigations 
were performed in more than 95% of cases except for creatine phosphokinase (n=66, 90%) and 
tuberculin skin test (n=58, 79%). After the obligatory tests, one patient was diagnosed with drug 
fever (Figure 2). After performing FDG-PET and testing for cryoglobulins, a diagnosis was reached 
in 24 patients. In 10 patients, new PDCs leading to the final diagnosis (SLE in 2 patients, polymyalgia 
rheumatica in 3 patients, adult onset Still’s disease in 2 patients, microscopic poly-angiitis, Henoch 
Schonlein purpura, and hypertriglyceridemia each in one patient) developed before second level 
tests were completed. In 9 patients, the fever subsided spontaneously and 16 patients had periodic 
fever, so only 12 patients with continuous fever qualified for second level tests. In one of these 
12 patients, pyelonephritis was diagnosed with abdominal CT whereafter no further tests were 
performed. Abdominal CT was performed in 9 of the remaining 11 patients (82%), thoracic CT in 7 
patients (64%), fundoscopy in 4 patients (36%), and bone marrow biopsy each in only one patient 
(9%). In 2 out of 4 patients older than 55 years, temporal artery biopsy was performed. In none of 
these 11 patients, an explanation for the fever was found. 
Utility of investigations in the diagnostic process
Laboratory investigations
Including obligatory laboratory tests, other chemical tests, immunological serology, and 
endocrinological investigations, a total number of 3124 laboratory tests were performed (repeated 
measurements of the same parameter in one patient were not counted). None of these tests 
directly revealed the diagnosis. Abnormal liver tests, present in 20 patients (27%), contributed to 
the final diagnosis in only 3 patients (4%). The presence of antinuclear antibodies was helpful in 
diagnosing SLE in all 4 patients diagnosed with this disease, but showed false positive results in 8 
patients. In one patient with microscopic polyangiitis, the presence of anti neutrophil cytoplasmic 
antibodies (ANCA) was helpful while ANCA were also present in 5 patients without vasculitis. 
Endocrinological investigations did not contribute to the final diagnosis in any of the patients.
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Microbiology
In 53 patients, 509 microbiological serologic tests were performed (repeated measurements of the 
same parameter were not counted). Except for Yersinia enterocolitica serology, these tests were never 
helpful in establishing a diagnosis. Serology for cytomegalovirus (n=37), Epstein Barr virus (n=34), 
hepatitis B virus (n=21), hepatitis C virus (n=23), HIV (n=22), Borrelia burgdorferi (n=22), Brucella 
spp. (n=25), Coxiella burnetii (n=22), Toxoplasma gondii (n=25), and syphilis (n=21) were most often 
requested. In 29 patients (40%), serology for Yersinia enterocolitica was performed. Yersinia serology 
was negative in 15 patients and in 10 patients the results were considered equivocal (IgA negative 
and IgG positive for at least 2 bands, IgA and IgG positive for 1 band, or IgA and IgG weakly positive 
for 1 or more bands). Positive results (IgA and IgG repeatedly positive for at least 2 bands) were 
obtained in 4 patients who were diagnosed with chronic persistent yersiniosis as cause of the fever. 
In three patients, all symptoms disappeared after antibiotic treatment and in one patient, symptoms 
disappeared and inguinal lymphadenopathy markedly decreased without treatment.
 A total of 743 blood cultures, 170 urine cultures, and 280 other cultures were performed. In none of 
these patients, however, blood or urine cultures led to the cause of the fever. In 10 patients, positive 
blood cultures were found (1.2% of all blood cultures). In one patient treated with continuous 
ambulatory peritoneal dialysis (CAPD) who was diagnosed with abdominal abscesses, Escherichia 
coli, Proteus mirabilis, and Enterococcus spp. were repeatedly cultured from the CAPD fluid, which 
proved to be the micro-organisms causing the abscesses after surgical drainage. In 6 patients, 
blood cultures grew coagulase-negative Staphylococci (n=3), Corynebacterium (n=1), diphteroid 
rods (n=1), and Propionibacterium (n=1), which were all considered to be contamination by the 
treating physician. In the remaining 3 patients with blood cultures growing Streptococcus viridans, 
Stenotrophomonas maltophilia, and Enterococci combined with coagulase-negative Staphylococci 
each in one patient, the fever persisted after appropriate antibiotic treatment followed by negative 
blood cultures and was considered to be unrelated to the bacteremia. In 9 patients who did not have 
convincing symptoms or signs of a urinary tract infection, urinary culture results were considered 
to be false positive (5% of all urine cultures), because after adequate treatment of the assumed 
urinary tract infection, bacteriuria disappeared while the fever remained unchanged. In one patient 
eventually diagnosed with pyelonephritis, urinary culture (obtained after 2 days of antibiotic 
treatment) was considered false negative. With regard to the number of cultures performed per 
patient, no difference was found between the university hospital and the general hospitals.
Imaging techniques (Table 4)
Chest X-ray was considered false negative in 4 patients with pulmonary NHL, mediastinal NHL, 
and SLE pleuritis (n=2). Abdominal ultrasound was performed in 58 patients (79%). An abdominal 
CT had been performed in 6 of the remaining patients before inclusion or referral to the university 
hospital. In the other 9 patients, abdominal CT was preferred by the treating physician, usually 
because of a longer waiting time for abdominal ultrasound. In 18 patients, abnormal abdominal 
ultrasound did not lead to the diagnosis and caused unnecessary investigations, so these were 
considered false positive. In one patient with diverticulitis, abdominal ultrasound was classified as 
false negative because FDG-PET and subsequent abdominal CT revealed the diagnosis. Assuming 
158
_____  Chapter 9  _____________________________________________________________________________________________________________ ______________________________  A prospective multi-center study on FUO: the yield of a structured diagnostic protocol  _____ 
159
all other normal chest X-rays and abdominal ultrasounds were true negative, sensitivity and 
specificity were calculated (Table 4).
Table 4 Diagnostic utility of imaging techniques, endoscopy, histological investigations, and laparotomy in 73 patients 
with FUO
Investigation
No. of 
patients Helpful False positive
Sensitivity
(95% CI)
Specificity
(95% CI)
Chest X-ray 73 (100%) 6 (8%) 8 (11%) 60% (26-88%) 87% (77-94%)
Sinus X-ray 32 (44%) 0 2 (6%) NC NC
Orthopantomogram 22 (30%) 0 2 (9%) NC NC
Barium enema 10 (14%) 0 1 (10%) NC NC
Enteroclysis 6 (8%) 0 0 NC NC
Abdominal ultrasound 58 (79%) 6 (10%) 18 (31%) 86% (42-100%) 65% (50-78%)
Abdominal CT 60 (82%) 12 (20%) 17 (29%) 92% (64-100%) 63% (48-77%)
Chest CT 46 (63%) 9 (20%) 8 (17%) 82% (48-98%) 77% (60-90%)
FDG-PET 70 (96%) 23 (33%) 10 (14%) 88% (74-99%) 77% (63-89%)
Echocardiography 19 (26%) 0 4 (22%) NC NC
Bronchoscopy 5 (7%) 1 (20%) 0 NC NC
Gastroscopy 21 (29%) 0 3 (14%) NC NC
Colonoscopy 19 (26%) 1 (5%) 2 (10%) NC NC
Temporal artery biopsy 14 (19%) 1 (7%) 0 NC NC
Bone marrow biopsy 19 (26%) 2 (11%) 1 (5%) NC NC
Liver biopsy 7 (10%) 1 (14%) 3 (43%) NC NC
Duodenal biopsy 12 (16%) 0 1 (8%) NC NC
Colonic biopsy 13 (18%) 0 2 (15%) NC NC
Lymph node biopsy 11 (15%) 5 (46%) 3 (27%) NC NC
Skin biopsy 8 (11%) 5 (63%) 0 NC NC
Laparotomy 4 (6%) 2 (50%) 1 (25%) NC NC
CT = computer tomography
FDG-PET = 18F-fluorodeoxyglucose positron emission tomography
NC = not calculated
Sinus X-rays and orthopantomograms were not helpful in our patient population. The results of 
2 sinus X-rays and 2 orthopantomograms were considered false positive. Also, barium enemas or 
enteroclysis never helped revealing a final diagnosis in this study. In one patient, barium enema 
showed diverticulosis and could not rule out diverticulitis, but abdominal CT and colonoscopy 
did not reveal any signs of diverticulitis, so barium enema was considered false positive. In this 
population of patients with FUO, echocardiography was never helpful. In 4 patients without cardiac 
causes explaining the fever, abnormal echocardiography showing a small pericardial effusion in the 
patient with diverticulitis, dubious vegetations of the mitral or aortic valve without endocarditis 
according to the Duke criteria (n=2), and thickened septum was considered false positive. 
Abdominal CT, performed in 60 patients, was helpful in establishing a diagnosis in 12 patients (20%). 
Results of abdominal CT were considered false positive in 17 patients (28%, 12 patients without a 
final diagnosis and 5 patients with a diagnosis not explaining the abnormality). Abdominal CT was 
considered false negative in one patient who was eventually diagnosed with diverticulitis in whom 
only the last of 3 abdominal CT-scans was considered abnormal after comparison to the FDG-PET 
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results. In 46 patients, chest CT was performed, which was helpful in 9 (20%). False positive results 
were found in 8 patients without evidence of pulmonary disease (17%). Chest CT was considered false 
negative in a patient with NHL and in a patient with aortitis of the thoracic aorta. FDG-PET, performed 
in 70 patients, contributed to the final diagnosis in 23 patients (33%) and results were categorized 
as false positive in 10 patients (14%, 9 patients without a diagnosis). FDG-PET was considered false 
negative in 2 patients (3%) with small pleural effusions who were eventually diagnosed with SLE 
and one patient with pyelonephritis. The results of FDG-PET will be discussed in detail elsewhere. 
Assuming all other abdominal and chest CT-scans and FDG-PET-scans were true negative, sensitivity 
and specificity were calculated (Table 4).
Histological investigations (Table 4)
Bone marrow aspiration was performed in 21 patients, but never contributed to the diagnosis. Bone 
marrow biopsy, performed in 19 patients, was helpful in establishing a diagnosis in one patient 
with NHL and one patient with bone metastases of an adenocarcinoma with an unknown primary 
tumor. In both patients, bone marrow aspiration had not revealed the diagnosis. Temporal artery 
biopsy was performed in 14 patients (10 with PDCs for vasculitis, 2 with FDG-PET results suggesting 
vasculitis, and 2 as part of the second level tests), but in only one patient in whom FDG-PET already 
pointed to large vessel vasculitis, temporal artery biopsy was useful to confirm the diagnosis 
of temporal arteritis. Liver biopsy was performed in 7 patients. In one patient, lobular hepatitis 
supported the suspected diagnosis of persistent yersiniosis and thus contributed somewhat 
to the diagnosis. In 3 patients, the results were considered false positive: hepatitis suggestive 
of a drug reaction in the patient with diverticulitis and non-specific hepatitis and steatosis in 
two patient without a diagnosis and no signs of progressive liver disease or viral hepatitis after 
follow-up of 8 and 11 months, respectively. Lymph node biopsy was performed in 11 patients with 
lymphadenopathy. Lymph node biopsy supported persistent yersiniosis in 3 patients. Reactive 
changes were found in 3 patients without a final diagnosis (considered to be false positive) and in 2 
patients with Still’s disease (true positive). Skin biopsy, performed in 8 patients with skin changes, 
was helpful in 5 patients diagnosed with drug fever (n=2), Henoch Schonlein purpura, SLE, and 
Still’s disease. Other successful histological investigations performed because PDCs were present 
or because of abnormal FDG-PET results were pulmonary wedge excision, confirming infection of 
known bronchiectasis, SLE, and NHL, each in one patient, histological examination of an excised 
tonsil confirming tonsillitis in one patient, and biopsy of the peritoneum showing a granulomatous 
infiltrate with necrosis supporting the diagnosis of persistent yersiniosis in one patient. Autopsy 
confirmed the presence of NHL in one patient.
Endoscopy and laparotomy or laparoscopy (Table 4)
Bronchoscopy was performed in only 5 patients and supported the diagnosis in one patient 
eventually diagnosed with acute infection of bronchiectasis after pulmonary wedge excision. 
Gastroscopy, performed in 21 patients, and colonoscopy, performed in 19 patients, were never 
useful. Gastroscopy showed false positive results in 3 patients (ischemic changes, duodenal 
ulceration and bulbitis, polyp suspected for malignancy). Colonoscopy was false positive in 2 
patients (rectal ulceration and local redness with normal biopsy results). Laparotomy or laparoscopy 
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was performed in 4 patients with PDCs for abdominal pathology: in one patient, lymphadenopathy 
caused by persistent yersiniosis was confirmed and in one patient peritonitis was found, which was 
later diagnosed as SLE peritonitis. In one patient, laparotomy showed lymphadenopathy, but biopsy 
showed only reactive changes and follow-up of almost one year has not revealed a diagnosis, so 
laparotomy was considered as false positive.
Factors predicting the likelihood of reaching a diagnosis
Statistically significant predictors for reaching a diagnosis are shown in Table 5. The chance of 
establishing a diagnosis was higher in patients with continuous fever and in patients in whom the 
fever persisted for less than 180 days before inclusion. Foreign descent appeared to be a significant 
predictor of reaching a diagnosis although these patients were diagnosed with diseases (SLE and 
large vessel vasculitis), which do not appear to relate to their ethnicity. Surprisingly, also otalgia 
was a significant predictor. Two of these patients were diagnosed with large vessel vasculitis, 
which could explain the otalgia, but the 5 remaining patients were diagnosed with diseases not 
explaining the otalgia (adult onset Still’s disease, hypertriglyceridemia, pneumonia, NHL, and 
psoriatic arthritis, respectively). In none of 11 patients with normal C-reactive protein (CRP) and 
normal erythrocyte sedimentation rate (ESR), a diagnosis could be reached compared to 36 of 
62 patients with elevated CRP and/or ESR (58%, P <0.0005), so elevated ESR or CRP is also an 
important factor in predicting the likelihood of reaching a diagnosis. Abnormal results of either 
chest X-ray, abdominal ultrasound, or abdominal CT were not predictive of reaching a diagnosis. 
Abnormal chest CT (performed in 46 patients) and abnormal FDG-PET (performed in 70 patients), 
however, were significant predicting factors. 
Table 5 Predictors of the likelihood of reaching a diagnosis in 73 patients with FUO
Parameter
No diagnosis (n=37)
No./Total No. (%)
Diagnosis (n=36)
No./Total No. (%) RR (95%CI)
Continuous fever 18/37 (49%) 30/36 (83%) 2.6 (1.3-5.4)
Fever present <180 daysA 18/37 (49%) 31/36 (86%) 3.0 (1.4-6.8)
Foreign descentB 0/37 2/36 (6%) 2.6 (1.1-6.4)
Otalgia 1/37 (3%) 7/36 (19%) 2.0 (1.3-2.9)
Elevated CRP or ESRC 26/37 (70%) 36/36 (100%) -
Elevated LDH 2/37 (5%) 9/36 (25%) 1.9 (1.3-2.8)
Leukopenia 0/37 2/36 (6%) 2.1 (1.6-2.7)
Thrombocytosis 2/37 7/36 (19%) 1.7 (1.1-2.7)
Chest CT abnormal 6/26 (23%) 12/20 (60%) 2.3 (1.2-4.6)
FDG-PET abnormal 9/35 (26%) 24/35 (69%) 2.4 (1.4-4.2)
A Fever present less than 180 days before inclusion in the study
B Either the patient or one or both parents were not born in The Netherlands
C Calculation of relative risk not possible because all patients with a diagnosis had an elevated CRP or ESR
CRP = C-reactive protein
ESR = erythrocyte sedimentation rate
LDH = lactate dehydrogenase
 FDG-PET = 18F-fluorodeoxyglucose positron emission tomography
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Discussion
In this prospective multi-center study of 73 patients recruited from one university hospital and 5 
community hospitals, the proportion of undiagnosed cases (51%) seems high, but the percentage 
of undiagnosed cases tends to increase in more recent studies. In the only two series of patients 
with classical FUO studied after 1990 in northwestern Europe, no diagnosis was reached in 30% 
[4] and 53% [12], respectively. There are several possible explanations. First, 35% of all patients 
were referred after extensive investigations elsewhere and it has been speculated that more 
difficult-to-diagnose cases are referred. The percentage of referred patients in this study, however, 
is similar to other recent studies (Table 6) reporting percentages of undiagnosed cases from 11 to 
53% [4,7,9,10,12,14]. Furthermore, in the present study, secondary referral was not a significant factor 
predicting the likelihood of reaching a diagnosis. 
Table 6 Comparison of previous FUO series with inclusion of patients from Europe and the USA since 1980 
First author
(country) Design
Patients
(recr. period)
Secondary 
referral
Periodic 
fever
Cause of the fever (%)
inf. neopl. NIID misc. unknown
Knockaert [9] 
(Belgium)
Prospective
1 UH
199
(1980-1989)
28% 23 7 25 20 26
Barbado [7] 
(Spain)
Prospective
1 UH
85
(1982-1989)
45% 11 28 34 12 15
Kazanjian [8]
(US)
Prospective
3 GH
86
(1984-1990)
33 24 26 5 9
De Kleijn [10]
(NL)
Retrospective
1 UH
53
(1988-1992)
53% 34% 21 19 23 8 30
Tabak [11]
(Turkey)
Retrospective
1 UH
117
(1984-2001)
34 19 29 4 14
De Kleijn [4,18]
(NL)
Prospective
8 UH
167
(1992-1994)
38% 34% 26 13 24 8 30
Ergonul [14] 
(Turkey)
Prospective
1 UH
80
(1993-1999)
33% 52 18 16 3 11
Vanderschueren [12] 
(Belgium)
Prospective
1 UH
185
(1990-1999)
32% 42% 11 10 18 8 53
Saltoglu [13] 
(Turkey)
Prospective
1 UH
87
(1994-2002)
59 14 18 2 7
Present study 
(NL)
Prospective
1 UH/5 GH
73
(2003-2005)
34% 34% 16 7 22 4 51
recr. period = recruitment period
UH= university hospital, GH = general hospital
US = United States, NL = The Netherlands
Inf. = infection, neopl. = neoplasm, NIID = non-infectious inflammatory disease, misc. = miscellaneous
A more probable explanation is the diagnostic strictness we, and also others with relatively 
high percentages of undiagnosed cases [4,9,10,12], have applied. Diagnoses lacking persuasive 
confirmatory tests (e.g., adult-onset Still’s disease, polymyalgia rheumatica) were only accepted 
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if sufficient standard criteria were met and follow-up allowed exclusion of other diseases. Since 
periodic fever was strongly related to a reduced chance of reaching a diagnosis in this study and 
the chance of reaching a diagnosis in these patients is known to be significantly smaller than in 
patients with continuous fever [4,12,28], the high percentage of patients with periodic fever (34%) 
appears to be an important factor explaining the high number of undiagnosed cases. Another 
factor contributing to the seemingly high diagnostic failure rate might be that a diagnosis is more 
frequently reached before 3 weeks have elapsed because patients with fever tend to seek medical 
advice earlier and because better diagnostic techniques, such as CT or MRI, are widely available 
resulting in more hard-to-diagnose cases meeting the definition of FUO. Another contributing 
factor, as suggested by Vanderschueren et al. [12], could be the observation that most patients with 
FUO without a diagnosis do well [4,29], which may lead to a less aggressive diagnostic approach 
in clinically stable patients once diseases with immediate therapeutic or prognostic consequences 
have been ruled out to a reasonable extent. This could be especially true for patients with periodic 
fever who are asymptomatic in between febrile episodes. In the present study, the outcome of 
patients without a diagnosis was as favorable as in previous studies [4,12,29]. 
The spectrum of diseases causing FUO has changed as a result of changes in the broad spectrum 
of diseases causing FUO and the availability of new diagnostic techniques. The proportion of 
abdominal abscesses and tumors, for example, has decreased in recent series because of earlier 
detection by ultrasound. Also, infective endocarditis has decreased in frequency as blood culture 
techniques have improved. In addition, some diagnoses in recent series, such as Lyme disease, 
acute HIV infection, and Sweet’s syndrome, were unknown four decades ago. The percentage 
of patients diagnosed with infection in our study is similar to the results of other recent studies 
performed in northwestern Europe [4,9,10,12] (Table 6). In most studies from southern Europe 
[11,13,14], infections account for a much larger proportion of diagnoses (34 to 59%), which can be 
explained by the high incidence of tuberculosis (29 to 70% of all infections). In the only study 
from southern Europe with a lower percentage of infections [7], 8 of 9 infections were caused by 
tuberculosis also. In one study from the US [8], the percentage of infections was also higher, which 
could possibly be explained by not excluding HIV-patients and by selection of FUO cases from all 
infectious disease consultations instead of from the general patient population. The patients in our 
study did not suffer from rare infections but exhibited rather atypical manifestations of common 
illnesses, which has already been emphasized as an important factor in patients with FUO by 
Petersdorf and Beeson [1]. The number of patients eventually diagnosed with NIID will probably 
not decrease in the near future, because fever may precede more typical manifestations or 
serological evidence by months in these diseases. Moreover, many of NIID can only be diagnosed 
after prolonged observation and exclusion of other diseases. In other recent series, the proportion 
of patients diagnosed with malignancy roughly varies between 10 and 20%. In two studies, a higher 
incidence of malignancy was found, but both of these studies had a remarkably low percentage 
of patients without a diagnosis suggesting different patient characteristics [7,8]. The widespread 
early use of diagnostic techniques such as ultrasound and CT have resulted in a steady decline of 
malignancy explaining FUO.
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To enable adequate comparison between FUO studies, using a uniform definition and uniform 
entry criteria is very important. Selection bias increases when patients presenting to the outpatient 
department are included, because prospective case finding is harder and standardized diagnostic 
protocols are more difficult to implement. However, inclusion of these patients in future studies, 
as we did in the present study, is essential. Since Petersdorf and Beeson first defined FUO, health 
care has shifted from the inpatient to the ambulatory setting. Nowadays, most patients with FUO 
will be hospitalized if this is required by their clinical condition, but not for diagnostic purposes 
only. A vast proportion of patients who met the definition of FUO in the past would be omitted 
from future studies if the requirement of study in the hospital is maintained (11 patients in our 
study, for example). Also, the criterion no diagnosis after admission to the hospital for 1 week (or 3 
days as was previously suggested by others) is a time-related criterion, which may cause important 
differences, as it is dependent on the experience of the physician. Furthermore, many differences 
in management and diagnostic facilities exist between hospitals or countries. We strongly 
recommend that, in future FUO studies, this criterion is changed to a quality-related criterion 
requiring a minimum list of certain investigations to be performed. Defining the necessary initial 
investigations will remain a matter of debate, but it is generally agreed that the initial diagnostic 
protocol required for a case to qualify as FUO should at least include the tests that were obligatory 
in our study. Further tests should be based on the local prevalence of certain diseases.
Classic test characteristics are difficult to apply in FUO studies since there is no diagnostic gold 
standard against which diagnostic tests may be measured. Determining the denominator for 
calculation of sensitivity and specificity is difficult since a significant proportion of all cases remain 
undiagnosed. Therefore, it seems more appropriate to rate diagnostic tests as useful-positive or 
helpful. The use of diagnostic tests in our patient population proved to be abundant. Although 
obligatory tests, the first stage investigations, and FDG-PET were performed in more than 95% of 
patients, the second stage screening tests (Figure 1) were completed in only one out of 12 patients 
qualifying for this part of the protocol. Therefore, this study does allow us to draw conclusions on 
the overall diagnostic value of many diagnostic techniques, but not, or to a lesser extent, on the 
screening diagnostic value of some of these techniques.
Only rarely do biochemical tests directly lead to a certain diagnosis. In our study, nonspecific liver 
test abnormalities, present in 27% of all patients, only rarely contributed to the final diagnosis, 
which is in agreement with data from previous studies showing that abnormal liver tests are not 
predictive of a diagnostic liver biopsy in FUO [30,31]. The diagnostic yield of immunologic serology 
is also relatively low. Although antinuclear antibodies and ANCA sometimes contributed to the 
diagnosis, these tests were more often false positive and are of little use without PDCs pointing to 
specific immunologic disorders. Based on results from a larger prospective study [18], the absence 
of specific symptoms in many patients, and the relatively low cost of the test, investigation of 
cryoglobulins appears to be a valuable screening test in patients with FUO although in our current 
population, cryoglobulinemia was diagnosed in only one patient who was not suspected of this 
disease.
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De Kleijn et al. [18] studied the screening diagnostic value of microbiologic serology in 167 patients 
with FUO and concluded that these investigations should not be performed early in the diagnostic 
work-up in patients without PDCs for specific infections. In the present study, serologic tests, 
although abundantly performed, contributed to the final diagnosis in only four patients with 
chronic yersiniosis, which supports this conclusion.
Although on average 16 cultures were performed in each patient, culture results supported the 
final diagnosis in only one patient. Of course, the obligation of the diagnosis being uncertain after 
performing at least three blood cultures and a urine culture before meeting the definition of FUO 
is an important reason for this. What physicians should learn from this, however, is that performing 
more than three blood cultures or more than one urine culture is useless in patients with FUO in 
the absence of PDCs (i.e. a high clinical suspicion of endocarditis). In the present study, only one 
patient used antibiotics at the time of inclusion when blood and urine cultures were performed, 
which might explain why additional blood cultures never contributed to the diagnosis in contrast 
to the study by De Kleijn et al. [18].
The diagnostic yield of imaging techniques is often difficult to establish, because it is dependent 
on the imaging techniques that are used in an earlier stage. We tried to minimize this problem by 
including chest X-ray and abdominal ultrasound in the obligatory part of the diagnostic protocol 
and by dividing the protocol in several stages. Abdominal ultrasound was chosen as obligatory test 
above abdominal CT, because of the relatively low cost, no radiation burden, and the absence of 
side effects. Of course, none of the patients in whom abdominal ultrasound or chest X-ray directly 
led to the diagnosis were included in this study. In several patients meeting the criteria for FUO, 
however, abdominal ultrasound or chest X-ray contributed to the diagnosis. Despite the high 
number of false positive ultrasounds and the relatively low sensitivity of chest X-rays, we believe 
that these simple low-cost diagnostic tests remain obligatory in all patients with FUO in order to 
separate diseases that can be easily diagnosed from the real FUO cases.
In the present study, FDG-PET proved to be helpful in 33% of all patients. The value of FDG-PET in 
this patient population is discussed in greater detail in a separate article concluding that FDG-PET 
as part of a structured diagnostic protocol is valuable in the general population of FUO-patients. The 
diagnostic yield of abdominal CT in our study (20%) is similar to results from two previous studies 
investigating the usefulness of abdominal CT in FUO [18,32]. Specificity of chest CT was similar to 
the results from the study by De Kleijn et al. [18], but specificity of abdominal CT appeared to be 
lower (63 vs. 80%). As stated above, this might be explained by the imaging techniques already used 
(FDG-PET in most patients in the present study vs. no FDG-PET in the previous study). Despite the 
limited specificity of abdominal CT and the probably limited additional value of chest CT after 
normal FDG-PET, chest and abdominal CT may be used as screening procedures at a later stage of 
the diagnostic protocol due to their non-invasive nature and high sensitivity. In our study as well as 
in the study by De Kleijn et al. [18], the diagnostic yield of echocardiography, X-rays of the sinuses, 
radiological or endoscopic evaluation of the gastrointestinal tract, and bronchoscopy were very low 
when PDCs were absent, so these tests should not be performed as screening procedures.
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Bone marrow aspiration was of no use in the absence of PDCs for bone marrow disorders in both 
the present study and the study by De Kleijn et al. [18] and is thus not recommended as a screening 
procedure. Bone marrow biopsy was useful in 2 patients without PDCs for bone marrow disorders 
in our study, but in both patients FDG-PET already pointed to the diagnosis. With addition of 
FDG-PET, which is very sensitive in detecting lymphoma, carcinoma, and osteomyelitis, the value 
of bone marrow biopsy as a screening procedure is probably less than in the study by De Kleijn 
et al. [18]. Some studies have shown a high prevalence of temporal arteritis among patients with 
FUO [9,12], up to 17% in elderly patients [33]. In the present study, temporal artery biopsy was 
useful in only one patient in whom vasculitis was already suspected after FDG-PET. Since temporal 
arteritis often starts with non-specific symptoms such as fever, diagnosis can be very difficult. 
Early diagnosis, however, is important to enable adequate treatment to prevent complications. 
Temporal artery biopsy can still be recommended for patients of 55 years or older in a later stage 
of the diagnostic protocol, because FDG-PET will not be useful if the vasculitis is limited to the 
temporal arteries due to the small diameter of these vessels and because of high FDG-uptake in 
the overlying brain. In the past, liver biopsies have often been performed as a screening procedure 
in patients with FUO. In one retrospective analysis of 24 patients with FUO, liver biopsy revealed 
3 cases of histoplasmosis and one case of tuberculosis [30], all very uncommon causes of FUO in 
Europe and the USA. In another study, liver biopsy was performed in 43 patients (14% diagnostic), 
but these cases represented only 10% of the FUO patients seen in that hospital [31], indicating 
considerable selection bias. Furthermore, in both our study and the study by De Kleijn et al. [18], 
liver biopsy as part of the later stage of a screening diagnostic protocol was helpful in only one 
patient each. Liver biopsy is an invasive procedure with the possibility of complications and even 
death. Therefore, we believe that liver biopsy should not be performed as a screening procedure in 
all patients with FUO.
In many reviews of FUO since the 1970s, the importance of PDCs has been emphasized by advising 
the physician to observe Sutton’s law “to go where the money is” [5,34,35]. Two retrospective 
studies showed significantly lower chances of reaching a diagnosis when PDCs were absent [10,36]. 
The value of PDCs was investigated in only one prospective study [18], however, which showed that 
the presence of PDCs does not increase the likelihood of reaching a diagnosis. Because of the low 
percentage of patients without PDCs in that study and the absence of patients without PDCs in our 
study, these findings should be interpreted carefully. We have no doubt that the search for PDCs is 
the physician’s most important tool to unravel the cause of the fever, but both the present study 
and the study by De Kleijn et al. show that the majority of PDCs is misleading. In univariate analysis 
of patients with and patients without a diagnosis, significant predictive factors for reaching a 
diagnosis were continuous fever, duration of fever for less than 180 days, foreign descent, otalgia, 
elevated ESR, CRP, or LDH, leucopenia, thrombocytosis, abnormal chest CT and abnormal FDG-
PET. Of most of these factors, it is understandable why reaching a diagnosis is more likely, but 
especially in case of “otalgia” and “foreign descent”, this is much more difficult or even impossible, 
raising questions about the usefulness of these factors.
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The vast majority of FUO studies have been performed in university hospitals. Patients with 
FUO are often referred to those institutions because of the local expertise, which is also true for 
RUNMC. It is questionable whether the results from such studies can be applied to the general 
population of patients with FUO. Two prospective studies were performed in general hospitals in 
the 1970s [15] and the 1980s [8], but, as far as we know, this is the first study directly comparing 
patients with FUO referred to one university hospital and several general hospitals in the same 
region during the same time period. Gleckman et al. [15] studied 34 patients referred to one small 
general hospital (180 beds) in the Boston area. In 35% of these patients, no diagnosis was reached. 
In 18% of all cases, infection was causing the fever, in 9% malignancy, in 12 % NIID, and in 26% the 
cause could be categorized as miscellaneous. In the more recent study by Kazanjian [8], 86 patients 
with FUO were recruited from 3 general hospitals in Rhode Island (Table 6). Diagnostic techniques 
have improved remarkably since Gleckman’s study and FDG-PET was added to the diagnostic 
possibilities since Kazanjian’s study. In our study, significantly more patients with periodic fever 
were found in the university hospital. Since diagnosis is more difficult in this patient population 
and our university hospital has specialized in periodic fever, this was to be expected. The fact that 
half of all patients were referred to RUNMC after extensive investigation elsewhere while in the 
general hospitals all patients were directly referred explains the significantly longer duration of 
fever before the present analysis. There were, however, no significant differences between the 
causes of FUO or the percentage of patients in whom no diagnosis was reached, so conclusions 
about the structured diagnostic protocol used in this study are applicable to the general population 
of FUO patients.
In conclusion, the proportions of patients with FUO that are eventually diagnosed with infection 
or malignancy have decreased in recent years while the percentage of undiagnosed cases has 
increased significantly. In patients with FUO, empiric testing should be based on the relative 
frequencies of the different causes and their importance to the health of the patient. In the 
absence of PDCs for certain infectious diseases, serologic tests are nearly always useless. Except 
for tests from the obligatory part of our protocol and measurement of cryoglobulins in an early 
stage, followed by FDG-PET, and in a later stage by abdominal and chest CT, temporal artery 
biopsy in patients of 55 years or older and possibly bone marrow biopsy, other tests should not be 
used as screening procedures in the hope that something abnormal will be found. Ordering other 
screening tests has many disadvantages, such as false positive results, the possibility of adverse 
reactions or complications, increasing costs of testing, and as stated before by De Kleijn [18] “a 
soporific effect on the doctor’s diagnostic mental activities”. Repeating a thorough history-taking 
and physical examination and waiting for new PDCs to appear seems to be preferable to ordering 
more screening tests. If the fever persists and the source remains elusive after completing the later 
stage investigations, supportive treatment with NSAIDs can be helpful. Empirical therapeutic trials 
with antibiotics, steroids, or antituberculous agents should be avoided, except in patients whose 
condition is deteriorating. 
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General discussion
In this thesis, the results of several retrospective and three prospective clinical studies in patients 
with fever of unknown origin (FUO) and patients with various infectious and inflammatory 
diseases are described. Although 18F-fluorodeoxyglucose (FDG) positron emission tomography 
(PET) has become an established imaging tool in oncology, it has only recently entered the 
field of infectious and non-infectious inflammatory diseases. Over the past years, a variety of 
other radiopharmaceuticals have been used for the scintigraphic visualization of infectious 
and inflammatory diseases and the number of these compounds is still increasing. General 
characteristics of an ideal infection-imaging agent should include efficient accumulation and good 
retention in inflammatory foci, rapid clearance from the background, easy low-hazard preparation 
and wide availability at low cost. Absence of accumulation in non-target organs, specifically in the 
blood pool and the bowel is also important. Early diagnostic imaging and a one-day protocol are 
generally preferred especially in case of severe and acute illnesses. Delivering high radiation doses 
or using radiolabeled compounds with possible side effects is in general unwanted and should be 
considered only when significant clinical benefit is to be expected. 
Conventional radiopharmaceuticals routinely used in clinical practice (67Ga and 111In-labeled or 
99mTc-labeled leukocytes (WBC)) have disadvantages and limitations, such as handling of potentially 
infected blood products (WBC), high radiation burden (67Ga), instability of the labeling (99mTc-
WBC), and the long time span between injection and diagnosis (67Ga). FDG rapidly accumulates 
in infectious and inflammatory foci and it is cleared very rapidly from almost all other sites of the 
body, including the blood compartment. Variable physiologic FDG-uptake in the bowel is possible 
and can thus lead to false positive results, although this problem was not frequently encountered 
in our studies. Another advantage of FDG-PET is that completion of the protocol only takes 2 
to 3 hours. Side effects of FDG have never been encountered thus far, nor have adverse effects 
been described in literature. One FDG-PET scan results in a very acceptable radiation exposure of 
approximately 5 mSv as compared to for example the radiation exposure of an abdominal CT scan 
(8-15 mSv), a 67Ga-scan (16.5 mSv) or 111In-leukocyte-scan (11 mSv). In many cases, differentiation 
between infection and non-infectious inflammation is preferred, which is not possible by using 
FDG-PET. However, this is not true for patients with FUO. In these patients scintigraphic imaging 
is most often used to evaluate the presence of focal abnormalities, which can subsequently be 
further evaluated by specific diagnostic procedures. The fact that FDG-PET detects infectious 
and inflammatory diseases as well as malignancy can even be considered as an advantage in FUO 
patients. Another obvious disadvantage of FDG-PET is the relatively high cost and the currently 
limited availability. However, when FDG-PET performance for infection and inflammation is 
confirmed in larger prospective studies and the number of PET systems further increases, the high 
diagnostic yield of FDG-PET may very well become a clinically significant and also cost-effective 
modality, since adequate early diagnosis limits the number of other non-contributing (invasive) 
tests required and the time to diagnosis and thereby the duration of hospitalization for diagnostic 
purposes.
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From the case reports presented in chapter 2 and a review of previous clinical studies using 
FDG-PET in the diagnosis of infection and inflammation described in chapter 1, it was concluded 
that FDG-PET is a promising new imaging technique in patients with various infectious and 
inflammatory disorders warranting further studies. Our retrospective study of the value of 
FDG-PET in patients with various types of vasculitis in chapter 3 shows that FDG-PET is useful in 
diagnosing and determining the extent of various forms of vasculitis. In this study, it was concluded 
that FDG-PET might become a useful tool for evaluating the effect of treatment of vasculitis that 
cannot reliably be visualized by conventional techniques. Previous clinical studies focused only on 
diagnosis of giant cell arteritis and Takayasu arteritis, while we also found increased FDG-uptake 
in polyarteritis nodosa, Wegener’s granulomatosis and Churge-Strauss syndrome. Thus FDG-PET is 
also possibly valuable in the latter patients. However, for a validation of FDG-PET in patients with 
suspected vasculitis and for determination of its value in the follow-up of response to treatment, 
prospective studies in a larger number of patients are needed. 
In the pilot study of FDG-PET for visualization of lipodystrophy in HIV-infected patients described 
in chapter 4, markedly increased FDG-uptake in patients with lipodystrophy and absence of this 
phenomenon in patients without lipodystrophy provided support for one of the hypotheses of the 
cause of lipodystrophy: increased glucose-uptake as a result of metabolic stress of adipose tissue 
in response to highly active antiretroviral therapy. We have shown that FDG-PET is able to visualize 
lipodystrophy. As such, FDG-PET may become a tool to monitor lipodystrophy during the course of 
HIV-treatment. Moreover, in clinical trials, the lipodystrophy-inducing effect of newly developed 
antiretroviral regimens may be monitored objectively by this approach. However, widespread 
use of FDG-PET in HIV-infected patients suspected of lipodystrophy cannot be recommended in 
clinical practice before these results are confirmed by larger clinical trials. 
In a retrospective study in a highly selected patient population, the results of FDG-PET in patients 
suspected of metastatic infection described in chapter 5 are very promising. Even though several 
conventional imaging techniques were used in most patients, a new infectious focus that changed 
treatment strategy was found in 45%. A larger prospective study in an unselected patient population 
has been initiated to investigate if the addition of FDG-PET to the diagnostic strategy in patients 
with Gram-positive bacteremia is superior to the standard diagnostic strategy not including FDG-
PET by evaluating the effects on patient outcome and costs. Based on the results described in 
chapter 5, it is hypothesized that FDG-PET enables early diagnosis of metastatic complications, 
resulting in a reduction of the number of unnecessary days in hospital for diagnostic purposes 
and a reduced number of relapses, because fewer metastatic lesions are missed when compared 
to conventional diagnostic techniques, which is expected to result in a reduction of the number of 
days in hospital due to relapse. 
From previous clinical studies and our retrospective study described in chapter 7, it can be 
concluded that FDG-PET is a valuable imaging technique in patients with FUO. However, for a 
final validation of FDG-PET in patients with FUO and for better determination of its position in the 
order of diagnostic tests, a prospective multicenter study of FDG-PET being part of a structured 
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diagnostic protocol was performed (chapters 8 and 9). The results from this prospective study 
confirmed that FDG-PET is a valuable imaging technique as part of a diagnostic protocol in the 
general patient population with FUO. Despite the low contribution of FDG-PET in periodic fever, it 
is advised that FDG-PET should also be added to the diagnostic protocol in these patients, because 
it has a very high negative predictive value and it can thus prevent further unnecessary diagnostic 
tests. Based on previous studies comparing 67Ga and FDG-PET in patients with FUO and resulting 
from favorable characteristics of FDG-PET, conventional scintigraphic techniques may be replaced 
by FDG-PET in institutions where PET is available. In the future, integrated PET-CT scanners will 
become increasingly available, which is expected to improve the value of FDG-PET for these 
patients further due to better anatomical detail. The yield of a structured diagnostic protocol 
including FDG-PET was further studied in chapter 9. Based on these results, a recommendation is 
provided on such a diagnostic protocol for all patients with FUO.
The studies described in this thesis represent an overview of infectious and inflammatory diseases 
in which FDG-PET can be of diagnostic value. It should be noted that at present, the diagnostic 
value of FDG-PET is only sufficiently studied in patients with FUO to recommend its use as part of 
a structured diagnostic protocol in clinical practice. Although results were invariably promising, in 
most other cases results of larger prospective studies should be awaited before widespread clinical 
use can be recommended. Although the use of FDG-labeled leukocytes has shown promising 
results in small clinical studies, handling of potentially infected blood products and the laborious 
preparation remain important problems that need to be solved. At present, neither FDG nor any 
other radiolabeled compound perfectly meets all of the characteristics of an ideal infection-
imaging agent. In clinical practice, the choice of the imaging agent should be based on careful 
evaluation of each individual case, local availability of the radiopharmaceutical and of a PET-facility 
until the results of larger clinical studies are available.

Summary
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Summary
In management of patients with fever of unknown origin (FUO) or suspected infectious or 
inflammatory disease, timely identification and localization of infectious and inflammatory lesions 
is essential for optimal treatment. Often symptoms and signs guide the clinician towards the 
possible localization of the infection or the inflammatory focus, but in many cases further diagnostic 
imaging is necessary.  Nuclear medicine offers powerful noninvasive techniques for visualization of 
infectious and inflammatory disorders using whole body imaging enabling the determination of both 
localization and number of inflammatory foci. Over the past decades, several radiopharmaceuticals 
have been developed for this purpose. Nowadays, radiopharmaceuticals such as 67Ga-citrate, 
labeled leukocytes, labeled IgG and labeled antigranulocyte monoclonal antibodies are routinely 
used for evaluation of infectious and inflammatory disorders. Each of these techniques, however, 
has its limitations with regard to radiation exposure, biodistribution, preparation, or safety, so there 
is still need for a more suitable agent. Since activated inflammatory cells take up large amounts of 
glucose as a result of an increased metabolic rate, 18F-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) represents a promising imaging technique in patients suspected of infectious or 
inflammatory disorders. Initial studies of FDG-PET in diagnosis of FUO, orthopedic infections and 
vasculitis have provided encouraging results. The aim of the studies presented in this thesis was 
to further investigate the clinical value of FDG-PET in diagnosis of FUO and several infectious and 
inflammatory diseases.  
In chapter 1, the different approaches to scintigraphic imaging of infection and inflammation, 
already in use or under investigation, are reviewed. A wide variety of approaches depicting the 
different stages of the inflammatory response have been developed: non-specific radiolabeled 
compounds, such as 67Ga-citrate and radiolabeled polyclonal human immunoglobulin, which 
accumulate in inflammatory foci due to enhanced vascular permeability and radiolabeled 
compounds with specific accumulation in inflammatory lesions resulting from binding to activated 
endothelium, the enhanced influx of leukocytes (e.g. radiolabeled autologous leukocytes or anti-
granulocyte antibodies), the enhanced glucose-uptake by activated leukocytes (FDG) or direct 
binding to micro-organisms. Scintigraphy using autologous leukocytes, labeled with 111In or 99mTc, 
is still considered the ”gold standard” nuclear medicine technique for the imaging of infection and 
inflammation, but a gradual shift from non-specific, cumbersome or even hazardous approaches to 
more sophisticated, specific approaches is ongoing. Recently, FDG-PET has been shown to delineate 
various infectious and inflammatory disorders with high sensitivity. Previous studies examining the 
value of FDG-PET in FUO, osteomyelitis and spondylodiscitis, prosthetic joint infection, vasculitis, 
inflammatory bowel disease, sarcoidosis, and rheumatoid arthritis are briefly reviewed.
In chapter 2.1, three patients are described in whom FDG-PET led to the diagnosis of polyarteritis 
nodosa, aortitis due to Wegener’s granulomatosis, and giant cell arteritis, respectively. These three 
cases illustrate the promising role of FDG-PET in imaging vascular inflammation. In addition, an 
overview of all previous studies investigating the use of FDG-PET in patients with vasculitis is 
provided.
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In chapter 2.2, the results of seven FDG-PET scans in three patients with autosomal dominant 
polycystic kidney disease (ADPKD) suspected of renal or hepatic cyst infection are presented. FDG-
PET identified the infected cysts in two episodes of renal cyst infection, two episodes of hepatic 
cyst infection and one episode of both renal and hepatic cyst infection. In one case, FDG-PET was 
normal after antibiotic treatment for hepatic cyst infection and again at a time when hepatic cyst 
infection was suspected, but eventually excluded. It is concluded that FDG-PET is a promising new 
imaging technique enabling early identification of renal and hepatic cyst infections in ADPKD 
patients.
In chapter 2.3, the history of a patient with FUO in whom extensive diagnostic tests including 111In-
leukocyte scintigraphy did not reveal the cause of the fever is reported. FDG-PET subsequently 
pointed to the diagnosis of septic thrombophlebitis of the portal vein (pylephlebitis). Also, a review 
of the literature on pylephlebitis is provided.
In chapter 2.4, three patients with catheter-associated candidemia are described. In these patients, 
FDG-PET led to the unexpected diagnosis of Candida lung abscesses, which was confirmed by 
computed tomography and favorable response to antifungal therapy. It is concluded that FDG-
PET enables early identification of sites of disseminated candidiasis and that it can be used in the 
evaluation of therapy. 
In chapter 3, the results of all FDG-PET-scans performed because of suspected vasculitis (n=20), 
because of follow-up of vasculitis (n=5) or because of fever of unknown origin with results 
indicating vasculitis (n=2) between January 1999 and April 2003 were reviewed. These results were 
compared to the final diagnosis, based on the “American College of Rheumatology 1990 criteria”. 
FDG-PET results were considered to be true positive in 10 patients, true negative in 14 patients 
and false negative in three patients resulting in a positive predictive value of 100% and a negative 
predictive value of 82%. Therefore, FDG-PET is a promising new imaging technique in diagnosing 
and determining the extent of various forms of vasculitis, including giant cell arteritis, polyarteritis 
nodosa, Takayasu arteritis, Churge-Strauss syndrome, and Wegener’s granulomatosis. Furthermore, 
FDG-PET may become a useful tool for evaluating the effect of treatment of vasculitis.
In chapter 4, the results of a pilot study investigating FDG-PET for visualization of lipodystrophy 
in HIV-infected patients are presented. Lipodystrophy is accompanied by increased adipose tissue 
inflammatory activity. Together with mitochondrial toxicity of nucleoside reverse transcriptase 
inhibitors, this induces metabolic stress causing increased glucose-uptake. Markedly increased 
subcutaneous FDG-uptake was observed in 3 out of 4 HIV-infected patients with lipodystrophy 
treated by a stavudine-containing treatment-regimen. This phenomenon was absent in HIV-
infected controls without lipodystrophy. Our data show that FDG-PET is able to visualize 
lipodystrophy. In addition, this supports the hypothesis that stavudine-related lipodystrophy 
is associated with increased glucose-uptake as a result of metabolic stress of adipose tissue in 
response to antiretroviral therapy.
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In chapter 5, the results of all FDG-PET-scans ordered because of suspected metastatic infection 
(n=40) between October 1998 and September 2004 were analyzed retrospectively. These results 
were compared to conventional investigation techniques and the final clinical diagnosis. Metastatic 
complications were eventually diagnosed in 75% of all episodes. Although a median number of four 
diagnostic procedures to search for metastatic infection had been performed before FDG-PET was 
ordered, FDG-PET diagnosed a clinically relevant new focus resulting in a change of therapy in 45% 
of cases. The positive predictive value of FDG-PET was 91% and the negative predictive value was 
100%. These results suggested that FDG-PET is a valuable imaging technique in patients at high risk 
of metastatic infectious disease even when the results of other diagnostic procedures are normal. 
In chapter 6, a review is provided describing the adjusted definition of FUO and possible causes 
of continuous and periodic FUO. A diagnostic algorithm is proposed in which the most important 
step is a history taking, physical examination and the obligatory investigations in a search for 
potentially diagnostic clues (PDCs). First, factitious fever and drug fever should be ruled out. 
Further diagnostic procedures should be guided by a list of most probable diagnoses. In patients 
without useful PDCs, certain diagnostic procedures, divided in first stage and second stage 
investigations should be performed. If no diagnosis is reached and the clinical condition is stable, 
waiting for new PDCs is recommended. In patients with recurrent fever, the diagnostic work-up 
should consist only of the search for PDCs matching known recurrent syndromes. If undiagnosed 
fever persists, supportive treatment with NSAIDs can be helpful. Most patients with undiagnosed 
FUO have benign self-limiting or recurrent fever. It is concluded that only if patients deteriorate, 
other therapeutic trials should be considered. 
In chapter 7, all FDG-PET scans ordered because of FUO (n=35) or suspected focal infection or 
inflammation (n=55) between January 1999 and December 2002 were reviewed. These results were 
compared to the final diagnosis. Of 35 patients with FUO, a final diagnosis was established in 19 
patients (54%). Of the total number of scans, 37% were clinically helpful. Positive predictive value 
of FDG-PET in these patients was 87% and negative predictive value was 95%. In the patients with 
suspected focal infection or inflammation, positive predictive value of FDG-PET was 95% and 
negative predictive value was 100%. It is concluded that FDG-PET appears to be a valuable imaging 
technique in evaluation of FUO and suspected focal infection or inflammation. Furthermore, 
FDG-PET could become a useful tool for evaluating the effect of treatment of infectious and 
inflammatory processes that cannot reliably be visualized by conventional techniques. 
In none of the previous studies examining the role of FDG-PET in patients with FUO, a structured 
diagnostic protocol was used nor were patients from general hospitals included. In chapter 8, the 
results of a prospective multi-center study designed to validate the use of FDG-PET as part of a 
structured diagnostic protocol in the general population of patients with FUO are described. From 
December 2003 to July 2005, 70 patients with FUO were recruited from our university hospital 
(n=38) and five community hospitals (n=32) in the same region. The final clinical diagnosis was 
used for comparison with the FDG-PET results. Of all scans, 33% were clinically helpful. Positive 
predictive value of FDG-PET was 70% and negative predictive value was 92%. Contribution of FDG-
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PET to the final diagnosis did not differ significantly between patients diagnosed in the university 
hospital and patients in the community hospitals. FDG-PET contributed significantly more often 
to the final diagnosis in patients with continuous fever than in patients with periodic fever. FDG-
PET was not helpful in any of the patients with normal erythrocyte sedimentation rate (ESR) and 
C-reactive protein (CRP). It is concluded that FDG-PET is a valuable imaging technique as part of a 
diagnostic protocol in the general patient population with FUO and a raised ESR or CRP. Despite 
the low contribution of FDG-PET in periodic fever, FDG-PET should nevertheless be added to the 
diagnostic protocol in these patients, because it has a very high negative predictive value.
Results from the same FUO study described in chapter 8 regarding the final diagnoses and the 
number and sort of additional diagnostic tests are presented in chapter 9. Patients from our 
university hospital were characterized by more secondary referrals and a higher percentage of 
periodic fever than those referred to the community hospitals. Infection was the cause of the fever 
in 16%, a neoplasm in 7%, non-infectious inflammatory diseases in 22%, miscellaneous causes in 
4%, and in 51%, the cause of fever was not found. There were no differences in the number and 
sort of final diagnoses or regarding the number and type of investigations between the university 
and community hospitals. Significant predictors for reaching a diagnosis included: continuous 
fever, fever present for <180 days, elevated ESR, CRP, or LDH, leucopenia, thrombocytosis, 
abnormal chest CT and abnormal FDG-PET. For future FUO studies, we recommend to abandon 
the requirement of hospital admission and to use a quality-related criterion of a set of obligated 
investigations. Except for tests from the obligatory part of our protocol and cryoglobulins in an 
early stage, followed by FDG-PET, and in a later stage by abdominal and chest CT, temporal artery 
biopsy in patients of 55 years or older and possibly bone marrow biopsy, other tests should not be 
used as screening investigations. Since significant differences between patients investigated in the 
university hospital and the community hospitals were absent, it is concluded that our structured 
diagnostic protocol is applicable to FUO in general.
Chapter 10 contains a general discussion of the results presented in this thesis and their possible 
future implications.
Samenvatting
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Samenvatting
Bij patiënten met koorts zonder bekende oorzaak ofwel febris e causa ignota (febris e.c.i.) en 
bij patiënten met een mogelijke infectie of ontsteking is het van belang dat zo snel mogelijk de 
juiste diagnose wordt gesteld zodat op korte termijn begonnen kan worden met een gerichte 
behandeling. Vaak wordt de behandelend arts door klachten en lichamelijke verschijnselen 
gewezen in de richting van de aard en lokalisatie van de infectie of ontsteking. Toch is bij veel van 
deze patiënten aanvullend beeldvormend onderzoek nodig. Voor het lokaliseren van ontstekings- 
of infectiehaarden kan gebruik gemaakt worden van radiologische technieken, zoals röntgenfoto’s, 
echografie, CT-scans of MRI, maar ook van scintigrafische technieken. Bij scintigrafisch onderzoek 
krijgt de patiënt een radiofarmacon toegediend. Dit is een middel dat radioactief gelabeld is, 
waardoor gammastraling wordt uitgezonden. Deze straling kan met behulp van een gammacamera 
zichtbaar gemaakt worden. Door nu een radiofarmacon te kiezen dat zich ophoopt in infectie- 
en ontstekingshaarden, kunnen deze haarden afgebeeld worden. In de laatste dertig jaar zijn 
verschillende van deze radiofarmaca ontwikkeld. Voor het opsporen van infecties en ontstekingen 
wordt tegenwoordig routinematig gebruik gemaakt van 67gallium-citraat, radioactief gelabelde 
witte bloedcellen (leukocyten), radioactief gelabeld immuunglobuline (IgG) en radioactief 
gelabelde antistoffen tegen witte bloedcellen. Elk van deze stoffen heeft echter nadelen, zoals 
een hoge stralenbelasting, hoge opname van de stof in weefsels of organen zonder ontsteking, 
gecompliceerde bereiding of de noodzaak tot het werken met mogelijk besmet bloed. Er is daarom 
behoefte aan een radiofarmacon dat deze nadelen niet of in mindere mate heeft. 
    
 18F-fluorodeoxyglucose (FDG) positron emissie tomografie (PET) is een nieuwe techniek die 
routinematig gebruikt wordt bij patiënten met kanker, maar die de laatste jaren ook een rol begint 
te spelen bij het afbeelden van infecties en ontstekingen. Het FDG is een suikermolecuul, dat 
gelabeld wordt met de positron-emitter 18F. Positronemissie houdt in dat positief geladen deeltjes 
(positronen) worden uitgezonden. Een positron versmelt met het dichtstbijzijnde negatief geladen 
elektron, waarbij de deeltjes worden omgezet in twee gammastralen, die onder een hoek van 180o 
worden uitgezonden en kunnen worden gedetecteerd door een PET-camera. Door het gelijktijdig 
detecteren van twee fotonen is de resolutie van een PET-camera beter dan van een gammacamera. 
FDG hoopt zich fysiologisch op in hart, hersenen, nieren en blaas en in wisselende mate in de 
darm, maar ook in kwaadaardige cellen en in geactiveerde ontstekingscellen, zodat het gebruikt 
kan worden voor de afbeelding van tumoren en infectie- en ontstekingshaarden. De resultaten 
van eerdere studies naar de waarde van FDG-PET in de diagnostiek van febris e.c.i., orthopedische 
infecties en niet-infectieuze vaatontsteking (vasculitis) waren veelbelovend. Het doel van de 
studies in dit proefschrift was om de klinische waarde van FDG-PET bij patiënten met febris e.c.i. 
en verschillende infecties en ontstekingen verder te onderzoeken. 
In hoofdstuk 1 wordt een overzicht gegeven van de verschillende scintigrafische technieken, die 
in de praktijk gebruikt worden bij de detectie van infecties en ontstekingen en van technieken 
die op dit moment nog verder onderzocht worden. Een grote verscheidenheid aan radiofarmaca 
is ontwikkeld die verschillende stadia van het ontstekingsproces afbeelden. Verschillende niet-
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specifieke radiofarmaca zijn in gebruik, zoals 67gallium-citraat en radioactief gelabeld IgG, die 
zich ophopen in ontstekingshaarden vanwege de verhoogde doorlaatbaarheid van de vaatwand, 
die ontstaat ten gevolge van deze ontsteking. Andere radiofarmaca hopen zich specifiek op in 
ontstekingshaarden door binding aan geactiveerde cellen aan de binnenzijde van de bloedvatwand 
(endotheel), door verhoogde instroom van witte bloedcellen (bijv. radioactief gelabelde leukocyten 
of anti-granulocytenantistoffen), door toegenomen glucoseopname in geactiveerde witte 
bloedcellen (FDG) of door directe binding aan micro-organismen. De leukocytenscan, het gebruik 
van witte bloedcellen van de patiënt zelf, die buiten het lichaam gelabeld worden met 111indium 
of 99mtechnetium, wordt beschouwd als de gouden standaard voor wat betreft de scintigrafische 
afbeelding van infectie en ontsteking. Langzamerhand vindt er echter een verschuiving plaats van 
niet-specifieke, tijdrovende of zelfs risicovolle methoden naar meer verfijnde, specifieke methoden. 
In de afgelopen paar jaar is gebleken dat ook FDG-PET in staat is om infecties en ontstekingen af 
te beelden met een hoge sensitiviteit. Er wordt een kort overzicht gegeven over de resultaten van 
eerdere studies naar de waarde van FDG-PET bij febris e.c.i., infecties van het skelet, geïnfecteerde 
gewrichtsprotheses, vasculitis, ontstekingsziekten van de darm, sarcoidose en reumatoïde artritis. 
Vasculitis is een ontsteking van de vaatwand, die kan leiden tot ernstige aantasting van allerlei 
organen. Er bestaan verschillende vormen van vasculitis en klachten zijn bij dit ziektebeeld vaak 
aspecifiek. Er zijn geen klinisch-chemische testen die specifiek zijn voor vasculitis. Ook is het 
afbeelden van vasculitis met echografie, CT en MRI vaak moeilijk, zodat een diagnose in veel 
gevallen pas laat gesteld kan worden. In hoofdstuk 2.1 worden drie patiënten beschreven bij wie 
een FDG-PET-scan heeft geleid tot de diagnose van verschillende vormen van vasculitis, namelijk 
respectievelijk polyarteritis nodosa, de ziekte van Wegener en reuscelarteritis. Deze drie casus 
illustreren de veelbelovende rol van FDG-PET bij de afbeelding van vaatwandontsteking. Daarnaast 
wordt een overzicht gegeven van alle eerdere studies waarbij gekeken werd naar het gebruik van 
FDG-PET bij patiënten met vasculitis.
In hoofdstuk 2.2 worden de resultaten beschreven van 7 FDG-PET scans bij 3 patiënten met de 
autosomaal dominante vorm van congenitale cystennieren. Dit is een aangeboren aandoening 
waarbij in de loop van het leven vele grote cysten in beide nieren en vaak ook in de lever ontstaan. 
Hierbij neemt de nierfunctie af en is er een grote kans op infectie van de cysten, waarbij het zeer 
moeilijk is om met conventionele technieken, zoals echografie of een CT-scan, een geïnfecteerde 
cyste te onderscheiden van een niet-geïnfecteerde cyste. Bij deze 3 patiënten die verdacht 
werden van een geïnfecteerde nier- of levercyste, identificeerde FDG-PET de geïnfecteerde 
cysten betrouwbaar in 2 episoden met geïnfecteerde niercysten, 2 episoden met geïnfecteerde 
levercysten en één episode met zowel een geïnfecteerde niercyste als een geïnfecteerde 
levercyste. In één geval normaliseerde de FDG-opname na antibiotische behandeling van een 
geïnfecteerde levercyste. Tevens was de FDG-PET-scan normaal op een moment dat gedacht werd 
aan een geïnfecteerde levercyste, maar de klachten later verklaard bleken te worden door een 
andere oorzaak. Er wordt geconcludeerd dat FDG-PET een veelbelovende nieuwe beeldvormende 
techniek is die een vroege en betrouwbare diagnose van geïnfecteerde nier- en/of levercysten bij 
patiënten met congenitale cystennieren mogelijk maakt. 
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In hoofdstuk 2.3 wordt een patiënt met febris e.c.i. beschreven bij wie de oorzaak van de koorts 
niet bekend was ondanks zeer uitgebreide diagnostiek inclusief een leukocytenscan. Met behulp 
van FDG-PET werd vervolgens een infectie van de poortader van de lever, ook wel septische 
tromboflebitis van de vena portae ofwel pyleflebitis, gediagnosticeerd. Verder wordt een 
overzicht gegeven van de beschikbare literatuur over deze zeldzame en moeilijk te diagnosticeren 
aandoening.
In hoofdstuk 2.4 worden drie patiënten beschreven met positieve bloedkweken voor de gist 
Candida gerelateerd aan een infectie van een centrale lijn voor parenterale voeding of medicatie. Het 
is bekend dat een bloedbaaninfectie met Candida (candidemie) evenals andere bloedbaaninfecties 
kan leiden tot infectiehaarden elders in het lichaam (strooihaarden). Bij deze drie patiënten leidde 
een FDG-PET-scan onverwacht tot het vinden van strooihaarden in de longen. Deze diagnose werd 
bevestigd door een CT-scan en de goede reactie op medicamenteuze therapie. Deze drie casus 
laten zien dat met FDG-PET een vroege diagnose van strooihaarden bij candidemie mogelijk is en 
dat deze techniek gebruikt kan worden bij het vervolgen van het effect van de behandeling.
In hoofdstuk 3 worden de resultaten weergegeven van alle FDG-PET-scans die verricht werden in 
de periode van januari 1999 tot en met april 2003 vanwege de verdenking op vasculitis (n=20), het 
vervolg van een eerder gediagnosticeerde vasculitis (n=5) of vanwege febris e.c.i. met een uitslag 
passend bij vasculitis (n=2). Het resultaat van de FDG-PET-scan werd vergeleken met de uiteindelijke 
diagnose, die gebaseerd was op de criteria van het “American College of Rheumatology” uit 
1990. Op grond van deze criteria worden verschillende vormen van vasculitis onderscheiden 
en ingedeeld. FDG-PET was goed-positief bij 10 patiënten, goed-negatief bij 14 patiënten en 
fout-negatief bij 3 patiënten. Met een positief voorspellende waarde van 100% en een negatief 
voorspellende waarde van 82% lijkt FDG-PET een veelbelovende nieuwe diagnostische techniek 
voor de diagnose en de bepaling van de uitgebreidheid van verschillende vormen van vasculitis, 
inclusief reuscelarteritis, polyarteritis nodosa, Takayasu arteritis, Churge-Strauss-syndroom en de 
ziekte van Wegener. Verder wijzen deze resultaten erop dat FDG-PET een bruikbare methode kan 
worden voor het vervolgen van het effect van behandeling van vasculitis.
In hoofdstuk 4 wordt een prospectieve pilotstudie beschreven waarin de bruikbaarheid van 
FDG-PET bij het afbeelden van lipodystrofie bij patiënten met een HIV-infectie wordt onderzocht. 
Lipodystrofie is een bijwerking van de medicamenteuze HIV-therapie (antiretrovirale therapie) en 
wordt gekenmerkt door onder andere vetophoping in de buik(wand) en afname van de hoeveelheid 
vet in het gezicht en onderhuids in de ledematen in combinatie met veranderingen in de suiker- 
en vetstofwisseling. De oorzaak van dit syndroom is niet geheel duidelijk. Het gaat in elk geval 
gepaard met een verhoogde (ontstekings)activiteit van het vetweefsel. Samen met bijwerkingen 
op celniveau (mitochondriële toxiciteit) van bepaalde medicijnen die gebruikt worden bij de 
behandeling van HIV (nucleoside reverse transcriptase remmers) veroorzaakt dit metabole stress 
met als gevolg verhoogde opname van glucose. Stavudine is één van de bovengenoemde nucleoside 
reverse transcriptaseremmers. Duidelijk verhoogde onderhuidse FDG-opname werd gezien bij 
3 van de 4 HIV-patiënten met lipodystrofie die behandeld werden met een stavudinebevattend 
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medicatieregime. Verhoogde FDG-opname was afwezig bij HIV-geïnfecteerde controlepatiënten 
zonder lipodystrofie. Aldus bleek het mogelijk te zijn om lipodystrofie af te beelden met behulp 
van FDG-PET. Daarnaast ondersteunen deze resultaten de hypothese dat stavudine-gerelateerde 
lipodystrofie is geassocieerd met verhoogde glucoseopname ten gevolge van metabole stress van 
vetweefsel in reactie op antiretrovirale therapie.
In hoofdstuk 5 worden de resultaten beschreven van alle FDG-PET-scans (n=40) die verricht 
werden bij patiënten die verdacht werden van strooihaarden bij een bacteriële bloedbaaninfectie 
(bacteriëmie) of candidemie in de periode van oktober 1998 tot en met september 2004. De uitslag 
van de FDG-PET-scans werden vergeleken met die van veel routinematig gebruikte beeldvormende 
technieken en de uiteindelijke klinische diagnose. Uiteindelijk werd bij 75% van deze patiënten 
één of meerdere strooihaarden gediagnosticeerd. Hoewel er gemiddeld al 4 beeldvormende 
onderzoeken verricht waren voordat FDG-PET werd aangevraagd, werd met behulp van FDG-
PET bij 45% een nieuwe klinisch relevante infectiehaard gediagnosticeerd hetgeen resulteerde 
in aanpassing van de behandeling. In deze groep patiënten met een hoog risico op strooihaarden 
was de positief voorspellende waarde van FDG-PET 91% en de negatief voorspellende waarde 
100%. Deze resultaten suggereren dat FDG-PET een waardevolle beeldvormende techniek zou 
kunnen zijn bij patiënten met een hoog risico op strooihaarden zelfs als andere beeldvormende 
onderzoeken geen afwijkingen laten zien.
In hoofdstuk 6 wordt een overzicht gegeven van de nieuwe aangepaste definitie van febris e.c.i. 
en van mogelijke oorzaken van continue koorts en periodieke koorts. Er wordt een diagnostisch 
algoritme voorgesteld waarin het zorgvuldig afnemen van de anamnese, het lichamelijk onderzoek 
en de verplichte onderzoeken in een zoektocht naar potentieel diagnostische “clues” (PDC’s) de 
belangrijkste stap zijn. PDC’s zijn alle symptomen en afwijkende uitslagen van onderzoeken die 
de behandelend arts op het spoor kunnen zetten van een bepaalde ziekte. Na het uitsluiten van 
zelfveroorzaakte koorts en geneesmiddelenkoorts moet verdere diagnostiek gebaseerd worden 
op een beperkte lijst met de meest waarschijnlijke diagnoses. Bij patiënten zonder bruikbare 
PDC’s, wordt geadviseerd bepaalde onderzoeken te verrichten onderverdeeld in een eerste en 
tweede stap. Als dan nog steeds geen diagnose gesteld kan worden en de klinische conditie 
van de patiënt stabiel is, lijkt het raadzaam om af te wachten en alert te zijn op het ontstaan van 
nieuwe PDC’s.  In patiënten met periodieke of aanvalsgewijs optredende koorts wordt geadviseerd 
om alleen diagnostiek te doen naar aanleiding van PDC’s passend bij specifieke oorzaken van 
periodieke koorts. Ondersteunende behandeling met NSAID’s (bepaalde ontstekingsremmers, 
zoals diclofenac of naprosyne) kan geprobeerd worden bij patiënten bij wie geen diagnose gesteld 
wordt. Bij de meeste patiënten bij wie het aanbevolen aanvullend onderzoek in deze fase geen 
diagnose oplevert, is febris e.c.i. een goedaardig en vaak zelflimiterend ziektebeeld. Daarom 
worden andere therapeutische proefbehandelingen bijv. met antibiotica, corticosteroïden (bijv. 
prednison) of middelen tegen tuberculose alleen aangeraden bij patiënten met een snelle klinische 
verslechtering.
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Hoofdstuk 7 beschrijft een retrospectieve studie naar de waarde van FDG-PET bij 35 patiënten 
met febris e.c.i. en 55 patiënten die verdacht werden van een focale infectie of een focaal 
ontstekingsproces. De resultaten van de FDG-PET-scans, verricht in de periode van januari 1999 
tot en met december 2002, werden vergeleken met de uiteindelijke klinische diagnose. Bij 19 
van de 35 patiënten met febris e.c.i. (54%) kon uiteindelijk een diagnose gesteld worden. Van 
alle FDG-PET-scans droeg 37% bij aan het stellen van de diagnose. Bij de patiënten met febris 
e.c.i. was de positief voorspellende waarde 87% en de negatief voorspellende waarde 95%.  Bij 
de patiënten die verdacht werden van een focale infectie of ontstekingsproces was de positief 
voorspellende waarde 95% en de negatief voorspellende waarde 100%. Geconcludeerd wordt dan 
ook dat FDG-PET een waardevolle beeldvormende techniek lijkt te zijn bij patiënten met febris 
e.c.i. en bij deze patiëntenpopulatie met de verdenking op verschillende infecties en ontstekingen. 
Verder zou FDG-PET een waardevolle techniek kunnen worden bij het evalueren van het effect van 
behandeling van infectieuze en inflammatoire aandoeningen in die gevallen waarbij de afwijkingen 
niet goed afgebeeld kunnen worden met conventionele technieken.
In geen van de eerdere studies waarin de waarde van FDG-PET is onderzocht bij patiënten met 
febris e.c.i. is een gestructureerd diagnostisch protocol gebruikt. Ook werden in geen van deze 
studies patiënten uit algemene ziekenhuizen geïncludeerd. In hoofdstuk 8 worden de resultaten 
beschreven van een prospectieve studie, die opgezet werd om het gebruik van FDG-PET als 
onderdeel van een gestructureerd diagnostisch protocol te valideren in de algemene populatie 
patiënten met febris e.c.i.. Tussen december 2003 en juli 2005 werden 70 patiënten met febris 
e.c.i. geïncludeerd. Van deze 70 patiënten waren er 38 afkomstig uit het UMC St Radboud en 
32 uit 5 algemene ziekenhuizen in dezelfde regio. De resultaten van de FDG-PET-scans werden 
vergeleken met de uiteindelijke klinische diagnose. Van alle FDG-PET-scans droeg 33% bij aan de 
uiteindelijke diagnose. De positief voorspellende waarde van FDG-PET was 70% met een negatief 
voorspellende waarde van 92%. De bijdrage van FDG-PET aan de uiteindelijke diagnose verschilde 
niet significant tussen patiënten die gediagnosticeerd werden in het UMC St Radboud en patiënten 
die afkomstig waren uit de algemene ziekenhuizen. FDG-PET droeg significant vaker bij aan de 
uiteindelijke diagnose bij patiënten met continue koorts dan bij patiënten met periodieke koorts. 
Bij geen van de patiënten met zowel een normaal C-reactief proteïne als een normale bezinking 
(CRP en BSE, bepaalde ontstekingsparameters in het bloed) droeg FDG-PET bij aan de diagnose. Er 
wordt geconcludeerd dat FDG-PET, als onderdeel van een diagnostisch protocol,  een waardevolle 
afbeeldingstechniek is bij alle patiënten met febris e.c.i. die een verhoogde BSE en/of een verhoogd 
CRP hebben. Ondanks de lage bijdrage van FDG-PET aan de uiteindelijke diagnose bij patiënten 
met periodieke koorts, zou FDG-PET bij deze moeilijk te diagnosticeren patiëntenpopulatie 
vanwege de zeer hoge negatief voorspellende waarde toch toegevoegd moeten worden aan het 
diagnostisch protocol.
In hoofdstuk 9 worden de resultaten met betrekking tot de uiteindelijke klinische diagnose 
en het aantal en de soort aanvullende diagnostische onderzoeken, verkregen uit dezelfde 
febris e.c.i.-studie, die beschreven werd in hoofdstuk 8, gepresenteerd. De patiëntengroep die 
gediagnosticeerd werd in het UMC St Radboud werd gekenmerkt door meer verwijzingen vanwege 
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een “second opinion” en een hoger percentage patiënten met periodieke koorts in vergelijking met 
patiënten verwezen naar de algemene ziekenhuizen. De koorts werd veroorzaakt door een infectie 
bij 16% van alle patiënten, door kanker in 7%, een niet-infectieuze inflammatoire aandoening in 
22%, overige verklaringen werden gevonden in 4% en bij 51% kon geen diagnose gesteld worden. 
Er was geen verschil in het aantal en de soort diagnostische onderzoeken tussen het UMC St 
Radboud en de algemene ziekenhuizen. Een uiteindelijke diagnose werd significant vaker gesteld 
bij patiënten met continue koorts, een duur van de koorts korter dan 180 dagen, verhoogde BSE, 
CRP of lactaatdehydrogenase (LDH, een bepaald enzym o.a. afkomstig uit de lever), een tekort aan 
witte bloedcellen (leukopenie), een overmaat aan bloedplaatjes (thrombocytose), een afwijkende 
CT-scan van de borstorganen (CT-thorax) en/of een abnormale FDG-PET-scan. Voor toekomstige 
febris e.c.i.-studies adviseren wij om de eis van een ziekenhuisopname te laten vallen en om een 
kwalitatief criterium bestaande uit een aantal verplichte onderzoeken te gebruiken in plaats van 
een tijdsgerelateerd criterium. Behalve de verplichte onderzoeken uit ons diagnostisch protocol, 
gevolgd door FDG-PET en in een latere fase door een CT-scan van thorax en abdomen, een biopt 
van de arteria temporalis bij patiënten ouder dan 55 jaar en mogelijk een beenmergbiopsie, moeten 
andere diagnostische testen niet gebruikt worden als screenende onderzoeken bij patiënten met 
febris e.c.i.. Omdat er geen significante verschillen waren tussen het UMC St Radboud en de 
algemene ziekenhuizen, concluderen wij dat het voorgestelde diagnostisch protocol van toepassing 
is op alle patiënten met febris e.c.i..
In hoofdstuk 10 wordt aan de hand van de resultaten van dit proefschrift besproken wat de 
mogelijke rol van FDG-PET zou kunnen zijn bij de diagnostiek van patiënten met febris e.c.i. 
en infecties en ontstekingen. Tevens wordt het mogelijke vervolg van de onderzoeken in dit 
proefschrift toegelicht.
Dankwoord
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Dankwoord
Mijn dank gaat uit naar iedereen die aan de totstandkoming van dit proefschrift heeft bijgedragen. 
Een aantal mensen wil ik in het bijzonder bedanken:
Prof. dr. W.J.G. Oyen, beste Wim, je gaf mij alle gelegenheid mijn eigen weg te vinden in de uitvoering 
van dit project. Altijd zag je met mij nieuwe mogelijkheden om de klinische toepasbaarheid van 
FDG-PET bij niet-oncologische aandoeningen verder te onderzoeken. Je waardevolle en zeer snelle 
correcties van de manuscripten heb ik heel erg gewaardeerd. 
Prof.dr. F.H.M. Corstens en prof. dr. J.W.M. van der Meer hebben mij de mogelijkheid gegeven om 
aan dit promotie-onderzoek te kunnen beginnen. Beste Jos, bij mijn laatste ”opleidingsjaargesprek” 
regelde jij ter plaatse met prof. Corstens dat mijn wens om promotie-onderzoek te gaan doen, 
vervuld kon worden. Met je verhelderende blik en je originele ideeën heb je een onmisbare bijdrage 
geleverd aan de totstandkoming van dit proefschrift. Beste Frans, bedankt voor het vertrouwen dat 
je in mij had, ook toen het IL-8-onderzoek door allerlei tegenslagen geteisterd werd. Jij hebt er op 
een creatieve manier voor gezorgd dat dit proefschrift met een inmiddels aangepast onderwerp 
toch tot stand kon komen.
Prof. dr. B.J. Kullberg, beste Bart-Jan, in de laatste fase van mijn promotie-onderzoek, tijdens mijn 
opleiding tot infectioloog, heb jij gezorgd dat ik enige tijd mijn handen vrij kreeg voor de afronding 
van dit proefschrift. Hoewel je pas in een latere fase betrokken werd bij het PET-onderzoek, was 
met name het commentaar op het strooihaardenartikel en op de subsidie-aanvraag bij ZonMW 
voor het vervolg van deze studie zeer waardevol. Mijn dank hiervoor.  
Alle studiecoördinatoren en hun medewerkers uit de verschillende ziekenhuizen wil ik van harte 
bedanken voor hun inspanningen om de prospectieve febris e.c.i.-studie tot een goed einde te 
brengen: Aart Mudde (Slingeland Ziekenhuis te Doetinchem), Clemens Richter, Gerben Ferwerda, 
Oscar Hoiting en Christof Majoor (Rijnstate Ziekenhuis te Arnhem), Ton Dofferhoff (Canisius-
Wilhelmina Ziekenhuis te Nijmegen), Tineke Smilde (Jeroen Bosch Ziekenhuis te ’s-Hertogenbosch), 
Koen Simons en dr. Van den Wall Bake (Maxima Medisch Centrum te Veldhoven). Ook dank ik Ton 
Rijnders voor zijn medewerking bij het verrichten van de PET-scans bij de patiënten uit Arnhem 
en het ter beschikking stellen van deze gegevens. Lily de Kleijn wil ik bedanken voor haar advies 
bij het opzetten van deze klinische studie die in zekere zin een vervolg is op haar prachtige febris 
e.c.i.-studie. 
Paul Krabbe van de afdeling Medical Technology Assessment wil ik bedanken voor zijn adviezen bij 
het opzetten en uitwerken van de prospectieve febris e.c.i.-studie. Leo van Rossum, bedankt voor 
het ontwikkelen van de zeer bruikbare en “doktersvriendelijke” database.
André van der Ven en Bert Zomer van de afdeling interne geneeskunde, jullie enthousiasme en 
grote hulp bij het recruteren van patiënten voor de lipodystrofiestudie hebben er toe geleid dat 
deze studie in een razend tempo voltooid kon worden. Bedankt hiervoor.
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Mijn mede-auteurs, voor zover nog niet genoemd, dank ik voor hun essentiële bijdrage aan de 
diverse artikelen.
Ook wil ik natuurlijk alle patiënten die hebben deelgenomen aan de PET-studies bedanken voor 
hun vaak belangeloze medewerking. Daarnaast bedank ik alle internisten en arts-assistenten die 
hun patiënten hebben aangemeld voor deelname aan één van de klinische PET-studies.
De in dit proefschrift beschreven onderzoeken waren vanzelfsprekend niet mogelijk geweest 
zonder de hulp van veel (oud-)medewerkers van de afdeling nucleaire geneeskunde. In het 
bijzonder wil ik alle PET-laboranten bedanken voor hun geduld en begrip als er weer eens een 
studiepatiënt in het altijd volle PET-programma gepast moest worden. Ook de (voormalige) arts-
assistenten nucleaire geneeskunde, Wouter Vogel, Baudewijn Hendrickx, Maarten Vinken, Erik 
Vegt en Marc Zuijdwijk wil ik bedanken voor het opsporen van mogelijk geschikte studiepatiënten 
tussen de vele klinische aanvragen. Jacqueline, bedankt voor je hulp bij het zoeken van artikelen, 
het terugvinden van ”onvindbare” statussen, het in grote hoeveelheden kopiëren van eindeloos 
lange formulieren en talloze andere klusjes. Hoewel jij het altijd vanzelfsprekend leek te vinden, 
heeft jouw vaak spontaan aangeboden hulp mij veel tijd en frustratie gescheeld.
Manuel Koppe, dankzij jou werden er tijdens mijn zwangerschapsverlof en later op mijn vrije 
woensdagen toch verwoede pogingen ondernomen om patiënten te includeren. Fidel Vos, jij 
hebt ervoor gezorgd dat tijdens mijn zwangerschapsverlof alle patiënten met febris e.c.i. werden 
geïncludeerd en netjes werden vervolgd. Ik wens je veel succes en plezier bij het voortzetten van 
de infectiegerelateerde PET-onderzoeken.
Beste mede-aquariumbewoners, ook al heb ik na een jaar de rust van een andere kamer opgezocht, 
toch wil ik jullie natuurlijk bedanken voor jullie gezelligheid en alle belangstelling voor die vreemde 
dokter van wie het niet altijd duidelijk was, wat zij nou de hele dag deed. Beste Ernst, Peter en Lioe-
Fee, helaas was ons kamergenootschap telkens van korte duur. Bedankt voor het aanhoren van 
mijn onderzoeksfrustraties en het zorgen voor afleiding en relativering op zijn tijd, onder andere 
door het uitwisselen van wetenswaardigheden over onze kinderen. Johan, jij zorgde ervoor dat ik 
bij computerproblemen altijd weer snel verder kon. Zelfs heb je tijdelijk niet alleen je kamer maar 
later ook nog je eigen computer ter beschikking gesteld. Astrid en Hadewych, als mijn huidige 
kamergenoten hebben jullie door het altijd flexibel omgaan met de verdeling van klinische taken 
en natuurlijk jullie gezelligheid een belangrijke bijdrage geleverd aan de laatste fase van dit 
proefschrift. Ook Juul, Mihai en Fidel bedankt voor jullie collegiale opstelling, die het combineren 
van klinisch werk, onderzoek en een gezinsleven wat gemakkelijker maakt.
Marion, hoewel je het ondanks jullie eigen drukke leven vanzelfsprekend vindt, waarderen wij het 
zeer dat Alex altijd bij jullie terecht kan als wij weer eens niet op tijd thuis kunnen zijn.
Beste Lara en Lioe-Fee, jullie hebben ieder op een eigen manier mijn onderzoekstijd de afgelopen 
jaren van dichtbij meegemaakt. Ik ben heel blij dat jullie nu mijn paranimfen willen zijn.
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Beste Piet en Marlea, de afgelopen jaren hebben jullie ons vaak uit de brand geholpen door in alle 
vroegte de files te trotseren om weer eens extra op de kinderen te komen passen. Ook waren jullie 
altijd geïnteresseerd in alle onderzoeksperikelen. Zonder jullie hulp had het voltooien van onze 
proefschriften zeker veel langer geduurd. Bedankt!
Lieve pap en mam, zonder jullie was ik nooit zover gekomen. Altijd konden we weer rekenen op 
jullie praktische en emotionele steun. Ook was het altijd gezellig om weer eens even in Veghel te 
zijn of om echt te ontspannen tijdens een gezamenlijke vakantie in Zwitserland. 
Lieve Alex, je begreep niet waarom papa en mama zoveel tijd nodig hadden om een boekje te 
schrijven. Wees gerust, na het boekje van papa is nu ook het boekje van mama echt af. Er komt 
weer meer tijd om samen te voetballen en andere leuke dingen te doen. Lieve Eva, je kreeg er 
nog allemaal niet zoveel van mee, maar met je vrolijke lach en ondeugende gezichtje kreeg je 
me aan het einde van een drukke dag altijd weer aan het lachen. Lieve Michiel, het boekje is af, 
onze promotietijd zit er op. Bedankt voor je eindeloze geduld en je onvoorwaardelijke steun de 
afgelopen jaren. Ik houd van jullie.
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ACR criteria American College of Rheumatology 
1990 criteria
ACUP adenocarcinoma with unknown 
primary
ADPKD autosomal dominant polycystic kidney 
disease
AIDS acquired immunodeficiency syndrome
ALT alanine aminotransferase
ANCA  antineutrophil cytoplasmic antibody
AST aspartate aminotransferase
CAPD continuous ambulatory peritoneal 
dialysis
CI confidence interval
CNS central nervous system
CRP C-reactive protein
CT computerized tomography
CVC central venous catheter
CWH Canisius Wilhelmina Hospital, 
Nijmegen, The Netherlands
ERCP endoscopic retrograde cholangio-
pancreaticography
ESR erythrocyte sedimentation rate
Fab’/F(ab’)2 antibody fragments
FAPA syndrome fever, aphthous stomatitis, pharyngitis, 
adenitis syndrome
FDG 18F-fluorodeoxyglucose
f-Met-Leu-Phe formyl-methionyl-leucyl-phenylalanyl
FUO fever of unknown origin
GH general hospital
GGT gamma glutamyltransferase
HAART highly active antiretroviral therapy
HAMA human antimouse antibodies
HIG human polyclonal immunoglobulin
HIV human immunodeficiency virus
HMPAO hexamethylpropylene amine oxime
HNP human neutrophil peptide
HYNIC hydrazinonicotinamide
ICAM-1 intercellular adhesion molecule-1
ICU intensive care unit
IgA/IgD/IgG immunoglobulin A/D/G 
IL interleukin
IL-1ra interleukin-1 receptor antagonist
JBH Jeroen Bosch Hospital, 
’s-Hertogenbosch, The Netherlands
LDH lactate dehydrogenase
LTB4 leukotriene B4
Mab monoclonal antibody
MCP-1 monocyte chemoattractant protein 1
MIC minimal inhibitory concentration
MMC Maxima Medical Center, Veldhoven, 
The Netherlands
MRA magnetic resonance angiography
MRI magnetic resonance imaging
NC not calculated
NCA non-specific cross-reacting antigen
NHL non-Hodgkin lymphoma
NIID non-infectious inflammatory diseases
NL The Netherlands
NPV negative predictive value
NRTI nucleoside reverse transcriptase 
inhibitor
NSAID non-steroidal anti-inflammatory drug
OSEM ordered subsets-expectation 
maximization
PDCs potentially diagnostic clues
PEG polyethylene glycol
PET positron emission tomography
PF-4 platelet factor 4
PMNs polymorphonuclear cells
PPV positive predictive value
RH Rijnstate Hospital, Arnhem, The 
Netherlands
RR relative risk
RUNMC Radboud University Nijmegen Medical 
Center
SH Slingeland Hospital, Doetinchem, The 
Netherlands
SLE systemic lupus erythematosis
SSEA-1 stage specific embryonic antigen-1
TPN total parenteral nutrition
TRAPS tumor necrosis factor receptor-
associated periodic syndrome
UBI human antimicrobial peptide 
ubiquicidin
UH university hospital
US United States
WBC white blood cells
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